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Antihypertensive pharmacotherapy is associated with poor adherence. No validated method 
exists to establish patients’ likely adherence level. A systematic review and a single, Swedish 
community pharmacy practice-based pilot study were undertaken investigating blood pressure 
(BP) optimization from pharmacist-led, community pharmacy-based antihypertensive 
adherence interventions titrated to individual patients.  
The systematic review showed generic interventions are often used for optimizing BP. 
Different intervention outcomes vary: positive, negative and no effect has been demonstrated.  
Pilot study participants (n=153) were categorised into adherence subgroups (A=Adherent, 
IR=Intentionally non-adherent rational, II=Intentionally non-adherent irrational, 
U=Unintentionally non-adherent) based on responses to questionnaire format adherence 
screens. Interventions were designed intuitively to optimize adherence for each subgroup: 
changes in blood pressure and adherence attitudes were assessed.  
A significant reduction in mean systolic BP (SBP) (3 mmHg, P<0.05), with no change in 
mean diastolic BP (DBP) was seen overall. However, outcomes varied with subgroup: 
adherence was enhanced in the U subgroup (decreased SBP: 3 mmHg; DBP: no change), but 
indications of a detrimental effect were observed in the II subgroup (SBP: no change; 
increased DBP: 3 mmHg). 
It is feasible to assign patients to different adherence subgroups in community pharmacy, 
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1 General introduction 
 Pharmaceutical care and the community pharmacist role in 1.1
hypertension management 
 
Pharmacists have a competence which is useful in medicines optimisation – to ensure safe and 
effective medicines use (West and Isom, 2014; WHO, 2003). This makes up a portion of the 
philosophy of “pharmaceutical care”. The concept of pharmaceutical care is a relatively new 
philosophy, with the pharmacist as a health care provider in cooperation with other health care 
professions and resources to work on the aim of achieving improved health and quality of life 
in patients and the public (WHO, 1994; WHO, 2003). Pharmaceutical care is largely defined 
as “the responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient’s quality of life” (Hepler and Strand, 1990; Wiedenmayer et al., 2006; 
Wiffen et al., 2012). 
There is a possibility that pharmacists could have extended roles in healthcare than what is 
established today (West and Isom, 2014). Community pharmacists being one of the largest 
healthcare professions in the world is more available to the patient compared to any other 
member of the healthcare staff (Mossialos et al., 2013). The profession could take on a role of 
having a larger clinical responsibility for patient care, such as in one of the most globally 
prevalent diseases – hypertension. Management of hypertensive patients with poor adherence 
could be done at a community pharmacy. The patient care would be done in collaboration 
with primary care. Those patients who exhibit physiological problems which cannot be dealt 
with at the community pharmacy would be undergoing treatment at a general practitioner or a 
specialist hypertension clinic. However, there are many challenges and obstacles along the 
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way to ensure an effective working system. Guidelines need to be developed to obtain a 
simple flow of the working roles involved (West and Isom, 2014). There is no overlap 
between developing the role of the community pharmacist and the evidence-base for practice 
and policy. Mossialos and co-workers in 2013 performed an umbrella review to identify 
published systematic reviews on the effectiveness of community pharmacist interventions.  
Thirty-three systematic reviews were identified since the year 2000. The systematic reviews 
explored the evidence for the increasing role of the community pharmacist. Results from the 
umbrella review point to a vague evidence base. However, many countries have already 
started to apply policies to provide the community pharmacist with increased patient-centred 
duties. Despite this, there is a requirement to perform research to examine policy changes 
within countries (Mossialos et al., 2013).  
 Medicines management, a patient-centred approach and medicines 1.2
optimisation 
 
Medicines management encompasses the therapeutic, economical and risk aspects of 
medicines (Wiffen et al., 2012). By providing consultation to resolve issues and concerns 
patients may be experiencing relating to medication-taking and whether these are justified 
will influence their medication-taking. A patient-centred approach is when the clinician and 
patient work together from the perspective of same opportunity and a mutual decision-making 
approach. This relates to bringing out the patient’s beliefs and provide information based on 
evidence. The patient-centred approach is inter-linked with the foundation of medicines 
optimisation (Grimes and Barnett, 2014). As the Royal Pharmaceutical Society in the United 
Kingdom states: ”Medicines optimisation is about ensuring that the right patients get the right 
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choice of medicine, at the right time. By focusing on patients and their experiences, the goal is 
to help patients to: improve their outcomes; take their medicines correctly; avoid taking 
unnecessary medicines; reduce wastage of medicines; and improve medicines safety” (Royal 
Pharmaceutical Society, 2013). A patient-centred approach with the determinants of blood 
pressure and adherence/non-adherence is presented in Figure 1.1. 
 
 
Figure 1.1 A patient-centred approach: determinants of blood pressure control (left) and adherence/non-adherence (right). 
The long arrows indicate relationships, whereas the small arrows preceding the determinants of blood pressure control 
indicate an increase (↑) or a decrease (↓) (Source: Personal collection). 
 
 History of blood pressure (BP) measurement 1.3
 
Considering history, in ancient Greece, both Hippocrates and Galen possessed the knowledge 
of arteries and veins. For more than 1000 years Galen’s theory was accepted. The theory 
being no connection between veins and arteries. This coupled with a forward and backward 
blood flow originating from the heart. It was until the Renaissance period, during the Middle 
Ages, when Galen’s theory was rejected. New experiments confirmed the modern 
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understanding of the heart and circulation. In 1616, a man named William Harvey described 
the circulatory system as a one-way system including capillaries (Nadar and Lip, 2009). 
Stephen Hales being an English clergyman measured blood pressure for the first time in a 
horse in 1733. A blood pressure machine was invented about 100-150 years later, which by a 
non-invasive manner measured blood pressure in humans (Kotchen, 2011; Nadar and Lip, 
2009). 
This was the basis for the instrument by Riva-Rocci in 1896, setting the stage for the modern 
devices. René Laennec invented the stethoscope which then assisted the Russian scientist NS 
Korotkoff in 1905 to check the pulse with an inflated blood pressure cuff, hence the term 
“Korotkoff sounds”. High blood pressure was noted as “hypertension”. “Benign essential 
hypertension” was distinct from “Malignant hypertension”. The condition of “Benign 
essential hypertension” was seen in conditions where it was thought to be somewhat of a 
positive outcome to maintain an elevated blood pressure. However, “Malignant hypertension” 
was categorized as a hypertensive state being harmful (Nadar and Lip, 2009).  
Not much change was seen in the way blood pressure was measured during the first 50 years 
of the 1900s. During the end of the 20th century, sophisticated blood pressure instruments 
were developed as a controversy surrounding health-related concerns to mercury. Electronic 
and aneroid devices have largely substituted the blood pressure instrument containing 
mercury. Despite this, mercury-containing instruments are still being used for calibration 





 Hypertension guidelines 1.4
 
During the 1970s and 1980s, larger studies as the Framingham study portrayed the 
relationship between hypertension and cardiovascular risk (Nadar and Lip, 2009). About the 
same time, the World Health Organization (WHO) and International Society of Hypertension 
(ISH) initiated a publication of hypertension guidelines. Recommendations for clinical 
decisions were described in these guidelines. Regional guidelines with subsequent updates 
were also developed in accordance with variations in healthcare and economic resources 
between countries. In the United States, The National Heart, Lung and Blood Institute issued 
“Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure”. 
Starting in 2003, the European Society of Hypertension (ESH) and European Society of 
Cardiology (ESC) launched their hypertension guideline (Kotchen, 2014). 
 Hypertension 1.5
 
Hypertension is described as an increased blood pressure which persists over time (Wilkins et 
al., 2011). Oxford Handbook of Nephrology and Hypertension defines hypertension as: “a 
level of blood pressure which places an individual at increased risk of cardiovascular events 
and, when treated, results in more benefit than harm” (Steddon et al., 2014). As seen by this 
definition, the hypertensive state itself presents a risk factor for various other cardiovascular 
conditions (Wilkins et al., 2011). There is a lengthy list of causes to hypertension. The disease 
can be attributed to either pathophysiological and/or environmental factors (Kaplan et al., 
2015).  The cause of hypertension is unknown in about 90-95% of the cases. This type of 
hypertensive state is referred to as primary or “essential hypertension”. The remaining 
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proportion where hypertension can be attributed to a certain cause is termed “secondary 
hypertension” (Kaplan et al., 2015; Wilkins et al., 2011). 
The prevalence of hypertension in adults around the world reached 25% in the year 2000 
estimation, equating to approximately 972 million people worldwide suffering from 
hypertension. This number is thought to increase to about 1,6 billion by the year 2025 
(Warrell et al., 2010). Blood pressure which is uncontrolled in the longer perspective sets the 
likelihood for cardio- and cerebrovascular morbidity and mortality among people (Gwadry-
Sridhar et al., 2013). As the life-span for people in developed countries increases, the 
prevalence of hypertension continues to rise (Kaplan et al., 2015).  
In developing countries, the rise of hypertension is connected to the increasing amount of 
people suffering from diseases such as diabetes and obesity. However, as there are only a 
small number of studies on the incidence of hypertension in the general adult population, not 
much is known about the incidence (Kaplan et al., 2015; Lacruz et al., 2015).  Within the next 
20 years, the World Health Organisation (WHO) predicts that hypertension will continue to 
be a preventable cause of early mortality. It is considered that hypertension will almost cause 
7.1 million deaths a year around the world (Warrell et al., 2010).  
 Blood pressure (BP) 1.6
 
The contraction phase of the heart is termed systole. During the systolic phase, the pressure in 
the left ventricle will reach about 120 mmHg which causes the blood to be released to the 
aorta. In turn, the pressure rise in the ventricle causes the aorta to stretch, due to the walls of 
the large arteries being elastic. This process also makes a forward flow of blood. The systolic 
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pressure reaches a maximum level of about 110 mmHg as arterial pressure (Ward and Linden, 
2013).  
Between two systolic phases is diastole, when the heart is filled with blood. The minimum 
arterial pressure before the next systolic phase is termed diastolic pressure, with a value of 
around 80 mmHg. Blood pressure is indicated as the systolic arterial pressure over diastolic 
arterial pressure. These values cannot be transformed into mean values as the heart is found to 
be around 60% in a diastolic state. Rather, it is feasible to calculate the mean arterial pressure 
as diastolic pressure+1/3 pulse pressure. The difference between systolic and diastolic 
pressure is termed pulse pressure. A pressure gradient is created when the heart pumps the 
blood into the arteries.  This means that the pressure in the arteries and veins is not the same. 
It enables a flow of blood throughout the vasculature (Stanfield, 2013; Ward and Linden, 
2013). 
The mean arterial pressure is also the product of cardiac output and total peripheral resistance. 
Cardiac output is the product of the heart rate and stroke volume, with heart rate being the 
number of contractions per minute.  During each heartbeat, both the left and right ventricle 
contract together. Hence, the heart rate is same for both the ventricles. A cardiac output at rest 
is about 5 L/minute. The stroke volume is the blood volume being pumped out from each 
ventricle per beat. During rest, the stroke volume is about 70 mL. This increases to about 20 L 
during exercise. To maintain the balance in cardiac output to venous return, the stroke volume 
is regulated accordingly. In response, the heart size is changed. In certain pathological 
conditions, there is a chronic heart enlargement. The walls of the ventricles stretch creating 
more muscle tension. The task to keep the blood pressure tuned in the ventricle becomes 
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arduous, as an enlarged ventricle needs to create sufficient pressure to respond to the cardiac 
output (Stanfield, 2013; Ward and Linden, 2013, Warrell et al., 2010). 
The occurrence of blood pressure varies with age with isolated diastolic blood pressure being 
the common feature in younger age groups. This can be explained by the presence of 
peripheral vascular resistance in younger people. As the aorta is being elastic in young people, 
it dampens the systolic pressure. The phenomenon is present until about age 50, whereby the 
peripheral vascular resistance is reduced. Hence, with an increase in age, the aorta becomes 
stiff. However, the systolic pressure will already increase from around age 40. For long it has 
been thought that diastolic blood pressure determined hypertension definition and goal blood 
pressure. Most cases of hypertension are found in the age groups over 50 years, meaning that 
systolic blood pressure is of most importance when considering cardiovascular risk (Warrell 
et al., 2010). However, it is also shown that an elevated SBP has a stronger impact on angina, 
myocardial infarction and peripheral arterial disease when compared to an elevated DBP 
which has a larger effect on abdominal aortic aneurysm (Rapsomaniki et al., 2014). 
The blood pressure classification set by the European Cardiology Society/European 




Figure 1.2. Definitions and classification of office blood pressure levels in mmHg (Source: Mancia, et al. (2013) 2013 
ESH/ESC Guidelines for the management of arterial hypertension, European Heart Journal, 34 (28): 2159-2219 by 
permission of Oxford University Press). 
 
 Adherence and non-adherence 1.7
 
In the literature, the concepts ‘adherence’, ‘compliance’ and ‘concordance’ are being used in a 
synonymous manner in relation to medication-taking behaviour. However, these concepts do 
not have a similar meaning (Hugtenburg et al., 2013; Snowden and Marland, 2013).  
The adherence project which started in year 2001 by the WHO, with the objective of 
generating an improvement in adherence to treatments of chronic conditions defined 
adherence as: “the extent to which a person’s behaviour – taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider” (WHO, 2003). The National Institute for Health and Care Excellence (NICE) 
in the UK defines adherence as “the extent to which the patient’s action matches the agreed 
recommendations (National Institute for Health and Care Excellence, 2009). A clinician takes 
patient-related factors such as beliefs and knowledge into account when referring to the term 
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“adherence” and the patient may not have a choice of the medication included in the treatment 
(WHO 2003; Wiffen et al., 2012). In this thesis when it is referenced to the level to which a 
patient takes their medication, the concept of adherence is being used. The term is used in the 
context of the explicit definition as stated by WHO in the year 2003 (WHO, 2003). 
Compliance refers to if a medicine has been administered or not, i.e. how far the patient has 
followed the clinical practitioner’s instructions on following the pharmacotherapy. It does not 
include an agreement between the patient and prescriber to follow the therapy (Osterberg and 
Blaschke, 2005; Snowden and Marland, 2013; Wiffen et al., 2012).  
The concept of concordance was introduced by a working group gathered by the Royal 
Pharmaceutical Society of Great Britain in 1995. Concordance is the approach to build an 
agreement between the prescriber and the patient to undertake the treatment (Snowden and 
Marland, 2013; Vrijens et al., 2012).  
Adherence rates to prescribed medicines are about 50 per cent, leading to reduced treatment 
benefits with the larger possibility of morbidity and mortality among patients (Nieuwlaat et 
al., 2014; WHO, 2003). Medication wastage is also a consequence of non-adherence to 
pharmacotherapy (Jackson et al., 2014). The societal cost becomes high when there is a cost 
of medicines waste due to non-adherence (Wiffen et al., 2012). Non-adherence also 
contributes to a negative economic impact on healthcare (Garfield et al., 2011; Osterberg and 
Blaschke, 2005).   
A definition of non-adherence is patients administering <80% of what has been instructed by 
the prescriber (Krousel-Wood et al., 2004; Nieuwlaat et al., 2014). However, this 80% cut-off 
point has been debated (WHO, 2003). Moreover, non-adherence can also take the form of 
11 
 
administering more than what has been instructed (Nieuwlaat et al., 2014; Osterberg and 
Blaschke, 2005). Despite this, it is more common with missed doses (Osterberg and Blaschke, 
2005). Factors which affect adherence can be grouped into social and psychological 
dimensions (Lehane and McCarthy, 2007a). The World Health Organization in 2003 set out 
five categories of factors influencing adherence: a) Socio-economic – in general, a less 
developed society leads to poor adherence; b) Health care team/health system – an inadequate 
health care system negatively affects adherence. However, the relationship between the 
clinician and the patient could improve adherence; (c) Condition - the requirements of the 
disease which the patient encounters influences adherence e.g. disability and disease severity; 
(d) Therapy - factors associated with the therapy e.g. a complex drug regimen, side-effects 
arising from treatment and the duration of treatment; (e) Patient – there will be a negative 
impact on adherence if the patient possesses poor knowledge and skills to manage symptoms 
arising from the illness and the treatment. Patient-related factors also include attitudes, beliefs 
and perceptions about the disease and treatment as well as expectations of treatment. The 
patient could lack an understanding of the cost/benefit of treatment (WHO, 2003).  
Both intentional and unintentional forms of non-adherence should be considered when 
examining non-adherence to medications. There is the possibility of these categories 
corresponding to each other, meaning there is no absolute mutual exclusiveness (Clifford et 
al., 2008).  Intentional non-adherence relates to when patients take on an active role including 
a reasoning process leading up to a decision of complying or not complying with instructions 
(Lehane and McCarthy, 2007b). The motivation of the patient and beliefs about administering 
medication influences intentional non-adherence. Unintentional non-adherence is connected 
to the capability of the patient to administer the medicine (Clifford et al., 2008). Patients who 
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are unintentional non-adherent are “passive” for reasons such as for example age, 
forgetfulness, cost and medication side-effects (Lehane and McCarthy, 2007b). In addition, 
there is the role of rational and irrational behaviour when considering non-adherence (Lehane 
and McCarthy, 2007b). It is important to establish the type of non-adherence to reach the best 
choice of intervention to optimize adherence (Lowry et al., 2005).  
 Irrational non-adherence 1.8
 
An irrational thought is defined as an unconscious mental process or irrational internal logic. 
Theories of health and adherence behaviour such as the Health Belief Model and Theory of 
Reasoned Action are thought to be formed on the basis that behaviour is rational (Horne et al., 
1999; Lehane and McCarthy, 2007b). However, there are some researchers who reason 
human decision-making and behaviour suffer from cognitive inconsistencies and biases. This 
leads to the processes of behavioural change in some instances not being objective or rational. 
The social cognitive theory lacks inclusion of unconscious mental processes and ”irrational” 
internal logic in health-behaviour reasoning. Therefore, behaviour due to irrational decision-
making could hold a partial explanation for the existence and upholding of non-adherence. 
Irrationality relating to non-adherence stems from a non-evidence based manoeuvre. It can be 
regarded as a failure to follow the prescribed regime without some definitive reasons not to 
e.g. side-effects and forgetfulness. There exist a few psychological theories which explain the 
occurrence of irrational behaviour (Lehane and McCarthy, 2007b). 
Psychological defence mechanisms are unconscious self-protective instincts/dispositions from 
a potential threat. They keep psychological health at balance but also serve to protect against 
illness. However, this leads to minimal or no motivation for taking in new information or 
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change a health behaviour such as medication adherence. Psychological reactance is a theory 
which describes irrational decision-making. The patient may not pay attention to treatment 
advice to protect and uphold their freedom even though there may be health risks involved. 
However, in psychological reactance, there is no strong connection to adherence behaviour. 
Another theory is cognitive heuristics leading to biases and not being able to think logically. 
An over- or underestimation of risk is seen in heuristics. Social cognition models reason that a 
risk/benefit analysis is done before an adherence decision is made. The way risk is interpreted 
could be influenced by a failing evaluation. The reasons for failure include ”rules of thumb” 
or mental shortcuts. Hence, tasks or the availability of information could trouble the 
concentration of the patient on the illness and necessity of medication (Lehane and McCarthy, 
2007b).  
 Theories of adherence 1.9
 
Explanations and models of medication adherence and non-adherence have changed over the 
time course. In the beginning, there was a focus on the role of physician-patient 
communication on patient satisfaction, understanding and forgetting as factors determining 
adherence. However, health behaviour research soon showed that it was not successful with 
information alone to modify the behaviour. Therefore, the patient’s beliefs, motivation and 
planning activity were factors for further examination. Social cognition and self-regulatory 
models displayed the importance of beliefs about the illness and treatment as well as the 
individuals’ own ability to follow treatment/advice (Jackson et al., 2014). 
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To understand the factors behind intentional non-adherence, researchers focused on social 
cognitive theory. The theory considers the flows of thought which affect social behaviour. 
The existing psychological theories explain health beliefs in adherence (Horne et al., 1999).  
There are so many factors of adherence appearing to be associated with adherence that there is 
no universal theory for adherence management. In the pilot study in Chapter 3, the 
intentional/unintentional sides of non-adherence are considered because they appear to be 
intuitively one area in community pharmacy that will be met. For example, some patients may 
be forgetful, another group of patients could be concerned about their medication. In the case 
of the therapy causing the patient to feel worse, the likelihood to recognize treatment benefits 
reduces (Kaplan et al., 2015). 
1.9.1 The Health Belief Model 
 
The Health Belief Model was constructed to provide an explanation to when an individual 
dismisses health-promoting behaviour or going for a screening. The model addresses that 
health-related behaviour, i.e. to adhere is weighed up with the observed awareness of the 
disease and positive effects of the behaviour. It also consists of the concept of barriers to 
performing the behaviour and which ideas could initiate the behaviour. The initiation of the 
health behaviour is dependent on stimuli. There is a connection between the health behaviour 
and an individual’s beliefs about the threat a disease poses - the health behaviour is connected 





1.9.2 The Necessity-Concerns framework 
 
Patient-related factors form a strong role with regards to beliefs/perceptions about treatment, 
the illness and healthcare system (Foot et al., 2016). Research into long-term conditions 
shows that key beliefs are connected to common-sense examinations of prescribed 
medications: the perceptions of the personal need for treatment (necessity beliefs) and 
concerns for potential adverse consequences (Horne et al., 2013). Beliefs about medications 
and concerns determine medication adherence (Kjeldsen et al., 2011).  Medication beliefs are 
influenced by factors such as symptoms, decisions on dose alteration to reduce side effects 
and financial reasons. There is an increased likelihood of medication beliefs determining 
medication adherence when non-adherence is not random, meaning non-adherence at this 
instance is a consequence of the patient deciding to go about to take the medicine in a 
different way (Foot et al., 2016). Belief about medications can consider intentional non-
adherence than when non-adherence is unintentional (Clifford et al., 2008). 
Beliefs about medicines form the necessity-concerns framework which has foreseen 
adherence in many illness categories (Foot et al., 2016). The necessity-concerns framework 
addresses key beliefs on patients’ attitudes and decisions about treatment (Horne et al., 2013). 
The Belief about Medicines Framework is built on the Health Belief Model: when a 
behaviour is chosen, a cost-benefit analysis is done where the observed benefits are weighed 
against the observed costs (Foot et al., 2016). A validated questionnaire called Belief about 
Medicines Questionnaire quantifies necessity beliefs and concerns which makes it possible to 




1.9.3 Meichenbaum and Turk’s adherence theory  
 
In the WHO report ”Adherence to long-term therapies: evidence for action” it is mentioned an 
adherence model formed by authors Meichenbaum and Turk. Four different factors influence 
adherence: knowledge and skills, beliefs, motivation and action. A weakness in any of these 
factors will lead to non-adherence (WHO, 2003). 
1.9.4 Theory of reasoned action/Theory of planned behaviour 
 
The Theory of reasoned action suggests that knowledge and ability of a patient to get hold of 
knowledge influences the development of beliefs. In a task, such as self-administering 
medicine the beliefs about the necessity of the medicine versus concerns of side-effects form 
the basis of adherence or non-adherence (Gatti et al., 2009). The theory of reasoned actioned 
transformed into the Theory of planned behaviour indicating activity is secondary to intention. 
The health-behaviour is determined by intentions. The source of intention is attitude, 
subjective rules and the observed control over behaviour (Horne et al., 2005; Ross et al., 
2004). Attitude relating to the behaviour is a product of the beliefs about the likely outcome 
and the recognized value of the outcome. The view of others regarding the behaviour and 
motivation to uphold these views are included in the subjective rule. Behavioural control is 
the dimension to which the individual recognizes to keep the behaviour under control. It is 
influenced by beliefs linked with control which is related to internal and external factors. 
Internal factors are skills and information, whereas external factors would e.g. be recognized 
barriers. Attitudes and subjective rules determine behaviour through intention. By contrast, 
observed control of behaviour has an impact on both intention and behaviour. Nonetheless, in 
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different circumstances, there could be variations in attitude, subjective rules and observed 
control over behaviour (Horne et al., 2005).     
1.9.5 Attribution theory 
 
Attribution theory describes the thinking processes surrounding the cause of situations (Horne 
et al., 2005). People’s perspective of social reality can be foreseen and controlled (Bowling, 
2009). When negative situations arise, there is an exploration of cause and outcome. This is 
based on past experiences and influences the upcoming answer and the adjustment to the 
illness. The causal theory can influence beliefs about cure, which then determines the 
behaviour and adjusting to disease. There exist internal and external causes as well as 
additional areas: stability – the time-line of the cause of disease, globality – overall or specific 
cause, universality – personal or generic factors and controllability – factors which could be 
controlled or uncontrolled (Horne et al., 2005).  
1.9.6 Locus of control beliefs 
 
The theory of controlling health was put into a measure which is referred to as health specific 
locus of control (HLOC). Health control is dependent on internal and external factors. 
Examples of internal factors are information or ability, whereas an example of an external 
factor would be opportunity (Bowling, 2009).  A revision to HLOC was made which 
transformed into the multidimensional health locus of control (MHLOC). This was done due 
to research showing that control beliefs could be grouped into separate scales. Beliefs relating 
to HLOC could foresee certain health behaviours. However, the measures of locus of control 
cannot appraise specific health behaviours. There is not a robust evidence base for locus of 
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control beliefs relating to adherence. A different perspective on this is that locus of control 
beliefs which are specific for the circumstance is strongly related to adherence compared to 
locus of control beliefs about overall health (Horne et al., 2005). 
1.9.7 Outcome efficacy and self-efficacy 
 
Beliefs surrounding the control and performance of behaviours as well as the efficacy of 
beliefs were described by Bandura in 1986. There are two forms of efficacies relating to these 
beliefs: a) outcome efficacy which transforms into an effective outcome b) self-efficacy 
which determines if the individual will/will not perform the behaviour. Self-efficacy is 
influenced by the individual’s own behaviour and others’ behaviour. The individual’s own 
behaviour is further affected by their partner. There is possibly more weight to self-efficacy 
when considering complex behaviours. An evidence base exists which shows a connection 
between self-efficacy and medication adherence. Moreover, beliefs about health control, 
outcome- and self-efficacy are influenced by the past and other thinking processes (Horne et 
al., 2005). 
1.9.8 Stages of change model/transtheoretical model 
 
In the stages of change model, also referred to as the transtheoretical model, a behavioural 
change process consists of five stages: a) Precontemplation - not thinking of behavioural 
change, b) Contemplation – thinking of behavioural change c) Preparation (getting ready for 
behavioural change) d) Action (undergoing behavioural change) e) Maintenance (behavioural 
change which is continued for a period). The five stages do not always run in a chronological 
order. Behavioural change is formed upon the present behaviour and the intention to change, 
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which therefore provides a foundation to comprehend the intentional behavioural aspect. For 
each stage, the model enables grouping of health behaviours and allows identification of 
interventions (Karupaiah et al., 2015, WHO, 2003). 
Another stages of change model termed as the Health Action Process Approach is built on 
Health Behaviour Model, Theory of Planned Behaviour and efficacy beliefs. The model was 
introduced by Schwarzer in 1992. It consists of two phases with the first phase seeking to 
decide the power of the intention. This phase is motivational and consists of attitudes to risk, 
self-efficacy and the likelihood of outcomes. The second phase referred to as volitional is 
when intention goes into a performance. Self-efficacy beliefs again influence this stage 
together with a plan and control of the performance (Horne et al., 2005). 
1.9.9 Self-regulatory model 
 
Leventhal’s self-regulatory model built on the basis that information provided as a threat was 
needed to increase motivation to execute a health behaviour. Despite this, it is required a plan 
to execute the behaviour (Horne et al., 2005). In the self-regulatory model, the health-related 
behaviour is determined by ideas forming themes of illness representations: identity/nature, 
time-line, cause, consequences and cure/control of the illness. Beliefs which surround these 
themes give rise to coping strategies (Ross et al., 2004). These influence adherence as this is a 
problem focused coping strategy with the patient as the problem-solver (Horne et al., 2005; 
Ross et al., 2004). Relating to adherence, the patients will weigh the proposed treatment with 
beliefs about the illness. This evaluation is a dynamic process and informs the patient on 
whether to adhere or not. The way the treatment is being portrayed is a determining factor in 
the self-regulatory model, together with the plan of executing the health behaviour as well as 
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the assessment of the plan (Horne et al., 1999, Horne et al., 2005). The success of the 
treatment is also a determining factor. If the treatment is not successful, the patient will not 
continue, may change to another coping strategy or have an altered perception of the illness 
(Horne et al., 2005; Ross et al., 2004). The necessity of treatment and concerns have a larger 
impact on adherence than illness beliefs (Horne et al., 2005). Therefore, there is a 
strengthening explanation of the self-regulatory model on adherence by adding an assessment 
of beliefs about medication (Horne et al., 1999). 
1.9.10 Information-motivation-behavioural skills model (IMB model) 
 
The IMB model is a model that has been used to gain an understanding of health behaviour 
activity (Gleason-Comstock et al., 2015). It proposes that action of a behaviour seeking to 
improve health is determined by information, motivation and skills (Osborn and Egede, 2010; 
WHO, 2003). Information relates to factors as knowledge and management of the disease. It 
also includes knowing the risk and the behaviour to deal with the risk. The patients’ beliefs, 
attitudes as well as social rules and support systems influence motivation. Acquisition of the 
required skills to put the behaviour into action forms the skills factor in the IMB model 
(Gleason-Comstock et al., 2015; WHO, 2003).  Both information and motivation can directly 
influence behaviour. However, there is no strong connection between information and 
motivation. Thus, if both information and motivation are present, it will increase the 





1.9.11 Medication error theory 
 
The Medication error theory was formed by Barber in 2002 and built upon Reason’s human 
error theory in organizations. Manoeuvres which are not safe can be divided into two 
categories: intended and unintended, which is like intentional and unintentional non-
adherence. Thus, intentional non-adherence is grouped in a violation which is a conscious 
diversion from the action the patient is supposed to execute in practice. These diversions can 
be positive (e.g. not taking a diuretic before going on a long journey or negative (e.g. 
choosing not to get the medication dispensed) (Barber, 2002; Horne et al., 2005). 
Intentional non-adherence can also be a knowledge-based or rule-based mistake. With a 
mistake, a patient executes an action in which it is intended to be the correct way to go about, 
though the patient is not aware of the wrong action. An example of a rule-based mistake is a 
concern of a side-effect making the patient stop administering the medication though the 
patient is not experiencing the side-effect. A knowledge-based mistake could be in a situation 
in which the patient has no medication supply at home. The reason for this is not to be blamed 
at the patient. There is a decision by the patient to delay the clinic visit to get a new 
prescription instead of going to the pharmacy getting an emergency refill (Barber, 2002; 
Horne et al., 2005). 
Unintentional non-adherence is categorized in slips or lapses. Slips could be for example 
accidentally taking the wrong pill. Slips occur due to the patient having inadequate 
concentration. Lapses occur due to poor memory, e.g. forgetfulness causing the patient to 
miss a dose (Barber, 2002; Horne et al., 2005).  
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1.9.12 Medication Adherence Model 
 
A theoretical medication adherence framework named the Medication Adherence Model 
which was published in 2002 looked at the processes relating to medication adherence in 
patients with hypertension. The model was built on previous cognitive theories. It describes 
the two categories of non-adherence: intentional decision were patients miss doses and 
unintentional interruption where medications are not taken. The key concepts in the 
framework are: 1) purposeful action: starting and keeping up an adherence decision is based 
on need, effectiveness and safety 2) patterned behaviour: medication-taking patterns are 
determined by access, routine and remembering 3) feedback where information, prompts and 
events are used by the patient to value and evaluate the health treatment. The feedback, in 
turn, influences purposeful action and patterned behaviour (Johnson, 2002).  
1.9.13 COM-B 
 
According to Jackson and co-workers, (2014) existing adherence models and frameworks are 
not sufficient. Firstly, they do not pay attention to automatic processes (e.g. habit). Secondly, 
there is no description of behaviours being dynamic such as the experience of adherence/non-
adherence leading to change in factors (e.g. beliefs about medications). Thirdly, the factors at 
a holistic level are neglected, i.e. the relationship between factors determining adherence and 
adherence itself. In addition, there is the overlap between intentional and unintentional non-
adherence. Finally, the current adherence theories do not provide information on how to go 
about to establish change (Jackson et al., 2014). 
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There are behaviour change techniques which develop and refine interventions. The methods 
which change health-related behaviours have been described in a taxonomy with 93 
techniques. It is possible in this taxonomy to categorize factors which explain health-related 
behaviours. This has resulted in a dynamic psychological model with mechanisms of 
behavioural change which is referred to as ”COM-B”. It builds on a US consensus meeting 
and existing theories of behaviour.  Factors which influence medication adherence found in 
three studies have been added to COM-B creating a framework for choosing interventions 
which suggest the possible intervention and specific interventions for each component. The 
three components Capability, Opportunity, Motivation are interlinked which in turn affect the 
performance of behaviour (Jackson et al., 2014). 
 Antihypertensive medicines adherence 1.10
 
In the late 1950s, there was the advent of safe and tolerated antihypertensive drugs e.g. 
thiazide diuretics. Almost a decade later, the first randomized controlled trial was conducted 
on blood pressure lowering agents for hypertension leading to positive cardiovascular effects. 
It did not take long until the importance of adherence to antihypertensive pharmacotherapy 
was identified (Gosmanova and Kovesdy, 2015).   
Large studies show the positive effects of BP control on reduced cardiovascular morbidity and 
mortality (Burnier, 2006). Besides, antihypertensive drugs have clearly shown positive 
outcomes: 20-25% reduction in acute coronary syndrome, 30-35% reduction in stroke and 
50% reduction in heart failure (Gosmanova and Kovesdy, 2015). According to WHO, 
identification and treatment of hypertension have shown vital health and economic benefits. 
Hypertension will increasingly be treated with antihypertensive medicines (Kaplan et al., 
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2015). Despite this, hypertension is everywhere still inadequately managed. The lack of 
adherence to blood pressure lowering medicines plays a major role (Morgado et al., 2011; 
WHO, 2013).  
The adherence rate to blood pressure lowering medicines depends on the population being 
studied but is in the range between 50-70 percent (WHO, 2003; Morgado et al., 2011). Rates 
could be higher for specific antihypertensive drug classes and in patients on monotherapy 
with a low number of doses (Gosmanova and Kovesdy, 2015). It is important to bear in mind 
that there is a difference between adherence in clinical trials and in the community. In clinical 
trials, there are highly motivated patients who are aware that adherence is being monitored 
(Burnier, 2006). 
It is vital to understand the barriers which inhibit the process of reaching BP targets 
(Gosmanova and Kovesdy, 2015). Reasons for non-adherence to antihypertensive medications 
can, for example, relate to the asymptomatic nature of hypertension, the chronic requirement 
for treatment, complex drug regimens, costs and beliefs about medications (Kaplan et al., 
2015; Lee et al., 2006; Morgado et al., 2011; Wiffen et al., 2012). Evidence shows that about 
50% of patients discontinue treatment within a year, even though treatment is being offered 
(Kaplan, 2015; WHO, 2003). 
A study conducted in England by Quine and co-workers, 2012 suggested and examined a 
framework for the psychological elements which determine antihypertensive medication 
adherence. Three groups of factors were included in the framework: a) demography, health 
status and medication regimen b) cognitions and motivation c) intention to adhere. 
Questionnaires were distributed by post to patients with hypertension from primary care 
centres. The first set of questionnaires examined the proposed framework and assessed 
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antihypertensive medication adherence using the 4-item Morisky Medication Adherence Scale 
(MMAS-4). After 8 weeks, antihypertensive medication was assessed with MMAS-4. The 
results indicate that cognitions and motivation form a major part of the framework. The 
authors suggest that motivational-type of interventions must especially be useful to target 
intentional non-adherence (Quine et al., 2012). 
Most hypertension patients have the goal blood pressure of <140/90 mmHg, a target which is 
a surrogate of adherence. There is a signal of non-adherence if the patient does not have 
controlled office blood pressure, even though the patient is on polypharmacy with 
antihypertensive drugs. Despite this, the signal of non-adherence can be skewed during office 
BP measurement by the patient experiencing a ”white-coat”-effect: a higher office BP in 
comparison to ambulatory measurement. There could also be the effect of ”white-coat”-
improved adherence surrounding the clinic visits: the patient will improve the adherence 
momentarily for the clinic visit. Therefore, BP should not be considered alone when assessing 
adherence to antihypertensive pharmacotherapy. It should be a marker used in conjunction 
with adherence screening tools (Gosmanova and Kovesdy, 2015). 
 Interventions to optimize antihypertensive medication adherence 1.11
 
The WHO in the year 2003 mentioned there is no specific approach or intervention to 
improve antihypertensive medication adherence. Further research is needed to which 
interventions are likely to improve antihypertensive medication adherence. However, it is 
required a behavioural change to reach optimized adherence to long-term medication therapy 
(WHO, 2003). This involves learning, adopting and upholding medication-taking behaviour 
using methods such as rewards and reminders. Interventions which are tailored are more 
26 
 
likely to be effective in reaching behavioural change compared to non-tailored interventions. 
Therefore, there is a need for comprehensive interventions which include cognitive, 
behavioural and affective methods which are customised. These interventions should be based 
on an objective assessment of the behaviour of administering medicines. In addition, 
clinicians should have an awareness of the prevalence of adherence in the hypertensive 
population (Burnier, 2006; WHO, 2003).  
Patel and Taylor in 2002 conducted a study where the relationship between illness attribution, 
perceived control and adherence to antihypertensive medications was investigated. The study 
was performed in 122 patients (18 years and above) with a goal to reduce BP. Patients 
underwent written and follow-up telephone questions on patients’ illness attributions, 
awareness of control and medication adherence. This study showed that acceptance of 
medical advice and information was dependent on beliefs about health condition. In turn, this 
shows that when patients’ beliefs about the disease are revealed and considered, better 
outcomes are reached (Patel and Taylor, 2002).  
Burnier, 2006 suggests that a comfortable drug regimen which is quite free of side-effects and 
a positive/supportive approach to treatment is the best way forward to improve adherence to 
antihypertensive pharmacotherapy (Burnier, 2006).   
It needs to be ensured that medicines do not have a negative impact on the quality of life of 
the patient. Therapy-related factors such as dosage regimen can be adjusted to less frequent 
administrations during the day, which is shown to increase adherence. Side-effects can be a 
therapy-related factor, where the patient reaches a decision that side-effects outweigh the 
future benefits of the medication therapy. In the presence of dose-dependent side-effects, the 
physician may alter the dose to a lower dose. This is to increase the adherence to the 
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medication therapy, although with the risk of not reaching optimal BP control. Consequently, 
the tolerability of the medication and dosing frequency influence the medication-taking 
behaviour. Adherence is improved with a good patient-clinician communication as well as 
regular treatment follow-up. A shared-decision making approach between the patient and 
physician should be sought, with the selection and adjustment of the pharmacotherapy being a 
joint decision. Patients should be given instruction on how to use their medications in a 
reasonable manner - emphasizing the necessity of medication and keeping BP control. The 
patients’ management relating to missed doses, recognizing and taking care of side-effects is 
crucial in obtaining optimized adherence. Training of healthcare staff is required for a non-
judgemental counselling and in the proper selection of antihypertensive medications (Burnier, 
2006; Osterberg and Blaschke, 2005: WHO, 2003).  
Moreover, self-monitoring of BP where patients are taught to measure and monitor their own 
BP will be useful in achieving improved rates of antihypertensive medication adherence. This 
in combination with patients learning to assess their own adherence (Osterberg and Blaschke, 
2005; WHO, 2003).  
 Methods of measuring medication adherence 1.12
 
Historically, adherence screening has been noted all the way back dating to the time of 
Hippocrates. There is no optimal way to measure adherence as each adherence screening tool 
present their own pros and cons (Osterberg and Blaschke, 2005). Rather, a triangulated 
approach of methods of measuring medication adherence provides a better picture and is used 
in research (Garfield et al., 2011; Osterberg and Blaschke, 2005). 
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There exist direct methods or indirect methods of measuring adherence. Therapeutic drug 
monitoring is a direct method where the drug concentration is for example measured in blood 
or urine. However, these methods are costly. Indirect measures include self-report 
questionnaires, pill counts, assessment of treatment response, electronic monitors and 
assessment of refill rates using pharmacy records. Self-report questionnaires are simple in 
practice, though patients may not be accurate about their adherence providing a good picture 
to the practitioner (Osterberg and Blaschke, 2005; Wiffen et al., 2012).  
1.12.1 Self-reported medicines adherence screening questionnaires 
 
Before initiating the pilot study described in Chapter 3, it was not known if the Belief about 
Medicines Questionnaire (BMQ) would have been sufficient alone. At the same time, the 8-
item Morisky Medication Adherence Scale (8-item MMAS) or Medication Adherence Report 
Scale (MARS) could have been used alone. However, the limitation is that these 
questionnaires are not being precise enough. Indeed, there is no universal method to screen 
adherence. The intention of triangulation is to add precision to the adherence screening and to 
determine the robustness of the questionnaires. Thus, the triangulative approach combines the 
pros and cons of different adherence models which provides for a more precise adherence 
screening.  
Sections 1.12.1.1 to 1.12.1.3 provide the theory for the self-reported medicines adherence 





1.12.1.1 8-item Morisky Medication Adherence Scale 
 
The 8-item Morisky Medication Adherence Scale (8-item MMAS) is a self-reported measure 
of medication taking. It was developed from an earlier validated 4-item scale. From the 4-item 
to the 8-item scale there have been added items including circumstances which surround 
adherence behavior. Each item in the scale measures specific medication-taking behavior. 
(Morisky et al., 2008). The reason for choosing this measurement instrument is that compared 
to other self-reported medication adherence scales, the 8-item Morisky scale has already been 
used in a study for medication adherence of patients with hypertension and thus naturally will 
serve as an optimal medication adherence measurement tool for this study. 
Morisky and co-workers conducted a study in the year 2008 where the primary objective was 
to examine the psychometric properties and test the concurrent and predictive validity of an 8-
item structured, self-reported medication adherence measure in primarily low income, 
minority patients with hypertension. The study included 1367 patients. According to the 
authors of the study, the 8-item medication adherence scale was reliable and significantly 
associated with blood pressure control. Furthermore, it is stated in this study that the 
medication adherence scale is relatively simple and practical to use in clinical settings. In 
addition, the authors state that this instrument can be used initially to identify patients with 
adherence problems, and can also be used to monitor adherence over the course of the 
treatment (Morisky et al., 2008). 
An evaluation of the association and concordance of a new 8-item self-report Morisky 
Medication Adherence Scale (MMAS) with prescriptions claims in a managed care 
population consisting of older adults with hypertension was done by Krousel-Wood and co-
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workers, 2009. This was a cross-sectional study were pharmacy records were taken for 
managed care adult hypertensive patients aged 65 years and above. A total of 87 study 
participants completed a survey including the 8-item MMAS. Medication Possession Ratio 
(MPR) was also one of the approaches used to assess adherence. This was calculated using 
the pharmacy data. The authors of the study conclude that the MMAS is significantly 
associated with antihypertensive pharmacy refill adherence. Furthermore, they state that 
although further validation of the MMAS is needed, it may be useful in identifying potential 
low medication adherers in clinical settings (Krousel-Wood et al., 2009).  
Holt and co-workers in 2012 conducted a cross-sectional analysis by using data from 1817 
participants in the Cohort Study of Medication Adherence among Older Adults. The authors 
examined the association between life events, antihypertensive medication adherence and the 
role of coping.  MMAS-8 was used to assess antihypertensive medicines adherence. Life 
events among the study participants that occurred 12 months before the study interview was 
assessed by the Holmes Rahe Social Readjustment Rating Scale (SRRS). Coping levels were 
assessed using an adapted version of the John Henry Active Coping Scale. The analysis 
showed that older adults with low coping skills and more life events had lower adherence to 
prescribed antihypertensive medications (Holt et al., 2012). 
Elliott and co-workers (2014) in a randomised controlled study evaluated the effectiveness of 
the New Medicines Service (NMS) in community pharmacies in England using the 8-item 





1.12.1.2 Medication Adherence Report Scale 
 
Another questionnaire for measuring self-reported medicines adherence is the Medication 
Adherence Report Scale which was developed in England. This questionnaire contains five 
statements surrounding self-reported adherence. The statements include: forgetfulness, 
altering the dosage, stopping to take the medication, missing a dose and taking less than 
instructed. Response categories for the statements are made of a 5-point Likert scale: 
1=always, 2=often, 3=sometimes, 4=rarely, and 5=never. This questionnaire is chosen as a 
method in the proposed study since it has been translated into Swedish with the back-
translation approved by the original author and has previously been used in a study performed 
in a pharmacy setting in Sweden (Mårdby et al., 2007).  
An examination of the intentional and unintentional aspects of medication non-adherence in 
patients diagnosed with hypertension was performed by Lehane and McCarthy in the year 
2007. A study population consisting of 73 participants with hypertension were recruited. 
These patients attended outpatients’ clinics of two university hospitals. MARS was included 
in a researcher administered questionnaire containing 3 other questionnaires (Lehane and 
McCarthy, 2007a). 
A German translation of MARS named MARS-D was used in a study aimed at assessing 
whether MARS-D was an appropriate instrument for measuring patient adherence. MARS-D 
was sent to 1488 patients with chronic diseases and patients with risk factors for 
cardiovascular disease. This study concludes that preliminary psychometric evaluation of 
MARS-D is encouraging. The authors state that MARS-D is an appropriate measure to detect 
patients at risk of non-adherence (Mahler et al., 2010) 
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The Medication Adherence Report Scale (MARS) was used in a study by Ramanath and co-
workers in 2012. The objective of this study was to know the impact of clinical pharmacist 
interventions on medication adherence and quality of life. Their study was a prospective, 
randomized, interventional study with 52 patients completing the study. The authors conclude 
that the impact of clinical pharmacist provided patient counselling had a positive impact on 
medication adherence and quality of life (Ramanath et al., 2012). 
1.12.1.3 Beliefs about Medicines Questionnaire 
 
The Beliefs about Medicines Questionnaire is a method to assess cognitive representations of 
medication. It is built up of two sections: BMQ-Specific and BMQ-General. These two 
sections can be used either together or independently. BMQ-Specific consists of two 5-item 
factors. It assesses beliefs about the necessity of prescribed medication, concerns about the 
prescribed medication based on beliefs about the danger of dependence and long-term toxicity 
and the disruptive effects of medication. BMQ-General contains 2 four-item factors: it 
assesses the beliefs surrounding that medicines are harmful, addictive, poisons which should 
not be taken continuously and that medicines are overused by doctors (Horne et al., 1999). 
The reason for choosing this questionnaire in the pilot study described in Chapter 3 is that it 
covers a wide range of patient perceptions on medicines use and therefore can capture the 
issues which patients face with their antihypertensive medicines usage with special reference 
to barriers to antihypertensive medicines adherence. 
Both the BMQ and MARS were used in a study performed in Sweden by Mårdby and co-
workers in 2007. The objective of this study was to analyze any association between general 
beliefs about medicines and self-reported adherence among pharmacy clients and to examine 
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general beliefs about medicines by background variables. The questionnaire data were 
collected by one of the researchers who approached pharmacy clients at 7 different 
community pharmacies in Gothenburg, Sweden. The study population consisted of 324 
pharmacy clients. 54% of these participants were considered non-adherent. In conclusion, 
General-Harm was associated with adherence to medication among Swedish pharmacy 
clients. Country of birth, education and medicine use influenced beliefs about medicines 
(Mårdby et al., 2007). 
1.12.2 Pill count 
 
Pill count involves comparing the remaining number of pills in the medicines package with 
the number of pills which would be remaining if the patient was adherent. Apart from being a 
straightforward method, there exist practical issues which are detrimental for its reliability; 
such as dumping pills, it may not be clear if the medicine was really administered, lack of 
instruction that tablet counting will be performed during research, patients bringing the pills 
etc. (Krousel-Wood et al., 2004; Smith, 2002).  
The validity of patient report, pharmacy dispensing records, and pill counts as measures of 
antihypertensive adherence using electronic monitoring as the validation standard was 
evaluated in a study by Choo and co-workers in 1999. This study included 286 members of a 
managed care organization who were at least 18 years of age, had prescription drug coverage 
and underwent monotherapy with antihypertensive medicine. Based on automated pharmacy 
dispensing records, prescription refill adherence was determined 12 months prior to 
enrollment in the study. A pill count was done during the study were pharmacists counted the 
34 
 
remaining number of tablets in the returned medication vials when the participants did a 
prescription refill during the study (Choo et al., 1999). 
De Souza and co-workers evaluated whether adherence to a drug regimen helped to identify 
patients with resistant hypertension. In this study, a study population of 44 hypertensive 
patients was prospectively studied. These patients were resistant to a 3-drug regimen and were 
followed for 12 months. The pill count method and a Morisky questionnaire were used to 
assess adherence (de Souza et al., 2009). 
A pill count was used as a method in a study done by Martin and co-workers in 2011. The 
purpose of this study was to examine the effectiveness of a community-based, multimedia 
intervention on medication adherence among hypertensive adults. This study was a 
randomized controlled trial in rural south Alabama, United States. Study participants were 
434 low-income adults receiving medication free of charge from a public health department or 
Federally Qualified Health Center. Registered nurses and a community health advisor 
assessed adherence by pill count when the study participant made a visit to the clinic to make 
a medication refill. The participants had to bring in their medicine bottles. Any remaining 
pills had to also be brought the clinic. This would enable the participant to receive a full 90-
day medicine supply. Data recorded regarding the returned pills consisted of the medication 
name, strength, dosing, the number of pills returned and the number of pills dispensed (Martin 
et al., 2011).  
1.12.3 Pharmacy refills 
 
Medication Possession Ratio (MPR) is a method used to assess medicine adherence by using 
pharmacy refill data. MPR is the ratio of the total days of medication supplied to the total 
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days between medication refills. The value of MPR is always >0 because the numerator will 
be >0. An MPR=1 corresponds to 100% compliance. To patients who get different 
antihypertensive medicines simultaneously (polypharmacy), a separate MPR should be 
calculated for each medication. An average MPR can then be calculated. Attention should be 
given when calculating an average MPR value, due to that compliance can vary between 
different medicines. In fixed-dose combinations (single medication containing two or more 
active ingredients) only one MPR should be calculated (Halpern et al., 2006).  
In an observational study conducted in the United States by Schmitt and co-workers, 2007 a 
Veterans Affairs (VA) cohort of patients with chronic kidney disease (CKD), patterns of 
medication adherence for all antihypertensive classes of prescriptions during a 2-year period 
were examined. The primary objective of this study was to examine the independent 
relationship between the level of adherence observed in clinical practice, and the achieved 
level of blood pressure control during the entire study period. A secondary objective was to 
describe the patient characteristics that may be associated with the level of adherence to 
antihypertensive medications in a CKD cohort. The study consisted of 7227 chronic kidney 
disease patients receiving at least one antihypertensive prescription between 2006 and 2007.  
Prescription information was taken from a database containing electronic records of outpatient 
prescriptions/refills information and other patient data. Medication Possession Ratio was used 
to assess antihypertensive medicines adherence. The authors of this study state that 33% of 
the CKD patients had poor medication adherence and that medication adherence worsened 
with declining renal function. In addition, the authors state that poor medication adherence is 
associated with a 23% greater risk of uncontrolled hypertension. In CKD practice, monitoring 
and improving adherence could contribute to better outcomes (Schmitt et al., 2007).  
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Mabotuwana and co-workers, 2009 performed a study in New Zealand in which they 
developed a computational framework to identify patient cohorts with poor adherence to long-
term medication through analysis of electronic prescribing patterns. This was illustrated using 
the electronic medical records of a New Zealand general practice among patients with 
hypertension and diabetes. The focus was on adherence to Angiotensin Converting Enzyme 
inhibitors (ACEinh) and/or angiotensin-II receptor blockers (ARB). Analysis of medication 
supply was based on the concept of MPR (Mabotuwana et al., 2009).  
MPR was included in a cohort study in China which evaluated the factors associated with 
adherence with ACE inhibitors. This study included all adult patients who were prescribed an 
ACE inhibitor and did at least 2 consecutive visits to any primary care clinics of one large 
territory of Hong Kong from January 2004 to June 2007. Data was obtained from a computer 
system adopted in the year 2000 were health care professionals were provided direct entry to 
the electronic clinical management system. Prescriptions at every clinical visit, the 
demographic details of patients and other clinical data were logged into this database. The 
study showed that 88% were adherent of 6408 eligible patients (Wong et al., 2010). 
There is the effect of noise at the beginning and/or end of the MPR data collection period, i.e. 
the patient already could have initiated a medicine’s package when the MPR data was 
collected. Toward the end of the MPR data collection, the patient may yet not have completed 





Figure 1.3. Example of noise in MPR during a 3-month time frame (Source: Personal collection). 
 
To reduce the noise, it is important to allow for an MPR data collection spanning over a long 
period, e.g. 6-9 months (see example in Figure 1.4)  
 
 




 Prescribing guidelines for antihypertensive medications in Sweden and 1.13
United Kingdom (UK) respectively 
 
In Uppsala County, Sweden, the prescribing guideline recommends an ACE inhibitor 
(ACEinh) or generic losartan/candesartan and/or a low-dose thiazide diuretic (TD) or a 
calcium-channel blocker (CCB) as first-in-line antihypertensive pharmacotherapy. Beta-
blockers (BB) are recommended in the case of co-morbidity, e.g. when having congestive 
heart failure or a migraine. An ACE inhibitor can be substituted with an ARB if the patient 
experiences side-effects such as a cough (Landstinget i Uppsala län, 2016; The Swedish 
Medical Products Agency, 2016). The prescribing guideline within Uppsala County largely 
complies with the national prescribing recommendations in Sweden: 
1st choice: a) ACEinh or ARB, dihydropyridine CCB or TD b) If optimal effect not achieved 
with monotherapy including one antihypertensive drug class: ACEinh or ARB + CCB or TD. 
c) If optimal effect not achieved including two antihypertensive drug classes: combine all 
three drug classes (ACEinh or ARB + CCB + TD) in full-dose 
2nd choice: a) BB b) Alpha blocker (Alpha) or spironolactone if first-in-line therapy is not an 
adequate.  
In comparison to the Swedish guidelines, NICE in the UK have categorized the choice of 
antihypertensive treatment into four steps:  
Step 1) Patients aged <55 years: An ACEinh or a low-cost ARB. If the patient does not 
tolerate an ACEinh, the medication can be substituted with a low-cost ARB. Patients aged 
>55 years and black people (African or Caribbean origin) of all ages: CCB. In those situations 
where a CCB is inappropriate or not tolerated: TD. Chlortalidone or indapamide is 
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recommended when starting or changing diuretics. However, in those patients with BP control 
who already are undergoing treatment with bendroflumethiazide or hydrochlorothiazide, the 
pharmacotherapy can remain unchanged.  
Although BB not being first-in-line antihypertensive pharmacotherapy, this drug class can be 
taken into account for young patients especially in the following situations: patients not 
tolerating or where there is a contraindication to ACEinh and ARB; female with potential to 
become pregnant; patients where there confirmation of increased activity in the sympathetic 
nervous system. If monotherapy with BB is not sufficient, a CCB should be added as dual 
therapy instead of a TD. The reason is to decrease the risk of the patient developing diabetes.  
Step 2) If BP remains uncontrolled after step 1: CCB + ACEinh or ARB. If a CCB is 
inappropriate or not tolerated: TD. Black people (African or Caribbean origin): ARB + CCB 
instead of ACEinh + CCB.  
Step 3) If BP remains uncontrolled after step 2: triple therapy with ACEinh or ARB + CCB + 
TD.  
Step 4) If the clinic BP is >140 mmHg/90 mmHg it should be treated as resistant hypertension 
after following triple therapy in optimal doses with ACEinh or ARB + CCB + diuretic. Four 
antihypertensive drugs can be considered or consulting a specialist for advice. Depending on 
the potassium level in blood, the patient can be prescribed either low-dose spironolactone or 
higher-dose TD. It is important to monitor sodium and potassium levels in the blood as well 
as the renal function when adding a diuretic for patients with resistant hypertension. Alpha or 
BB can be prescribed if diuretic pharmacotherapy is not tolerated by the patient or if 
contraindicated. A specialist should be consulted if BP control is not achieved with treatment 
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including four antihypertensive drugs (National Institute for Health and Care Excellence, 
2016). 
Both the Swedish and NICE guidelines state that ACEinh and ARB should not be combined 
(National Institute for Health and Care Excellence, 2016; The Swedish Medical Products 
Agency, 2016). This is due to increased risk of side-effects and the absence of a combined 
drug effect (The Swedish Medical Products Agency, 2016). 
 Previous studies  1.14
 
There have been earlier studies which have examined the potential to improve adherence to 
antihypertensive medications in community pharmacy, but these have limitations because 
they do not attempt to evaluate the adherence status of the patients and generally do not target 
an intervention to that status.  
Dating back to 1973, an American randomised controlled trial was performed by McKinney 
and co-workers on a small patient population with essential hypertension at a community 
pharmacy with an intervention and control group (McKenney et al., 1973). During almost 30 
years after this study was published, there was a research gap until the year 2000. In England, 
Blenkinsopp and co-workers (2000) conducted a randomised controlled trial in 20 community 
pharmacies with 180 patients completing the study. The objective of their study was to 
determine the effect of a community pharmacist-led intervention on adherence to 
antihypertensive pharmacotherapy. Outcome measures were blood pressure control, self-
reported adherence and patient satisfaction with pharmaceutical services. Pharmacists in the 
intervention group interviewed patients in relation to their hypertension treatment plan by 
using a structured protocol with questions. The authors conclude that simple intervention (oral 
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or written information, contact with/referral to the physician) had positive effects on blood 
pressure control, self-reported adherence and patient satisfaction with pharmaceutical services 
(Blenkinsopp et al., 2000). 
Among studies conducted in the beginning of the 2000s, it is observed an approach to 
adopting different study designs (Chabot et al., 2003; Garção and Cabrita, 2002; Hughes et 
al., 2002; Taylor et al., 2003). Even though the studies being relatively small-scale, there was 
a build-up of outcome measures such as quality of life on patients and the economic 
perspective of community pharmacist interventions on healthcare (Hughes et al., 2002; Zillich 
et al., 2005). Exploring the effects of high-intensity or low-intensity interventions in 
subgroups were of interest in studies performed in years 2002 and 2005 (Hughes et al., 2002; 
Zillich et al., 2005).  
The impact of ethnicity or socioeconomic status to blood pressure control was explored. Eight 
African-American patients with hypertension participated in a very small study by Taylor and 
co-workers in 2003 (Taylor et al., 2003). Another example of focusing on an ethnic group is 
seen in the study by Lai and co-workers (2007) including Latino/Hispanic patients (Lai, 
2007). Svarstad and co-workers (2013) conducted a study in the US with almost 500 African-
American patients (Svarstad et al., 2013). Chabot and co-workers (2003) reported blood 
pressure changes in high-income patients and low-income patients (Chabot et al., 2003).  
Evaluation of lifestyle factors on blood pressure control, e.g. BMI, physical activity, smoking 
cessation, alcohol consumption and salt restriction is seen especially among the modern 
studies (Aguiar et al., 2012; Aguwa et al., 2008; Chabot et al., 2003; Júnior et al., 2008; 
Nemerovski et al., 2013; Octavia and Florica, 2011; Pojskic et al., 2014; Sharma et al., 2014). 
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The modern studies are larger though with a more complex set of interventions. The studies 
will be explored in detail in the systematic review.  
 Community pharmacy system and adherence programmes in Sweden 1.15
 
The Swedish pharmacy market changed in the year 2009 following a long period of 
government-owned pharmacies since the year 1970. Prior to 1970, the pharmacies were 
privately owned. The re-regulation was done to increase the availability of pharmacies 
(Sporrong and Nordén-Hägg, 2014). This resulted in an increase of about 40% of pharmacies, 
meaning it now exists about 1300 pharmacies in Sweden (The Swedish Pharmacy 
Association, 2016). The achievement was especially seen in well-populated areas. The change 
of legislation resulted in the ownership of pharmacies to international companies, private 
entrepreneurs, government-owned pharmacies etc. (Sporrong and Nordén-Hägg, 2014; The 
Swedish Pharmacy Association, 2016). To ensure that each pharmacy met quality standards, 
the legislation set a condition of having a specially appointed pharmacist for this function 
(Sporrong and Nordén-Hägg, 2014).  
In Sweden, there are three categories of pharmacy staff, two of these having dispensing rights 
and can counsel patients. The first one is the pharmacist with a four to five-year long 
education at university level, the second being the dispensing pharmacist with a two to three-
year university education. The dispensing pharmacist is a profession only available in 
Sweden, Norway, and Finland. The third professional staff type is the pharmacist technician 
with a two-year upper secondary school education. Pharmacy technicians are not allowed to 
dispense medicines. However, they can offer patient counselling of over-the-counter products 
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(Södergård, 2008; Westerlund and Björk, 2006). The Swedish pharmacies have about 300000 
customers visits a day (The Swedish Pharmacy Association, 2016).  
Södergård conducted a review in 2008 to identify the practice, education, and research of 
pharmacists in Sweden on adherence to treatment. At the time, no adherence programmes 
were observed in Swedish pharmacies. However, the conclusion drawn by Södergård was that 
practice and education on adherence would change with the re-regulation of the Swedish 
pharmacy market (Södergård, 2008).  
In the year 2013, the Swedish government delegated the Swedish Medical Products Agency to 
perform a feasibility study on structured medicines reviews, to improve adherence to 
prescribed pharmacotherapy. The study was initiated in the year 2014 in patients on 
pharmacotherapy for asthma/chronic obstructive pulmonary disease. Despite this, a drawback 
of this study is that no effect outcome was evaluated (The Swedish Medical Products Agency, 
2014).  
 Thesis approach 1.16
 
This chapter has provided a general introduction to the underlying theory on adherence and 
hypertension management in community pharmacy.  
An inductive approach has been employed in the present thesis, whereby it was generally 
looked at the literature (not systematic) to obtain ideas to formulate the thesis approach, upon 
which the ideas were mind-mapped.  
The general view of the literature provided a conceptual framework on how to conduct the 
pilot study, allowing the first stage of aims and objectives to be developed. It was thought to 
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perform a systematic review and then conduct a pilot study. Furthermore, the findings from 
the specific systematic review allowed a second iteration of the aims and objectives of the 
pilot study. It was clear that the existing ways to establish patients’ likely adherence level 
were inadequate. Consequently, a novel approach to categorise patients according to their 





















 Aims and objectives 1.17
1.17.1 Systematic review 
 
 Aim:  
- to identify and evaluate mixed-method studies including pharmacist-led interventions 
within a community pharmacy setting aimed at blood pressure optimisation in patients 
undergoing oral antihypertensive medication therapy. 
 
 Objectives: 
- assess the outputs from database searches for systematic review inclusion or exclusion 
- summarise the included studies from the perspective of populations, interventions, 
comparators, outcomes and study design (PICOS) 
- assess the risk of bias of included studies with The Cochrane Collaboration’s tool for 
assessing risk of bias 
- calculate effect measures for the included studies 
- critically examine the included studies in the light of populations, interventions, 
comparators, outcomes and study design (PICOS) by performing a thematic analysis  
- assess publication bias by performing a visual inspection of funnel plots and statistical 









I) to assess the feasibility of screening antihypertensive medicine adherence in 
community pharmacy hypertensive patients 
II) to deliver community pharmacist-led interventions targeting adherence status 
according to adherence subgroups to optimise blood pressure (BP) 
 
 Objectives: 
- establish (a) any issues with the adherence screen 
      (b) any indications of outcomes from the allocated interventions  










2 A systematic review of pharmacist-led interventions 
within a community pharmacy setting aimed at 
optimising blood pressure (BP) in patients undergoing 
oral antihypertensive medication therapy 
The systematic review was developed in order the refine the examination of what had been 
done within the research domain of pharmacist-led, community pharmacy-based interventions 
to optimise blood pressure in patients with oral antihypertensive pharmacotherapy. 
 Introduction 2.1
 
Pharmacy practice and policy could possibly be transformed by pharmacist interventions 
being reported in systematic reviews. Appropriate evidence-based interventions may have a 
major role in developing the role of the pharmacist in healthcare (Charrois et al., 2009). The 
undertaking of systematic review and meta-analysis provides a way of gaining a summary 
perspective and judgement on the positive or negative effects and risk of interventions within 
healthcare. However, studies can be of varying quality, raising questions about their impact 
(Liberati et al., 2009). A systematic review employs a scientific approach with a research 
question and inclusion/exclusion criteria which determine studies to be included, assessment 
of study quality from the perspective of bias and outlines the results (Higgins and Green, 
2011; Khan et al., 2011). Quantitative results from individual studies can possibly be 
combined with statistical methods, known as a meta-analysis. Qualitative analysis when 
examining health interventions is emerging and becoming common practice in healthcare 
(Higgins and Green, 2011). Thematic analysis as a qualitative research method examines data 
by identifying, analysing and describing arrangements of data, i.e. described as themes, which 
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are ordered in response to the research question (Braun and Clarke, 2006). Mixed-methods 
approaches apply both qualitative and quantitative analysis in the same study. This latter 
approach provides more strength to available evidence compared to solely conducting either a 
qualitative or quantitative analysis (Tariq and Woodman, 2013). The mixed-methods 
approach has become established in healthcare research (Hadi and Closs, 2015). 
There should be transparent reporting of systematic reviews to facilitate judgements about the 
pros and cons of the studies: this led to the introduction of the quality of reporting of meta-
analysis (QUOROM) statement in 1999. The statement was later updated with the preferred 
reporting items for systematic reviews and meta-analyses (PRISMA). This provides a 
guidance on an open and thorough dissemination of systematic reviews and meta-analyses. 
The participants, interventions, comparators, outcomes and study design (PICOS) approach is 
suggested by PRISMA, which facilitates the reader to obtain major points of significance in 
the systematic review (Liberati et al., 2009).  
The Effective Practice and Organisation of Care (EPOC) Group belongs to the Cochrane 
Review Group. The latter is an international collaboration aiming to make Cochrane Reviews 
available for practice and policy decisions. As such, the EPOC Group focuses on conducting 
systematic reviews for promoting healthcare practice and organisation. Thus, the EPOC 
Group has set requirements and criteria for the undertaking of EPOC systematic reviews 
(Effective Practice and Organisation of Care, 2015; Effective Practice and Organisation of 
Care, 2016).  
There are tools for assessing quality in studies in systematic reviews. Many of these tools 
provide a score to different aspects of quality which will then give a summary score. 
Furthermore, there are tools which are based on checklists with questions. The Cochrane 
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Collaboration in years 2005 to 2007 developed a risk of bias assessment tool which instead 
enabled a domain-specific assessment of the risk of bias. It is difficult to validate the quality 
of assessment tools since the risk of bias assessment includes a subjective measure (Higgins 
and Green, 2011). 
 Research question 2.2
 
What is the scope of pharmacist-led interventions within a community pharmacy setting 
aimed at optimising blood pressure? 
 Rationale 2.3
 
It is thought to be a positive manoeuvre when community pharmacists counsel and intervene 
in patients undergoing antihypertensive treatment. However, it is not known if these 
interventions are positive, negative or have no effect. In addition, the research domain on 
community pharmacist interventions has not been particularly focused on examining the 
participants, interventions, comparators, outcomes and study design. Hence, the present study 
is a systematic attempt to examine this data coupled with a meta-analysis to possibly produce 









A systematic literature review was performed to identify and evaluate mixed-method studies 
of community pharmacist-led interventions within a community pharmacy setting aimed at 




A protocol was created where the research question, aims and inclusion criteria were pre-
specified (Appendix 5.1). The systematic review followed the PRISMA checklist (Liberati et 
al., 2009; Shamseer et al., 2015) and EPOC study design inclusion criteria (Effective Practice 
and Organisation of Care, 2013). As a mixed-methods study design was employed, a 
pragmatic approach to the EPOC study design criteria was sought, though not accommodating 
certain study designs. The reason for following the PRISMA protocol and EPOC criteria was 
that these tools are internationally recognized guidelines for systematic reviews.  
 
 
2.5.2 Eligibility criteria 
 
Participants: 18 years and above, undergoing treatment with minimum one oral 
antihypertensive medicine, with or without co-morbidities, within a community pharmacy 
setting 
Interventions: Interventions in a community pharmacy aimed at optimising blood pressure  
Outcomes: Blood pressure  
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Study design: A mixed-methods approach has been employed to include both qualitative and 
quantitative data. 
2.5.3 Information sources 
 
Searches were performed in the electronic databases Cinahl Plus, Cochrane Database, Embase 
Classic and Embase (1947 to 7 February 2014), Ovid MEDLINE In-Process & Other Non-
Indexed Citations and Ovid MEDLINE® (1946 to 9 February 2014; 16 February 2014), Ovid 
MEDLINE Daily Update (7 February 2014; 14 February 2014 for search term combination 
number 8), Ovid OLDMEDLINE (1946 to 1965) and PubMed. Grey literature was searched 
using Google, LexisNexis and Web of Science. There were no language restrictions in the 
searches. A repeated search was done in the electronic databases and Google during 
September 2016.  
2.5.4 Search 
 
Medical Subject Headings (MESH) search terms were used in accordance to the Medical 
Subject Headings for each electronic database: hypertension; antihypertensive agents; 








2.5.4.1 Electronic databases 
 
The search term combinations used for the electronic databases are stated in sections 2.5.4.1.1 
- 2.5.4.1.5. 
2.5.4.1.1 Cinahl Plus 
 
1. (MH “hypertension”) AND (MH “antihypertensive agents”) AND (MH “pharmacists”) OR 
(MH “pharmacy, retail”) AND (MH ”experimental studies”)  AND (MH “medication 
compliance”) AND (MH “blood pressure”) 
2. (MH “pharmacists”) AND (MH ”antihypertensive agents”) AND (MH “experimental 
studies”) AND (MH “medication compliance”) AND (MH “blood pressure”) 
3. (MH “pharmacy, retail”) AND (MH “hypertension”) AND (MH “experimental studies”) 
AND (MH “medication compliance”) AND (MH “blood pressure”) 
4. (MH “pharmacy, retail”) AND (MH “antihypertensive agents”) AND (MH “experimental 
studies”) AND (MH “medication compliance”) AND (MH “blood pressure”) 
5. (MH “pharmacists”) AND (MH “hypertension”) AND (MH “medication compliance”) 
AND (MH “blood pressure”) 
6. (MH “pharmacists”) AND (MH “antihypertensive agents”) AND (MH “medication 
compliance”) AND (MH “blood pressure”) 
7. (MH “pharmacy, retail”) AND (MH “hypertension”) AND (MH “medication compliance”) 
AND (MH “blood pressure”) 
8. (MH “pharmacy, retail”) AND (MH “antihypertensive agents”) AND (MH “medication 




2.5.4.1.2 Cochrane Database 
 
 
1. hypertension AND antihypertensive agents AND (pharmacists OR pharmacies) AND 
(intervention studies OR pharmaceutical care) AND medication adherence AND blood 
pressure 
2. pharmacists AND antihypertensive agents AND (intervention studies OR pharmaceutical 
care) AND medication adherence AND blood pressure 
3. pharmacies AND hypertension AND (intervention studies OR pharmaceutical care) AND 
medication adherence AND blood pressure 
4. pharmacies AND antihypertensive agents AND (intervention studies OR pharmaceutical 
care) AND medication adherence AND blood pressure 
5. pharmacists AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
6. pharmacists AND antihypertensive agents AND medication adherence AND 
pharmaceutical care AND blood pressure 
7. pharmacies AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
8. pharmacies AND antihypertensive agents AND medication adherence AND 









1. hypertension/ and antihypertensive agent/ and pharmacist/ or pharmacy/ and intervention 
study/ or pharmaceutical care/and medication compliance/ and blood pressure/ 
2. pharmacist/ and antihypertensive agent/ and intervention study/ or pharmaceutical care/ 
and medication compliance/ and blood pressure/ 
3. pharmacy/ and hypertension/ and intervention study/ or pharmaceutical care/ and 
medication compliance/ and blood pressure/ 
4. pharmacy/ and antihypertensive agent/ and intervention study/ or pharmaceutical care/ and 
medication compliance/ and blood pressure/ 
5. pharmacist/ and hypertension/ and medication compliance/ and pharmaceutical care/ and 
blood pressure/ 
6. pharmacist/ and antihypertensive agent/ and medication compliance/ and pharmaceutical 
care/ and blood pressure/ 
7. pharmacy/ and hypertension/ and medication compliance/ and pharmaceutical care/ and 
blood pressure/ 
8. pharmacy/ and antihypertensive agent/ and medication compliance/ and pharmaceutical 








2.5.4.1.4 Ovid MEDLINE 
 
 
1. hypertension/ and antihypertensive agents/ and pharmacists/ or pharmacies/ and 
intervention studies/ or pharmaceutical services/ and medication adherence/ and blood 
pressure/ 
2. pharmacists/ and antihypertensive agents/ and intervention studies/ or pharmaceutical 
services/ and medication adherence/ and blood pressure/ 
3. pharmacies/ and hypertension/ and intervention studies/ or pharmaceutical services/ and 
medication adherence/ and blood pressure/ 
4. pharmacies/ and antihypertensive agents/ and intervention studies/ or pharmaceutical 
services/ and medication adherence/ and blood pressure/ 
5. pharmacists/ and hypertension/ and medication adherence/ and pharmaceutical services/ 
and blood pressure/ 
6. pharmacists/ and antihypertensive agents/ and medication adherence/ and pharmaceutical 
services/ and blood pressure/ 
7. pharmacies/ and hypertension/ and medication adherence/ and pharmaceutical services/ 
and blood pressure/ 
8. pharmacies/ and antihypertensive agents/ and medication adherence/ and pharmaceutical 







1. hypertension AND antihypertensive agents AND pharmacists OR pharmacies AND 
intervention studies OR pharmaceutical care AND medication adherence AND blood 
pressure 
2. pharmacists AND antihypertensive agents AND intervention studies OR pharmaceutical 
care AND medication adherence AND blood pressure 
3. pharmacies AND hypertension AND intervention studies OR pharmaceutical care AND 
medication adherence AND blood pressure 
4. pharmacies AND antihypertensive agents AND intervention studies OR pharmaceutical 
care AND medication adherence AND blood pressure 
5. pharmacists AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
6. pharmacists AND antihypertensive agents AND medication adherence AND 
pharmaceutical care AND blood pressure 
7. pharmacies AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
8. pharmacies AND antihypertensive agents AND medication adherence AND 













 Search performed on April 30th, 2014 on first 20 outputs with search term 
combination number 1. Repeated search on May 9th and May 13th, 2014 on first 100 
outputs. 
 Search performed on May 13th, 2014 with search term combination numbers 2-9 on 
first 100 outputs. 
 Search performed on August 10th, 2014 with search term combination number 10 
on first 100 outputs. 
 
Random search performed in Google:  
 on February 6th, 2015 with search term combination number 11. Repeated search on 
June 4th, 2015 
 on April 13th, 2015 with search term combination number 12. Repeated search on 
June 3rd, 2015 
 on May 24th, 2015 with search term combination number 13  




1. hypertension adherence community pharmacy 
2. hypertension AND antihypertensive agents AND pharmacists OR pharmacies AND 
intervention studies OR pharmaceutical care AND medication adherence AND blood 
pressure 
3. pharmacists AND antihypertensive agents AND intervention studies OR pharmaceutical 
care AND medication adherence AND blood pressure 
4. pharmacies AND hypertension AND intervention studies OR pharmaceutical care AND 
medication adherence AND blood pressure 
5. pharmacies AND antihypertensive agents AND intervention studies OR pharmaceutical 
care AND medication adherence AND blood pressure 
6. pharmacists AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
7. pharmacists AND antihypertensive agents AND medication adherence AND 
pharmaceutical care AND blood pressure 
8. pharmacies AND hypertension AND medication adherence AND pharmaceutical care 
AND blood pressure 
9. pharmacies AND antihypertensive agents AND medication adherence AND 
pharmaceutical care AND blood pressure 
10. hypertension compliance community pharmacy 
11. hypertension community pharmacy 
12. pharmaceutical care blood pressure 
13. blood pressure control pharmacy 






All searches in LexisNexis performed under Sources: All News, All Languages 
 Search performed on March 23rd, 2014 with citations 1-8. 
 Search performed on April 2nd, 2014 with citation 9.  
1. Lau et al., 2010 
2. George et al., 2010 
3. Fikri-Benbrahim et al., 2012 
4. Svarstad et al., 2013 
5. Svarstad et al., 2009 
6. Aguiar et al., 2012 
7. Robinson et al., 2010 
8. Aguwa et al., 2008  
9.  Planas et al., 2009 
2.5.4.2.3 Web of Science 
 
 Search performed on March 23rd, 2014 with citations 1-8. 
 Search performed on April 2nd, 2014 with citation 9.  
 
1. Lau et al., 2010 
2. George et al., 2010 
3. Fikri-Benbrahim et al., 2012 
4. Svarstad et al., 2013 
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5. Svarstad et al., 2009 
6. Aguiar et al., 2012 
7. Robinson et al., 2010 
8. Aguwa et al., 2008 
9. Planas et al., 2009 
2.5.5 Study selection 
 
Studies were selected independently by two reviewers (the author and a Professor of Clinical 
Pharmacy). Any disagreements in study selection were resolved by discussion between the 
two reviewers.  
2.5.6 Data collection process 
 
Searches were performed in the electronic databases and grey literature. Study authors were 
contacted to retrieve additional data or obtain clarification relating to a specific study which 
revolved around whether the full study had been published, the name of authors, study design, 
bias, blood pressure data, data enabling calculation of odds ratio or mean difference. 
2.5.7 Data items 
 
The information which was collected from studies followed the headings Participants, 
Interventions, Comparators, Outcomes, Study Design (PICOS) from the PRISMA protocol 




2.5.8 Summary measures 
 
The effect measures were calculated as odds ratios (OR) with 95% confidence intervals using 
random effects model for dichotomous outcomes, i.e. those studies reporting the proportion of 
patients with controlled and uncontrolled systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) respectively at the end of the study. In the studies were proportions of patients 
were not separately reported for SBP and DBP, both these two outcomes were grouped 
together as a combined outcome and an OR with 95% confidence interval using random 
effects model was calculated. Blood pressure control was interpreted as defined in the 
individual study. Among those studies not reporting data supporting the calculation of an OR, 
the mean difference was calculated using the random effects model based on end study mean 
SBP and mean DBP values (continuous outcomes). All data were derived from results being 
reported as intention-to-treat. Forest plots were created in the software Review Manager 
version 5.3.5 (The Nordic Cochrane Centre, 2014). 
2.5.9 Planned methods of analysis 
 
A measure of consistency for the meta-analysis was performed using the I2 statistic. This 
followed thresholds as stated in the Cochrane Handbook: 0 % to 40%: not important; 30% to 
60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: 





2.5.10 Additional analyses 
 
A narrative, qualitative summary was performed as a thematic analysis according to the 
methodology proposed by Braun and Clarke (2006) (Braun and Clarke, 2006). The studies 
were read through initially to note down initial ideas. During a second phase, the studies were 
re-read with a focus on coding the entire data set. The codes were collated from each study 
and categorized under the headings of Participants, Interventions, Comparators, Outcomes 
and Study designs (PICOS) (Braun and Clarke, 2006; Liberati et al., 2009; Shamseer et al., 
2015). Thematic maps for each heading in PICOS were created based on the occurrence of the 
codes under each heading. The final themes were then created as a summary of the thematic 
maps.  
2.5.11 Risk of bias in individual studies and across studies 
 
The risk of bias was assessed for each included study according to The Cochrane 
Collaboration’s tool for assessing risk of bias. This risk of bias tool was chosen since it was a 
universal tool applied in systematic reviews. Although the risk of bias tool is used to only 
assess the risk of bias in randomized controlled trials, the tool was adapted for use in the 
mixed-methods approach. Where the study design was cluster-randomized, additional risk of 
bias was assessed including the elements recruitment bias, baseline imbalance, loss of 
clusters, incorrect analysis, and comparability of individually randomized trials (Higgins and 
Green, 2011). An overall study risk of bias was evaluated for each paper based on individual 
risk items.  
63 
 
2.5.12 Publication bias 
2.5.12.1 Funnel plots 
 
Publication bias was assessed by the construction of funnel plots using the software Review 
Manager version 5.3.5 (The Nordic Cochrane Centre, 2014). Funnel plots with and without 
grey literature were created for a) odds ratio as an effect estimate of SBP and DBP as a 
combined outcome and b) mean difference as an effect estimate of SBP and DBP 
respectively. Funnel plots were not created for odds ratio of SBP or DBP alone since the 
number of studies were too low to perform the analysis.  
2.5.12.2 Testing for funnel plot asymmetry 
 
Funnel plot asymmetry was tested statistically by performing the arcsine version of the test 
suggested by Rücker and co-workers (Higgins and Green, 2011; Rücker et al., 2008). The 
arcsine-Thompson test suggested by Rücker and co-workers was performed using the R 
statistics meta package on odds ratio as the effect estimate of SBP and DBP as a combined 
outcome (Appendix 5.2) (Rücker et al., 2008; R Core Team, 2016; Schwarzer et al., 2015; 
Schwarzer, 2016). The test was only performed on odds ratio as an effect estimate of SBP and 
DBP as a combined outcome since the Cochrane Handbook suggests there be a minimum of 







2.6.1 Study selection 
 
Identification of 535 records was obtained through searching in the electronic databases. From 
these 535 records, duplicates were removed narrowing the number to 10 records. An 
additional 20 records were identified and screened through grey literature searches in Google, 
LexisNexis and Web of Science resulting in 30 records screened in total. A further 9 records 
were excluded because a non-pharmacy healthcare profession was mainly involved in the 
study, the study design was not exclusively a community pharmacy setting, a high-risk 
cardiovascular population was involved, no blood pressure outcome was recorded, no blood 
pressure results were reported, only an abstract was available, or press releases relating to 
study authors were involved. Twenty-one full-text articles were included in the final 
systematic review. Among these, all 21 studies underwent qualitative synthesis and 13 studies 
included in the quantitative synthesis. See flow diagram in Figure 2.1 illustrating the 










2.6.2 Study characteristics:  Participants, Interventions, Comparators, Outcomes, 
Study Design (PICOS) 
 
The characteristics according to the PICOS classification of the included studies are presented 
in Table 2.1. Among the included studies there is a mixture of papers from different points 
across the timeline starting from the year 1973 onward. In total, there were 21 included 
studies (11 randomized controlled trials (RCTs), 2 before-after studies (BASs), 3 non-
randomised controlled trials (NRCTs), 1 repeated measures study (RMS) and 4 prospective 
cohort studies (PCSs)). Study duration among the studies varied from 3-15 months. Study 
visits to a community pharmacy ranged from weekly to quarterly intervals. In total, there were 
2509 patients who completed the studies. In general, the patients were within the age of 50 to 
60 years. The studies included counselling, BP measurement, referral to/contact with a 
physician, informational materials, reminder aids and diary keeping as interventions. The 




























































































































   























   












   
















   
   
   

























   
   
   
   
























   


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
























   










































































































































































































































































































































































































































































































































































































































































































































































































   
   

























   
   















































































































































































































































































































































































































































































































































































































































































































































































































   























   

















































































































































































































































































































































































































































































































































































































































































































































































































































































   























   


















































































   
   
























   
   


























































































































































































































































































































































































































































































































































































































































































































































































   
   
























   























   
























   

































































































































































































































































































































































































































































































































































































































































































































































































































































































   























   
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   























   


























   
   

























   
   









































































































































































































































































































































































































































































































































































































































































































































































































































































Abbreviations for Table 2.1: 
 
AD=Adherence; ADR=Adverse drug reaction; AH=Antihypertensive; BA=Before and After; BAS=Before and After Study; 
BMI=Body Mass Index; BP=Blood Pressure; CG=Control Group; CKD=chronic kidney disease; COPD=chronic obstructive 
pulmonary disease; CPV=Community pharmacy visits; CV=cardiovascular; DAA=Dose administration aid; DBP=Diastolic 
Blood Pressure; DRP=Drug-related problem; DTP=drug therapy-problem; EAP=Employee Assistance Program for disease 
management; ED=Educational; fin=final BP reading; FQ=Frequency; GP=General Practitioner; HBPM=home blood pressure 
monitoring; HCG=Hidden Control Group; HI=High-intensity; HMR=Home medicines review; IG=Intervention Group; 
ini=initial BP reading; INT=Intervention; LI=Low-intensity; LS=Lifestyle; MNCHP=Model Neighborhood Comprehensive 
Health Program, Inc.; MTM=Medication Therapy Management; MUR=Medication use review; NRCT=Non-randomised 
controlled trial; OC=Patients serve as their own control; PC=Pharmaceutical Care; PCG=Pharmacist Care Group; 
PCS=Prospective cohort study; PE=Physical Exercise; PHCU=primary health care unit; PMP=Patient medication profile; 
QoL=Quality of Life; RCT=Randomised controlled trial; RMS=Repeated measures study; RR=Refill reminder; S-A=Self-
administer; SBP=Systolic Blood Pressure; SCS=Smoking cessation program; SD: Standard deviation; SG=Study group; 
SGr=Subgroup; StDu=Study duration; TABS=Tool for Adherence Behaviour Screening; TG=Test group; UCG=Usual Care 
Group; WB=Witness batch; WSU= Wayne State University employees participating in employer wellness plan 
 
Since the meta-analysis was performed there have been identified 6 extra studies (3 RCTs, 1 
BAS and 2 PCS) (see Table 2.2). Study duration varied from 2 weeks to 9 months. In total 

































































   

























   































































   
   
   

























   
   
   























   
























































































































































































































































































































































































































































































   























   


























































































































































































































































































































































2.6.3 Results of individual studies 
 
A meta-analysis with odds ratios as an effect estimate was performed on 10 out of 21 studies 
with SBP and DBP as a combined outcome. Of 21 studies, 3 studies underwent a meta-
analysis with odds ratios for SBP or DBP outcomes respectively.  
Meta-analysis with mean difference was used as an effect estimate for 7 out of 21 included 
studies analysing both SBP and DBP respectively. 
It was not possible to go forward with meta-analysis throughout all 21 studies because of 
study design or data not being available to support the calculation of effect estimates. 
From Figures 2.2 to 2.6 all studies are relatively small-scale. The more modern studies appear 
to have a larger weighting.  It is important to bear in mind when comparing the Forest plots 
scaling in each figure differ to present the data in an acceptable format.  
 
2.6.3.1 Odds ratio 
 
Examination of the Forest plots in Figures 2.2 to 2.4 shows the mean values for each study are 
in the control group area in the Forest plot with large confidence intervals observed in the 







2.6.3.1.1 Systolic blood pressure (SBP) and diastolic blood pressure (DBP) as a combined 
outcome 
 
Odds ratio as an effect estimate of SBP and DBP as a combined outcome is presented as a 
Forest plot in Figure 2.2. The meta-analysis for SBP and DBP as a combined outcome 
employed a random effects model including 1252 patients where the pooled effect of 0.33 
mmHg increase in BP (95% CI, 0.23 mmHg to 0.47 mmHg, p<0.00001) implies no BP 
change. As seen in Figure 2.2, heterogeneity between studies relating to SBP and DBP as a 

























































































































































































2.6.3.1.2 Systolic blood pressure (SBP)  
 
Odds ratio as an effect estimate of SBP is presented as a Forest plot in Figure 2.3.  The meta-
analysis for SBP employed a random effects model including 263 patients where the pooled 
effect of 0.29 mmHg increase in SBP (95% CI, 0.12 mmHg to 0.72 mmHg, p=0.007) implies 
no SBP change. As seen in Figure 2.3. heterogeneity between studies relating to SBP is 






































































































































































2.6.3.1.3 Diastolic blood pressure (DBP) 
 
Odds ratio as an effect estimate of DBP is presented as a Forest plot in Figure 2.4.  The meta-
analysis for DBP employed a random effects model including 263 patients where the pooled 
effect of 0.28 mmHg increase in DBP (95% CI, 0.04 mmHg to 2.08 mmHg, p=0.21) is 
indicative of no BP change. As seen in Figure 2.4 heterogeneity between studies relating to 









































































































































































2.6.3.2 Mean difference 
2.6.3.2.1 Systolic blood pressure (SBP)  
 
Mean difference as an effect estimate of SBP is presented as a Forest plot in Figure 2.5. The 
meta-analysis for SBP employed a random effects model including 1173 patients where the 
pooled effect is a 9.65 mmHg decrease in SBP (95% CI, -5.34 mmHg to -13.96 mmHg, 
p<0.00001). There is an indication of a positive effect when mean difference is plotted as an 
effect estimate for SBP. As seen in Figure 2.5 heterogeneity between studies relating to SBP 










































































































































































2.6.3.2.2 Diastolic blood pressure (DBP) 
 
Mean difference as an effect estimate of DBP is presented as a Forest plot in Figure 2.6. The 
meta-analysis for DBP employed a random effects model including 1173 patients where the 
pooled effect is a 5.38 mmHg decrease in DBP (95% CI, -1.25 mmHg to -9.52 mmHg, 
p=0.01). There is an indication of a positive effect when mean difference is plotted as an 
effect estimate for DBP. As seen in Figure 2.6 heterogeneity between studies relating to DBP 










































































































































































2.6.4 Additional analysis 
2.6.4.1.1 Thematic analysis 
 
The themes and corresponding sub-themes emanating from the review papers are presented in 
Table 2.3. Interventions, Outcomes and Study design are the most significant: sub-themes 
principally involve Population and Comparators. However, even though certain sub-themes 





Table 2.3. Themes and subthemes from the thematic analysis. Themes are displayed as headings. Bullet points show 
the sub-themes which occur in studies indicated as numbered references. 
Population 
 
 Hypertension [1-21] 
 Patient screening [1-21] 
 Population characteristics [1-21] 
 Therapy [1-8, 10-21]* 
*not in [9] 
Interventions 
 
 Blood pressure [1-21]  
 Pharmaceutical care [1-21] 
 Resources [1-21] 
 Setting [1-21] 
 Staff [1-21] 
 Drug-related problems [1-15, 17-21] 
*not in [16]   
 Non-pharmacological treatment – lifestyle modification [1-17, 19-21] 
*not in [18] 
 Adherence [1-7, 9-16, 18-21] 
*not in [8, 17] 
 Guidelines [2-8, 10-21] 
*not in [1, 9] 
 Training [2, 4-11, 13-15, 17-21]* 
*not in [1, 3, 12, 16] 
 Quality of life [2, 3, 7, 9, 12, 15, 17-19]* 
*not in [1, 4-6, 8, 10, 11, 13, 14, 16, 20, 21] 
 Economy [4, 7, 10, 11, 14, 18, 19, 21]* 




Continuation of Table 2.3 
Comparators 
 
 Control [2-7, 10, 12-15, 17-19]* 
*not in [1, 8, 9, 11, 16, 20, 21] 
 Intervention [3, 5-7, 13, 17, 18]* 
*not in [1, 2, 4, 8-12, 14-16, 19-21] 
 Training [14, 15, 17, 18]* 
*not in [1-13, 16, 19-21]  
Outcomes  
 
 Blood pressure [1-21]  
 Adherence [1-7, 9-16, 18-21]* 
*not in [8, 17] 
 Pharmacotherapy [1, 2, 4-8, 10-15, 17-21]* 
*not in [3, 9, 16]  
 Non-pharmacological treatment – lifestyle modification [1-8, 10-12, 14, 16, 19]*  
*not in [9, 13, 15, 17, 18, 20, 21]   
 Satisfaction with service [3, 4, 7, 10, 11, 14, 17-20]* 
*not in [1, 2, 5, 6, 8, 9, 12, 13, 15, 16, 21]  
 Cardiovascular risk [1, 4, 7, 8, 11-14, 18]* 
*not in [2, 3, 5, 6, 9, 10, 15-17, 19-21]  
 Quality of life [2, 3, 7, 9, 12, 15, 17-19]* 
*not in [1, 4. 5, 6, 8, 10, 11, 13, 14, 16, 20, 21] 
 Perceptions [3, 4, 7, 11, 14, 18, 19]* 
*not in [1, 2, 5, 6, 8, 9, 10, 12, 13, 15-17, 20, 21]  
 Economy [4, 7, 14, 18, 19]* 
*not in [1-3, 5, 6, 8-13, 15-17, 20, 21]   
 Knowledge [3, 10, 11, 16, 17]* 
*not in [1, 2, 4-9, 12-15, 18-21]     
 Health resource usage [7, 21]*  
*not in [1-6, 8-20] 
Study design 
  
 Baseline characteristics [1-21] 
 Data collection [1-21] 
 Recruitment/screening [1-21] 
 Staff [1-21] 
 Study duration [1-21] 
 Barriers [1, 2, 4, 6-11, 13-15, 18-21]* 
*not in [3, 5, 12, 16, 17] 
 Ethics [3-9, 13-21]* 
*not in [1, 2, 10-12] 
 Bias [2-7, 9, 11, 13-15, 18, 19, 21]* 
*not in [1, 8, 10, 12, 16, 17, 20]  
 Funding [1, 2, 5, 8, 11, 13, 15-21]* 
*not in [3, 4, 6, 7, 9, 10, 12, 14] 
 Blinding [3-6, 14, 18, 19, 21]* 
*not in [1, 2, 7-13, 15-17, 20] 
 Intention-to-treat [5, 13, 17-19, 21]* 





Numbered references in Table 2.3: 1. Aguiar et al., 2012; 2. Aguwa et al., 2008; 3. Carvalho and Nagavi, 2007; 4. Chabot et 
al., 2003; 5. Fikri-Benbrahim et al., 2012; 6. Garção and Cabrita, 2002; 7. Hughes et al., 2002; 8. Júnior et al., 2008; 9. Lai, 
2007; 10. McKenney et al., 1973: 11. Nemerovski et al., 2013; 12. Octavia and Florica, 2011; 13. Planas, et al., 2009; 14. 
Pojskic et al., 2014; 15. Robinson et al., 2010; 16. Sharma et al., 2014; 17. Skowron et al., 2011; 18. Stewart et al., 2014; 19. 
Svarstad et al., 2013; 20. Taylor et al., 2003; 21. Zillich, et al., 2005 
 
2.6.5 Risk of bias within studies 
 
Risk of bias within the included studies with the dimension of bias (entry), the assessment of 
risk of bias (judgement) and the evidence for the assessment (support for judgement) with 
quotes and comments is presented in Table 5.1 in Appendix 5.2. 
Risk of bias across studies is shown in Table 2.4. The overall risk among most of the studies 













Table 2.4. Risk of bias across studies: an overall risk of bias assessment for each included study based on the risk of bias 
judgements made within the individual domains of The Cochrane Collaboration’s tool for assessing risk of bias (see Table 




McKenney et al., 1973 Unclear risk 
Hughes et al., 2002 Unclear risk 
Garção and Cabrita., 
2002  Unclear risk 
Taylor et al., 2003 High risk 
Chabot et al., 2003 Unclear risk 
Zillich et al., 2005 High risk 
Carvalho and Nagavi, 
2007 Unclear risk 
Lai, 2007 High risk 
Aguwa et al., 2008 High risk 
Júnior et al., 2008 Unclear risk 
Planas et al., 2009 Unclear risk 
Robinson et al., 2010 High risk 
Octavia and Florica, 
2011 Unclear risk 
Skowron et al., 2011 Unclear risk 
Aguiar et al., 2012 High risk 
Fikri-Benbrahim et al., 
2012 High risk 
Nemerovski et al., 2013 Unclear risk 
Svarstad et al., 2013 Low risk 
Pojskic et al., 2014 
(Pojskic, 2014a) High risk 
Stewart et al., 2014 Low risk 






2.6.7 Publication bias 
 
A comparison of funnel plots based on effect estimates odds ratio and mean difference 
respectively with and without grey literature is demonstrated in this section.  
2.6.7.1 Odds ratio: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) as a 
combined outcome 
2.6.7.1.1 Visual interpretation of the funnel plot including grey literature 
 
Figure 2.7 displays a funnel plot based on odds ratio as an effect estimate of SBP and DBP as 
a combined outcome. Grey literature has been included the funnel plot. Visual inspection is 
suggestive of a funnel, but there is also clear asymmetry on the right-hand side. Consequently, 
the visual interpretation indicates publication bias is less likely to be present.  
 
 
Figure 2.7. Funnel plot based on odds ratio as an effect estimate of SBP and DBP as a combined outcome. Grey literature 
has been included this funnel plot. Visual inspection is suggestive of a funnel, but there is also clear asymmetry on the right-
hand side. Thus, this indicates publication bias is less likely to be present. 
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2.6.7.1.2 Statistical analysis of funnel plot asymmetry 
 
The statistical analysis of funnel plot asymmetry shows a significant result (t=2.82, df=9, 
p=0.020) indicating asymmetry when grey literature is included the funnel plot. 
 
2.6.7.1.3 Visual interpretation of the funnel plot excluding grey literature 
 
Figure 2.8 demonstrates a funnel plot based on odds ratio as an effect estimate of SBP and 
DBP as a combined outcome. Grey literature has been excluded the funnel plot. Visual 




Figure 2.8. Funnel plot based on odds ratio as an effect estimate of SBP and DBP as a combined outcome. Grey literature 
has been excluded this funnel plot. Visual interpretation is indicating a funnel, but clearly, there is asymmetry because there 
are only four studies. Excluded grey literature consists of McKenney et al., 1973; Garção and Cabrita., 2002; Hughes et al., 
2002. Low INT; Chabot et al., 2003. High income group; Skowron et al., 2011; Pojskic et al., 2014.  
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2.6.7.2 Mean difference 
2.6.7.2.1 Systolic blood pressure (SBP)  
2.6.7.2.1.1 Visual interpretation of the funnel plot including grey literature 
 
Figure 2.9 displays a funnel plot based on mean difference as an effect estimate of SBP. Grey 
literature has been included the funnel plot. Visual inspection is suggestive of a funnel, but 
there is also asymmetry. This indicates publication bias is less likely to be present.  
 
 
Figure 2.9. Funnel plot based on mean difference as an effect estimate of SBP. Grey literature has been included this funnel 
plot. There is a suggestion of a funnel, but there is also asymmetry. Consequently, there is an indication of publication bias 





2.6.7.2.1.2 Visual interpretation of the funnel plot excluding grey literature 
 
Figure 2.10 demonstrates a funnel plot based on mean difference as an effect estimate of SBP. 
Grey literature has been excluded the funnel plot. Visual inspection is indicating a funnel, but 
clearly, there is asymmetry because there are only three studies.  
 
 
Figure 2.10. Funnel plot based on mean difference as an effect estimate of SBP. Grey literature has been excluded this funnel 
plot. Visual inspection is indicating a funnel, but clearly, there is asymmetry because there are only three studies. Excluded 
grey literature consists of Garção and Cabrita., 2002; Hughes et al., 2002. High and Low IG; Octavia and Florica, 2011; 




2.6.7.2.2 Diastolic blood pressure (DBP)  
2.6.7.2.2.1 Visual interpretation of the funnel plot including grey literature 
 
Figure 2.11 displays a funnel plot based on mean difference as an effect estimate of DBP. 




Figure 2.11. Funnel plot based on mean difference as an effect estimate of DBP. Grey literature has been included this funnel 




2.6.7.2.2.2 Visual interpretation of the funnel plot excluding grey literature 
 
Figure 2.12. demonstrates a funnel plot based on mean difference as an effect estimate of 
DBP. Grey literature has been excluded the funnel plot. Visual inspection is suggestive of 
funnel plot asymmetry when excluding grey literature.  
 
 
Figure 2.12.  Funnel plot based on mean difference as an effect estimate of DBP. Grey literature has been excluded this 
funnel plot. Visual inspection is suggestive of funnel plot asymmetry. Excluded grey literature consists of Garção and 





This systematic review came about recognizing the need to identify and evaluate mixed-
method studies on community pharmacist-led interventions within a community pharmacy 
setting aimed at blood pressure optimisation in patients undergoing oral antihypertensive 
medication therapy. The formulation of a structured question is a recommended pathway to 
conduct a systematic review (Khan et al., 2011). In contrast to what is somewhat considered a 
norm in the undertaking of systematic reviews, the present systematic review employed a 
mixed-method approach aiming to capture the evidence base in its entirety regardless of study 
design. Hadi and co-workers (2014) pinpoint that mixed-methods research would have a 
positive impact on pharmacy practice research (Hadi et al., 2014). To date and to what is 
known, this is the first comprehensive systematic review to have been undertaken within the 
current research domain using such an approach. Hence, this carries a risk in that there are 
studies containing a high risk of bias which could undermine the quality of the systematic 
review. Despite this, the present systematic review was primarily a scoping exercise 
constructed to explore the availability of evidence within the research domain.  
2.7.1 Study selection process 
 
Five different electronic biomedical databases were selected in which there was a varying 
quantity of search outputs, despite carefully selected MESH search term combinations 
tailored in accordance to each database. Interestingly, the grey literature provided a larger 
amount of records for screening compared to electronic databases.  
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Overall, the systematic review generated 21 studies for inclusion, a number which is moderate 
considering the time-scale since 1973. This could possibly reflect the change the pharmacist 
profession has undergone from preparation and dispensing of medications to working with 
patients in a pharmaceutical care perspective (Van Wijk et al., 2005). 
2.7.2 Summary of the evidence 
2.7.2.1 Participants 
 
First and foremost, the patient screening process being the initial phase of the study is vital to 
recruit patients with the characteristics of interest. As studies have been performed on 
different ethnic groups, patients with differing socio-economic status, patients with 
comorbidity and a wide age span among patients of 50 or 60 years, the question remaining is 
how to screen patients in a standardized way to provide an individually tailored approach to 
the community pharmacy service. Thus, one approach could involve the creation of an 
algorithm in the context of patient characteristics, screening and recruitment process to 
establish which subsets of patients should be recruited in the light of a likely benefit from 
community-pharmacist-led intervention/s.  
Secondly, across the time-scale from the older studies to the modern ones, there appears to be 
a trend towards inclusion of a larger number of patients in studies. Likewise, there is a 
varying number of patients completing the studies which is a known hurdle in clinical trials - 
to retain patients throughout the study. Indeed, this infers again that attention should be paid 
toward the screening process of patients at recruitment, to maximize the possibility of keeping 
the patients until study completion. A viable complementary approach to self-referred patients 
would be physician referral of patients to the community pharmacy service. 
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Thirdly, the finding that the pharmacotherapy sub-theme was not mentioned in any included 
studies inhibits knowledge of the pharmacotherapeutic factors contributing to blood pressure 
control, e.g. drug class, monotherapy, polypharmacy, duration of antihypertensive medication 
therapy. Indeed, apart from the pharmacotherapeutic data available at the community 
pharmacy, after obtaining the patient’s consent, the community pharmacist/researcher should 
seek assistance from the physician to confirm relevant patient characteristics and 
pharmacotherapeutic data enabling the delivery of patient-centred and tailored intervention/s. 
The researcher/clinician approaching the patient during the screening/recruitment process will 
undoubtedly raise an awareness in the patient and may act as an intervention itself which 
potentially could be a Hawthorn effect. This is recognized in an Australian study by Bajorek 
and co-workers (2016) as BP measurement was performed as part of the patient screening 
process. The screening process could even have restricted patient recruitment (Bajorek et al., 
2016). However, it is worthwhile to note that whilst this could have an impact on study 
results, it may be difficult in certain situations to avoid the BP measurement step of the 
patient screening process. What is more important is there being a setup in studies to evaluate 
potential covariates.  
2.7.2.2 Interventions 
 
To begin, the interventions among the studies consisted of referral to/contact with a physician, 
informational materials, counselling, BP measurement, reminders and diary keeping. In fact, 
the interventions appear to be applied generally to the hypertensive population, without 
acknowledgment of the highly individual attitude to drug-based therapies and which 
intervention is responsible for the blood pressure outcome. Among the studies in the present 
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systematic review, there is a complexity of interventions. In general, this agrees with a 
conclusion drawn in the year 2014 Cochrane review by Nieuwlaat and co-workers. 
Interventions to improve adherence to medications in a set of different medical conditions was 
investigated by an analysis of RCTs. The authors mention the steps of improving adherence to 
chronic medical conditions is currently complex (Nieuwlaat et al., 2014). In addition, the 
results from the meta-analysis of the current systematic review show that interventions do not 
produce any or only a minor positive effect. Thus, based on the evidence in the present 
systematic review, there is a need for standardization of interventions.   
A systematic review was conducted by the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) on interventions aiming at improving antihypertensive 
medication adherence in patients with essential hypertension. Publications ranging from the 
year 1979 to 2009 with various interventions and modes of delivering the interventions, as 
well as in various settings were included in their review. The authors bring forth several 
noteworthy limitations in studies aimed at improving antihypertensive medication adherence: 
interventions not being based on the determinants of non-adherence, not a proper description 
of the interventions, lack of consistency in adherence measurement, absence of studies 
relating antihypertensive medication adherence to blood pressure control, improper reporting 
of blood pressure and adherence. However, the authors mention that interventions which 
target medication knowledge among patients are likely to be clinically meaningful with 
regards to improving antihypertensive medication adherence. Nevertheless, it is unclear if this 
would result in blood pressure control. The authors also discuss there were some studies 
which included many interventions. In this situation, it is not clear whether a combination of 
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interventions or a single intervention leads to the positive outcome (Gwadry-Sridhar et al., 
2013). 
A Cochrane review by Schroeder and colleagues from 2004 aimed to assess the extent of 
different interventions in improving adherence to antihypertensive medications. The authors 
reviewed 38 RCTs including 58 different interventions in adult patients with hypertension in 
ambulatory care settings. They concluded that simplifying the dosing regimen is 
recommended as the primary step to improve adherence, although its effect on blood pressure 
outcome was not investigated. By contrast to the review by Gwadry-Sridhar and co-workers 
in 2013, educating the patient is not a promising strategy to optimising adherence. However, 
it is noted that because of the poor quality of included studies, their results should be 
interpreted with caution (Schroeder et al., 2004).  
A Cochrane review from 2010 by Glynn and co-workers studied the effectiveness of 
interventions aimed at improving blood pressure control in hypertensive patients in 
ambulatory settings. Again, educational interventions alone were not successful, this time 
regarding achieving blood pressure control (Glynn et al., 2010).  
Furthermore, the outcome of the thematic analysis shows that an appropriate level of 
community pharmacist competence is required when delivering interventions to hypertensive 
patients. It is vital that preparation of community pharmacists prior to delivering interventions 
is properly defined. Bajorek and co-workers (2015) evaluated a training programme preparing 
17 community pharmacists for hypertension management. The study showed that simulated 
and inter-professional training using different methods was effective. However, training could 





From the time of the first study included in this systematic review, (1973) onward, the RCT 
was progressively introduced into community pharmacy research which included intervention 
and control groups. This type of comparison now dominates the evidence base. On a positive 
note, this brings about good study quality since RCT’s will provide the lowest risk of bias. 
Another approach being taken is through a partition of intervention and control groups into 
subgroups when the groups possess variables of interest to be compared. Thus, this is a 
positive move toward individualized approach since BP outcomes may vary between different 
subsets of patients. By contrast, there are some studies which use a before-and-after study 
comparison which may increase the risk of bias, ultimately resulting in poor study quality 
(Khan et al., 2011; Wiffen et al., 2012).  
2.7.2.4 Outcomes 
2.7.2.4.1 Blood pressure (BP) outcome 
 
First, the blood pressure outcome among the studies is highly variable reflecting the 
differences in study design. Indeed, the present meta-analysis shows conflicting outcomes 
depending on the mode of calculating effect estimates; either there is no effect or an 
intimation of a positive effect on blood pressure. This makes it valuable to bear in mind that 
an elongated positioning of the studies is obtained when plotting mean differences in 
comparison to only plotting odds ratios. Despite this, the contribution of some patients may be 
experiencing a mild degree of a white-coat effect could be making the blood pressure values 
not as optimal as they could be. Explanations to the outcome of the meta-analysis can be 
traced back to two possible factors: a) many of the pharmacy interventions relating to usage of 
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medicines are simplistic and as such do not work bearing in mind that some manoeuvres 
which community pharmacists take with a good intention could make matters worse and/or b) 
the quality of some studies is low, ultimately resulting in poor results. It is not thought that the 
identification of extra studies since the meta-analysis was performed in the present systematic 
review will change the direction of the meta-analytic outcome since the BP results in these 
extra studies are highly variable. 
Secondly, it would appear that previous research is based on the premise that intervention/s 
lead to positive outcome/s. A systematic review by Cheema and co-workers (2014) reviewed 
community pharmacist-led interventions in blood pressure control, concluding that such 
actions provide a clinically important contribution to hypertension management (Cheema et 
al., 2014). The authors’ approach of only including studies with randomized controlled design 
restricts the acquisition of the full evidence base within the research domain of community 
pharmacist-led interventions in optimizing blood pressure making it difficult to ensure 
comparability of BP outcome with the present systematic review.  
Santschi and co-workers (2014) performed a meta-analysis by joining two previous 
systematic reviews. The analysis consisted of 39 RCTs with 14224 patients. The authors 
concluded that pharmacist interventions improved the management of BP. However, there 
was a spectrum of the efficacy of the interventions ranging from no effect to a large effect on 
BP. In addition, the analysis also included studies with study settings other than community 
pharmacy and in collaboration with other members of the healthcare team. Moreover, there 
was a substantial heterogeneity in BP between studies (Santschi et al., 2014).  
Morgado and co-workers (2011) conducted a literature review and meta-analysis to evaluate 
the impact of pharmacist-led interventions on antihypertensive medication adherence and 
108 
 
blood pressure reduction. The review included 15 studies with different study designs 
including 3280 patients in total. Again, this review also included studies performed outside of 
a community pharmacy setting. Interventions which improved antihypertensive medication 
adherence resulted in significantly lowered BP. Furthermore, the authors noted that most 
interventions resulting in improved adherence were complex. The meta-analysis was 
performed on 8 studies including 2619 patients showing significant improvements in SBP, 
DBP and achieving BP control (Morgado et al., 2011).  
In fact, the present systematic review shows there currently is no proper evidence to support 
the premise in earlier research of intervention/s leading to positive outcome/s. Therefore, 
interventions may have no impact or even a negative impact. 
Thirdly, study settings other than community pharmacy is recurrent. This is also the case in 
the systematic review by Stewart and colleagues (2015) in which there were studies which 
had a focus on cardiovascular disease programs especially with relevance to antihypertensive 
medication adherence or persistence (Stewart et al., 2015). The method and location of BP 
measurement should be precise as this may have an impact on varying BP results, i.e. when 
BP is measured by a community pharmacist, another member of health care staff or the 
patient alone by home blood pressure measurement.   
2.7.2.4.2 Other outcome measures 
 
The evidence base points to an array of outcome measures. Thus, in some circumstances 
measuring several variables causes confusion into which target outcomes researchers intend to 
explore and what implications these outcomes would have on community pharmacy practice. 
The inclusion of non-pharmacologic treatment as an intervention should not be 
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underrepresented as this is a complement to the pharmacotherapeutic approach. However, 
researchers should instead be rigid in the choice of outcome measures with relevance to the 
development of a community pharmacy-based service. Previous systematic reviews, in 
general, support the evaluation of the economic aspect/cost-effectiveness of interventions 
(Glynn et al., 2010; Schroeder et al., 2004) Moreover, the evidence base lacks the assessment 
of attitudes to antihypertensive medication adherence as attitudes form an integral part of 
determining adherence, thus resulting in BP control. Further investigation is warranted into 
the impact of the community pharmacy interventions on quality of life of hypertensive 
patients. Future studies should ensure use of validated data collection tools for the purposes of 
obtaining reliable data.  
2.7.2.5 Study design 
 
The measures of consistency indicate the existence of heterogeneity between the included 
studies. Indeed, a large portion of the studies in the present systematic review are not well-
designed. Study durations between 3-15 months and a varying frequency of study visits to the 
community pharmacy do not provide a clear picture of what is a standardized period of 
investigation or frequency of community pharmacy visits. Information on barriers 
surrounding current designs is lacking. Barriers should be highlighted to facilitate the 
development of improved study designs. Consequently, current designs are overly 





2.7.3 Risk of bias 
 
There are studies in the present systematic review which are clearly at high risk of bias of 
which we cannot base practice and policy on. However, there are studies which are assessed 
to be unclear in risk: this type of evidence makes it difficult to plan policy since there is no 
evidence available to support the judgement. This renders studies in the present systematic 
review with unclear risk of bias to be suspect.  
In addition, the thematic analysis has provided an indication of control groups not solely 
receiving usual care. The methodological approach of interventions being delivered to a 
control group during an ongoing study or towards study completion could possibly result in 
the advent of bias. 
Moreover, the process of blinding patients in research on systems involving pharmaceutical 
interventions is not always achievable (Machado et al., 2007; Morgado et al., 2011; 
Mossialos et al., 2013). Thus, non-blinding of patients increases the likelihood of bias in 
studies. It can be inferred that standardising the study design will inherently reduce bias. In 
general, this proposition is supported by Nieuwlaat and co-workers, 2014 who indicated bias 
can be reduced by applying appropriate study designs (Nieuwlaat et al., 2014).   
2.7.3.1 The Cochrane Collaboration’s tool for assessing risk of bias versus other quality 
assessment tools 
 
There exist various tools to assess bias in studies: older tools usually provide a summary score 
of bias for the study examined. The summary score method is simple in its approach. 
However, there have been raised issues concerning the summary score approach since it has 
been found to be inconsistent. Furthermore, such inconsistency causes an issue when bias is 
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being assessed in non-RCT studies. As such, The Cochrane Collaboration’s tool for assessing 
risk of bias instead utilises a domain-specific approach to bias which includes a degree of 
flexibility when assessing the risk of bias without the requirement of providing a number to 
bias (Katikireddi et al., 2015).  
The Cochrane Collaboration’s tool for assessing risk of bias was employed in the present 
systematic review. Although this tool was constructed and validated for use in RCTs, the 
present systematic review did not restrict its use of this tool solely to RCTs. Being aware that 
there is an immediate high risk of bias in a non-RCT when using the tool, it really provides no 
reason not to be able to extend assessment for application into other study designs, even 
though there exist specific tools to assess bias in non-RCT studies such as the Risk Of Bias In 
Non-randomized Studies - of Interventions (ROBINS-I tool) (Sterne et al., 2016). Using 
different types of risk of bias assessment tools in the same systematic review would possibly 
provide non-comparable assessments between studies in the mixed-methods approach. 
Consequently, The Cochrane Collaboration Tool for risk of bias assessment was incorporated 
into the mixed-methods design. 
2.7.3.2 Publication bias and funnel plot asymmetry 
 
Visual interpretation of the funnel plots shows the presence of funnels and/or asymmetry in 
the funnels. However, the statistical test for assessing funnel plot asymmetry indicates 
asymmetry. It is known that visual interpretation of funnel plots is subjective. Hence, there is 
a possibility that there are reasons other than publication bias which could possibly explain 
the contrasting outcomes of the visual interpretation of the funnel plots and the statistical 
analysis of funnel plot asymmetry. In the literature, there have been suggested potential 
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reasons such as poor methodological quality, heterogeneity between studies and chance itself 
(Higgins and Green, 2011). Nevertheless, the importance of grey literature screening when 
performing a systematic review cannot be underestimated. The screening facilitates the 
retrieval of as many studies as possible which may reduce the risk of publication bias.  
2.7.4 Limitations 
 
The database searches retrieved certain outputs which were ostensibly very interesting but 
unfortunately did not meet the inclusion criteria for the systematic review. An example of this 
is seen in the paper by Blenkinsopp and co-workers which did not report any clinical values to 
substantiate adherence (Blenkinsopp et al., 2000). This is particularly disappointing with a 
condition such as hypertension, where there is a very clear relationship between the clinical 
markers, i.e. blood pressure and adherence itself. Amariles and co-workers in 2012 performed 
a study which included a community pharmacy-based pharmaceutical care process referred to 
as the “Dader Method” (Amariles et al., 2012). Although an interesting process, their study 
included a high-risk cardiovascular population not being representative for the present 
systematic review.  
Some studies did not report data or consisted of a study design which did not make it possible 
to include the studies in the effect estimates calculations. Therefore, the present meta-analysis 
was narrowed to be performed on 13 out of 21 studies. When contact information was 
available for the author/s, attempts were made to contact the author/s to obtain supporting data 
to enable the calculation of the effect estimate, though this approach was not always 
successful. Because of this, it is of importance that when possible, data that is required to 
enable the calculation of effect estimates are reported.  In some included studies, proportions 
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of patients were not separately reported for SBP and DBP. It might be argued that treating the 
outcomes SBP and DBP separately might be more robust, but since there was not much data, 
it was better to calculate something from the available data. The expectation is that SBP and 
DBP would increase or decrease in a linked manner. Rare exceptions to this aspect exist. 
However, the exceptions were unlikely to be met. 
The analysis of funnel plot asymmetry could have been more robust: there was not sufficient 
data to create funnel plots for odds ratio of SBP and DBP respectively. Criteria for the 
statistical analysis of funnel plot asymmetry for continuous outcomes did not allow analysis 
of the funnel plot based on mean difference as an effect estimate of SBP or DBP.   
Since the present study employed a mixed-methods approach, targeting the EPOC study 
design criteria in a pragmatic way was not always applicable to certain studies. There exists 
no structure such as PRISMA for reporting of research utilizing a mixed-methods approach 
(Hadi et al., 2014). However, the studies in the present systematic review which did not fully 
adhere to the EPOC study design criteria and/or PRISMA protocol have been indicated in the 
results section and it is considered that this limitation will not have an impact on the 
quantitative and qualitative outputs of this systematic review.  
 Conclusion 2.8
 
In conclusion, the evidence-base is not consistent on community pharmacist-led interventions 
which optimise blood pressure in patients undergoing oral antihypertensive medication 
therapy. A clear strategy to target patients who will likely have a benefit from the community 
pharmacy service is required. This could be facilitated by physicians referring patients to the 
community pharmacy as a complement to patient self-referral. A collaboration between the 
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community pharmacist and physician could contribute to confirming relevant clinical 
parameters in the patient. 
Generic interventions for optimizing BP are being applied to the hypertensive patient 
population. In addition, together with previous systematic reviews aimed at improving blood 
pressure in hypertensive patients, it is clear from the evidence base of the present systematic 
review that there exists a multiplicity of interventions which are overly complex and do not 
indicate the effectiveness of different interventions. Blood pressure outcomes of the 
interventions do not point to a positive outcome. It is possible that certain interventions could 
result in no effect on BP or possibly even have a negative impact on BP. In addition, 
recommendations for interventions that are most appropriate under different circumstances is 
needed in future studies. Thus, ensuring a patient-centred approach by individually tailored 
interventions would pave the way for the provision of high-quality studies. 
The existence of an array of study outcomes made it difficult to focus on what researchers 
wanted to achieve to develop an effective community pharmacy-based service. New well-
designed studies providing evidence on outcomes at both community pharmacy and the 
patient level is required. Also needed is a standardized methodology with randomized 
controlled study design together with the standardisation of interventions. These measures 
would increase the likelihood of minimizing bias making it possible to form a solid 






3 A pilot study evaluating the impact of community 
pharmacist-led interventions to optimize 
antihypertensive medicines adherence 
The findings from the general literature and systematic review were refined into the 
experimental methodological approach in this pilot study to evaluate the adherence 
subgroups. 
 Introduction 3.1
3.1.1 Pharmaceutical care service 
 
The pharmacy profession has changed since the introduction of clinical pharmacy in the 
1980s. The view has become more toward safe, effective, rational and individualizing therapy 
to the patient. Evolving technology has also resulted in a change in community pharmacy 
with examples such as mail-order and internet (Allen Jr et al., 2012). As the science of 
medication emerges and becomes more complex, an adequate number of community 
pharmacists with a specific level of knowledge is needed. The pharmacist is the logical choice 
to provide pharmaceutical care (Cipolle et al., 2012, Puspitasari et al., 2016). The human 
lifespan continues to increase resulting in polypharmacy as chronic illnesses evolve. 
Likewise, the number of prescribers is increasing. Thus, it is not foreign to understand this 
complexity leading to drug-related problems. At the patient level, the occurrence of drug-
related problems and non-adherence reflect that medications are not properly managed. Here 
medication management has an essential role (Cipolle et al., 2012). 
The concept of medication management is seen from two perspectives: the prescription-
centred approach or a patient-centred approach. The latter is separated from the dispensing 
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process (Cipolle et al., 2012). Disease state management forming the patient-centred approach 
looks at improving adherence to treatment for the individual patient. This encompasses 
planning in collaboration with patients and other healthcare staff, communication with the 
physician and documentation of the management of disease (Allen Jr et al., 2012).  At the 
same time, the shift from the dispensing process and supplication of other pharmacy products 
to offering pharmaceutical care services presents its own challenges (Puspitasari et al., 2016). 
An attempt by the WHO has been made to provide guidance on investigations relating to a 
pharmacist-led, community pharmacy-based hypertension management program. The 
EuroPharm Forum and WHO CINDI Programme in 2005 produced a guidance document on 
pharmacy-based hypertension management. The reason is to increase blood pressure control 
in the community by including pharmacists to prevent, detect and manage hypertension. 
Continuous documentation of the activities and evaluation of the project are included (WHO, 
2005). Despite this, the guideline does not recognize that patients have individual attitudes to 
therapy. Consequently, the outcome may not be the same in patients who receive the generic 
intervention.  
3.1.2 Study design 
 
The before-and-after study design is commonly used in pharmacy practice research. Data 
collection is performed on variable/s at baseline and at follow-up after the intervention. 
Following this, the before and after data is compared. Despite the study design is simplistic, 
there is no inclusion of a control group making it difficult to know if the changes are caused 
by the intervention or if confounding factors are involved. At the same time, the data 
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collection can be designed to confirm if other factors are involved in producing change 
(Smith, 2002; Tsuyuki et al., 2014). 
A feasibility or pilot study provides an investigation on the efficacy and practical aspects of a 
study before going on to conducting a larger trial. Thus, any issues in the small-scale study 
can be captured and hopefully rectified before deciding to proceed with a larger study. In 
pharmacy research, it is common to employ triangulation. This will from different angles 
relate the study aims and objectives or validity of data to the combined use of various paths, 
methods and/or data within the same research investigation. Each single method used in 
triangulation will have its own pros and cons (Smith, 2002; Smith, 2010). 
 Methods 3.2
3.2.1 Research proposal 
 
The original research proposal for this pilot study is found in Appendix 5.4. 
3.2.2 Ethical approval 
 
Ethical approval for this study was obtained from Regional Ethical Review Board in Uppsala, 
case number 2013/017 (Appendix 5.5). 
3.2.3 Study design 
 
This pilot study was an open-label, prospective, longitudinal before-and-after study of six-
month duration with patients being their own control conducted in a single community 




3.2.4 Patient recruitment 
 
Patients aged 18 and above, who had been prescribed at least one antihypertensive agent or 
fixed combination of antihypertensive medications, for at least 3 months were recruited. All 
participants could understand, write and speak Swedish. Medication refills were completed at 
the study pharmacy throughout the duration of the study. Patients who were not self-
administering medicines or those participating in other clinical studies were excluded from 
the present investigation. 
Patients presenting with prescriptions for antihypertensive agents were approached 
sequentially and were provided with the study patient information leaflet (Appendix 5.5) and 
invited to participate. They were given at least 24 hours to consider participation. If they 
expressed interest to participate, an appointment with the study pharmacist at the community 
pharmacy was done during which opportunity to ask questions about the study was given and 
they were asked to complete and sign a consent form (Appendix 5.6). This appointment also 
served as the baseline visit. 
On entry into the study, each participant was assigned an individual three-digit participant 
code to anonymize data. Patient information was stored electronically protected by TrueCrypt 
data encryption technology.  
3.2.5 Study visits 
 




3.2.5.1 Visit 0 (Baseline visit) 
 
At the 40-minute baseline visit in the community pharmacy, participants completed an 
assessment of attitudes to antihypertensive medication adherence. This was performed 
through a triangulated approach using self-reported Morisky Medication Adherence Scale (8-
item MMAS - in Swedish translation obtained from the original author), Medication 
Adherence Report Scale (MARS), and Belief about Medicines Questionnaire (BMQ). The 
latter 2 questionnaires were in Swedish translation with both forward and back translation 
approved by its original author (Holt et al., 2012; Horne et al., 1999; Krousel-Wood et al., 
2009; Lehane and McCarthy, 2007; Mahler et al., 2010; Morisky et al., 2008; Mårdby et al., 
2007; Ramanath et al., 2012).  
Seated pulse, systolic and diastolic blood pressure measurements were made following 5 
minutes’ rest (Mancia et al., 2007; O’Brien et al., 2005; The British Hypertension Society, 
2012). Measurements were made using a clinically validated electronic blood pressure 
monitor (model 705 IT OMRON HEALTHCARE Co., Ltd. Kyoto, Japan) and 3 readings 
were made to check for conformity (The British Hypertension Society, 2012; The British 
Hypertension Society, 2016). It is considered the patient was most relaxed during the last 
repeat blood pressure measurement. The participant was informed about the results from the 
blood pressure and pulse measurement. 
3.2.5.2 Visit 1 (Interventions) – 3-months from baseline 
3.2.5.2.1 Adherence screening questionnaire scoring 
 
The scale scoring for the questionnaires was performed in accordance with instructions from 
the original authors. Low adherence on the 8-item MMAS was considered as a scale score of 
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<6, medium adherence 6 to <8, and high adherence at the maximum 8-item MMAS score of 
8. Ranges of the adherence scale score and adjusted mean score in the MARS questionnaire 
were between 5-25 and 1-5 respectively. For the BMQ, each of the four subscales could have 
a scale score range of 1-5.  
Participants were allocated into one of four adherence groups: adherent (A), intentional non-
adherent rational (IR), intentional non-adherent irrational (II) and unintentional non-adherent 
(U). However, as the categorization of patients progressed, it became apparent that a small 
number of patients could be allocated to two adherence subgroups simultaneously. 
 
3.2.5.2.2 The adherence subgroup categorization process 
 
Patients were assigned to the A subgroup when maximum adherence scores were obtained on 
both the 8-item MMAS and MARS. Both the MARS and 8-item MMAS consist of questions 
dealing with intentional and unintentional non-adherence. Moreover, these questions can be 
categorized from the perspective of rationality or irrationality. Figures 3.1 to 3.3. set out a 
schematic illustration on how the questionnaires used during the adherence screening enabled 
adherence subgroup categorization. 
Suspicions of non-adherence were always considered when the scores on the 8-item MMAS 
and MARS were below maximum. In these circumstances, the study pharmacist reviewed 
questionnaire responses to identify where the patient had provided answers that reduced the 
adherence score. These questions were then categorized as intentional or unintentional non-
adherence. The set thresholds in questionnaire scores for the adherence subgroup 
categorization process were based on intuition. Consequently, the occurrence of the 
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intentional versus unintentional non-adherence among these questions determined if the 































































































































































































































































































































































Figure 3.2. Categorization of MARS responses into sub-types of adherence. Codes before each statement indicate the 
numbering of the statement in the MARS questionnaire. The categorization into intentional non-adherent irrational (II) or 
unintentional non-adherent (U) adherence sub-types was based on the responses the patient provided in the questionnaire. 
 
For example, the patient may have responded that they had forgotten to take their blood 
pressure medication and that taking medication caused the patient to worry. This indicated 
unintentional non-adherent behavior resulting in allocation to the U subgroup.  
The division into rational or irrational was performed after the study pharmacist again looked 
at each question in MARS and 8-item MMAS to which the patient had provided answers that 
reduced the adherence score. Each question was noted as either rational or irrational. Thus, 
the occurrence of rationality versus irrationality questions was a deciding factor into the 
categorization. In addition, this categorization was further refined by the patient’s BMQ 
responses. This was done by the study pharmacist by examining the individual scale scores 




Figure 3.3. Categorization of BMQ responses into rational or irrational. Code before the belief statement indicates the 
numbering of the statement in the BMQ questionnaire. The categorization into rational or irrational was based on the 
responses the patient provided in the questionnaire. Some belief responses were regarded as either rational or irrational 
depending on a judgement made by the study pharmacist when the entire perspective of the patient’s questionnaire responses 
was examined. 
 
The necessity beliefs were all assessed as being rational beliefs. Therefore, the occurrence of 
a score of 4-5 (Agree – Strongly Agree) on the necessity scale pointed toward rationality. 
However, if the score was between 3-1 (Uncertain – Strongly Disagree) it was a pointer that 
the patient was more toward the irrational side. The beliefs which made up the concern, 
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overuse and harm scales were assessed as being irrational. Hence, a score of 4-5 would 
indicate irrationality whereas scores 3-1 would point toward rationality.  
Thus, we can see that the frequency of intentional versus unintentional non-adherence 
responses on the 8-item MMAS, MARS and rationality versus irrationality on the 8-item 
MMAS, MARS and BMQ decided the adherence subgroup categorization. 
3.2.5.2.3 Interventions 
 
At a study visit to the study community pharmacy three months from baseline, interventions 
intuitively designed to optimize adherence were delivered to each patient based on their 
individual results received on the 8-item MMAS, MARS and BMQ adherence screens. 
Participants received one of the following interventions provided by the study pharmacist 
according to their adherence subgroup categorization: 
 A: patients visited the community pharmacy to receive a generic patient medication 
explanation leaflet (I) describing facts on adherence to antihypertensive medication 
therapy and steps to be taken to improve adherence (Appendix 5.7). 
 
 IR: patients visited the community pharmacy to receive a patient medication 
explanation leaflet (I). 
 
 II: patients received targeted counselling (C) explaining their condition, medication 
mechanism, importance and outcomes of adherence (this targeted counselling took 
place in a separate, calm and quiet room in the pharmacy building). Counselling was 
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completed in a maximum 30 minutes per patient. The patient was during the 
counselling session also given a patient medication explanation leaflet (I). 
 
 U: patients received targeted counselling (C). Patients also received a patient 
medication explanation leaflet (I) and a reminder sheet (R) for use at home in a 
convenient, prominent position. The reminder sheet was customized to each patient, 
featuring tick boxes to demonstrate if and when a dose was taken (Appendix 5.8). 
3.2.5.2.4 Deviations from the intervention protocol 
 
There were situations necessitating deviation from the intervention protocol in which an 
alternative intervention or combinations of interventions were used. Such situations arose 
when questionnaire data was equivocal and indicated to address particular adherence issues.  
3.2.5.2.5 Patients requesting BP and pulse measurement at visit 1 
 
At visit 1 there were patients who requested for BP and pulse measurement, despite this not 
being a part of the study protocol. 
3.2.5.3 Visit 2 (Final visit) – 6 months from baseline 
 
At a final 40-minute study visit to the community pharmacy, patients completed 8-item 





3.2.6.1 Power calculation 
 
The calculation for the approximate sample sizes that would be required in each adherence 
subgroup for 80% power at the 5% significance level when comparing various proportions 
was performed in Microsoft Excel 2010 (Microsoft Corporation, 2010). The chosen success 
rate was titrated to the number of patients considered to be recruited in the authentic practice 
situation, i.e. the number of patients required in each adherence subgroup for 80% power at 
5% significance level: 70% success, 30% failure for intervention was 25 patients in each 
adherence subgroup.  
3.2.6.2 Statistical software 
 
Microsoft Excel 2010 was used to perform the calculations of the descriptive statistics 
(Microsoft Corporation, 2010). IBM SPSS Statistics version 22 was used to perform all the 
other statistical analysis (IBM Corp., 2013).  
3.2.6.3 Significance levels 
 
The definitions for the significance levels are: significant when p<0.05, very significant when 
p<0.01 and highly significant when p<0.001. 
3.2.6.4 Descriptive statistics 
 
Descriptive statistics including mean, median, standard deviation (StDev) and standard error 
(SE) were calculated in Microsoft Excel 2010 (Microsoft Corporation, 2010).  
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3.2.6.5 The Shapiro-Wilk test of normality and the Wilcoxon-signed rank test 
 
The Shapiro-Wilk test of normality was performed to obtain information on whether the 
blood pressure and pulse data at visit 0 and visit 2 followed a normal distribution. The blood 
pressure and pulse data at visit 0 and visit 2 did not fully comply to follow a normal 
distribution. Because of this, the nonparametric Wilcoxon signed-rank test was performed to 
analyse the mean changes in systolic BP (SBP), diastolic BP (DBP) and pulse between visit 0 
and visit 2. P values of <0.05 were taken as significant for both the Shapiro-Wilk test of 
normality and the Wilcoxon-signed rank test.  
3.2.6.6 Spearman correlation 
 
A Spearman correlation was performed to see if a correlation existed between the scores from 
the adherence screens (8-item MMAS, MARS and BMQ) and the outcomes SBP, DBP and 
pulse. This was performed in the overall study population, A and U subgroups. The 
correlation was not performed for the other subgroups as the patient numbers were too low. 
Raw data from each of the adherence screens (Morisky, MARS, BMQ) were treated as a 
continuum (0  x) and a Spearman correlation was performed with the outcomes SBP, DBP 
and pulse (repeat measurements, last repeat measurements) at visit 0 and visit 2 respectively. 





3.2.6.7 Multivariate analysis of variance (MANOVA) and multivariate analysis of covariance 
(MANCOVA) 
 
Multivariate analysis of variance (MANOVA) was performed to analyse between-groups 
differences at visit 0 and visit 2 respectively.  For visit 0 the independent variable was the 
adherence subgroups, whereas for visit 2 the statistic was performed with the adherence 
subgroups and allocated interventions as independent variables. The mean values of blood 
pressure and pulse repeats were the dependent variables. Post-hoc analysis with Tukey’s HSD 
and Bonferroni was performed to explore statistically significant univariate outcomes.  
To test potential covariates which could influence the blood pressure and pulse results, 
multivariate analysis of covariance (MANCOVA) was performed to test the relationship 
between groups and possibly influencing covariates. MANCOVA was performed sequentially 
for each covariate (SBP based on repeat measurements at visit 0, DBP based on repeat 
measurements at visit 0, pulse based on repeat measurements at visit 0, medication group, 
month at visit 0, gender of patient, age of patient at visit 0, patient on 
monotherapy/polypharmacy) to either establish them or reject them as possibly interfering 
factors. Post-hoc analysis of univariate outcomes was carried out with Bonferroni adjustment.  
The multivariate analysis was separately taken in the light of the following criteria for 
MANOVA and MANCOVA (Mayers, 2013):  
MANOVA 
 categorical independent variables 
 normally distributed dependent variables 
 not too many deviations 
 acceptable correlation between dependent variables 
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 homogeneity of variance between groups 
 equal correlation between dependent variables between groups 
 not too many dependent variables 
 
MANCOVA 
 correlation between the covariate and dependent variables 
 if the covariate is dependent on independent variables 
 covariates measured before interventions 
 covariate and dependent variables normally distributed 
 enough sample sizes and equal sample sizes 
 homogeneity of regression slopes (covariate and dependent variable) 
 
Both MANOVA and MANCOVA were planned to be performed on a pragmatic basis. 
However, all criteria were not always met and the interpretations of the MANOVA and 
MANCOVA results should be taken considering these constraints. In addition, ANOVA is a 
statistic which can stand medium level of deviation from normality (Petrie and Sabin, 2009). 







3.3.1 Study duration 
 
The study lasted from March 27th, 2013 to December 9th, 2014. Results were analyzed on an 
intention-to-treat basis.  
3.3.2 Study population 
 
The overall study population was 153 patients of which 147 patients completed all study 
visits. Six patients withdrew after visit 0. Reasons for withdrawal were that patient number 
517 and 518 cited time constraints, patient 562 halted antihypertensive pharmacotherapy 
according to the physician’s recommendation, patient 651 cited personal circumstances, 
whereas patient 652 cited both personal circumstances and time constraints. Patient 532 did 
not provide a reason for study withdrawal. 
In the overall study population, there were 77 male and 76 female patients. Mean age of the 
overall patient population was 66 years. There were 73 patients on monotherapy and 80 
patients on polypharmacy. 
The overall study population is presented in Table 3.1. in which the changes in SBP, DBP and 
pulse between visit 0 and visit 2 are shown. The desired outcome was a blood pressure change 
>0 equating to a reduction in mean SBP and DBP between visit 0 and 2. A blood pressure 
change <0 equated to an increase in mean SBP and DBP between visit 0 and 2. The 
antihypertensive pharmacotherapy for each patient is classified according to medication 




Blood pressure and pulse results in the results section are all based on repeat measurements 
unless otherwise stated. 
From Table 3.1, changes in BP for patients on mono or dual therapy indicate a positive 
change: a blood pressure reduction occurring between visit 0 and 2. Patients on triple, 
quadruple and quintuple therapies mainly have a negative change in blood pressure, i.e. their 






Table 3.1. Overall study populations with change in SBP, DBP and pulse between visit 0 and 
visit 2, their antihypertensive pharmacotherapy classified according to medication groups, 
adherence subgroups and the allocated intervention. Participants highlighted in italics are patient 
drop-outs. 
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
500 38 17 8 TD+(ACEinh)* II C+I 
568 -11 -24 6 LD II C+I 
522 -6 10 17 TPSD A AND II C+I 
630 -6 -1 3 TPSD U C+I+R 
506 -6 -10 4 BB U C+I+R 
507 5 -3 -7 BB 
A AND 
IR C+I 
523 -7 3 2 BB A C+I 
534 6 6 7 BB U C+I+R 
540 21 3 -4 
BB+(ARB)* 
+(ARBHCT)* U C+I+R 
542 12 12 2 BB A I 
549 15 8 -4 BB A I 
561 -3 -4 2 BB A C+I 
567 15 11 1 BB U C+I+R 
596 14 3 6 BB A I 
617 -1 0 0 BB II C+I 
620 2 -5 -7 BB A I 
626 -6 -13 -1 BB A I 
518    CCB   
519 5 13 10 CCB U C+I+R 
545 0 -1 -8 CCB A I 




    Continuation of  
Table 3.1 
  
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
557 -21 -15 3 CCB U C+I+R 
563 7 7 11 CCB U C+I+R 
577 17 8 8 CCB U C+I+R 
580 -6 -5 11 CCB A I 
587 6 5 -7 CCB A C+I 
592 32 23 28 CCB+(BB)* A C+I 
610 -7 -5 -1 CCB U C+I+R 
614 -3 1 -2 CCB U C+I+R 
618 -9 -5 -5 CCB A I 
638 17 11 -11 CCB A I 
646 1 -1 5 CCB U C+I+R 
648 -3 -10 -9 CCB U C+I+R 
514 5 0 0 ACEinh U C+I+R 
527 -21 -6 3 ACEinh 
A AND 
IR I 
551 8 6 -3 ACEinh U C+I+R 
569 -25 -6 2 ACEinh A I 
582 3 -3 11 ACEinh U C+I+R 
586 -20 -16 10 ACEinh A I 
589 -8 -6 -2 ACEinh II AND U C+I+R 
590 -8 -5 6 ACEinh A C+I 
600 -10 -3 1 ACEinh U C+I+R 
601 -14 -10 -5 ACEinh U C+I+R 
604 15 18 5 ACEinh U C+I+R 






    Continuation of  
Table 3.1 
  
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
611 -8 -4 4 ACEinh U C+I+R 
612 4 -1 -2 ACEinh II AND U C+I+R 
644 -13 -6 3 ACEinh A I 
647 -16 -11 0 ACEinh A I 
652    ACEinh   
503 




521 25 17 -18 ACEinhHCT U C+I+R 
539 -11 -9 0 ACEinhHCT U C+I+R 
555 11 2 23 ACEinhHCT U C+I+R 
574 7 2 -3 ACEinhHCT U C+I+R 
616 18 7 -9 ACEinhHCT U C+I+R 
541 -9 -8 5 ARB U C+I+R 
558 -3 0 -7 ARB A C+I 
562    ARB   
564 -12 -8 8 ARB U C+I+R 
571 -10 -11 3 ARB U C+I+R 
572 6 7 -3 ARB A C+I 
619 17 -5 -8 ARB A I 
629 29 4 -18 ARB A I 
632 24 13 2 ARB U C+I+R 
633 35 18 3 ARB A I 
641 23 1 -3 ARB A I 
512 -2 2 -2 ARBHCT A I 
547 -10 -5 13 ARBHCT U C+I+R 
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Table 3.1 
  
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
591 -18 -1 5 ARBHCT A I 
595 -4 -6 -18 ARBHCT U C+I+R 
628 29 15 -8 ARBHCT A I 
556 16 -2 -20 TD+ACEinh A I 
643 24 12 -12 TD+ACEinh U C+I+R 
621 -3 -6 1 TD+ARB U C+I+R 
516 -3 -8 0 LD+TPSD II C+I+R 
588 9 1 3 LD+BB U C+I+R 
536 17 2 -3 LD+CCB II C+I 
505 36 8 7 LD+ACEinh U C+I+R 
529 3 4 4 LD+ACEinhHCT A AND II C+I 
502 14 9 -8 PSD+BB A I 
613 6 5 5 PSD+ARB A I 
520 -2 -2 4 TPSD+ACEinh A I 
513 -3 5 -3 BB+CCB A AND II C+I 
537 -10 -8 -9 BB+CCB U C+I+R 
552 13 4 21 BB+CCB A C+I 
575 -5 -8 2 BB+CCB A C+I 
609 8 4 3 BB+CCB A C+I 
636 12 8 -4 BB+CCB U C+I+R 
650 -5 -7 -8 BB+CCB U C+I+R 
544 28 1 1 BB+ACEinh A I 
550 3 0 12 BB+ACEinh A C+I 
585 19 5 -8 BB+ACEinh A C+I 
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PN ChSBP ChDBP ChPulse AHMG ADSG INT 
606 8 8 1 BB+ACEinh A C+I 
608 3 5 1 BB+ACEinh U C+I+R 
627 15 -2 -11 BB+ACEinh A I 
640 -5 -1 -7 BB+ACEinh A I 
525 15 10 -3 BB+ARB U C+I+R 
528 -23 -18 -19 BB+ARB U C+I+R 
603 -6 -7 6 BB+ARB A C+I 
631 3 -10 3 BB+ARB A C+I 
634 3 -1 0 BB+ARB A I 
583 -1 1 -3 BB+ARBHCT II C+I 
649 -15 -3 -6 BB+ARBHCT A C+I 
511 0 -4 8 CCB+ACEinh A I 
535 13 6 13 CCB+ACEinh U C+I+R 
573 -22 -5 10 CCB+ACEinh A I 
570 -20 -9 -7 CCB+ACEinhHCT A C+I 
581 -6 -5 -17 CCB+ACEinhHCT U C+I+R 
598 1 1 -3 CCB+ACEinhHCT U C+I+R 
615 15 7 -24 CCB+ACEinhHCT A I 
622 2 6 1 CCB+ACEinhHCT U C+I+R 
645 31 15 -3 CCB+ACEinhHCT II C+I 
504 





510 -46 -24 -6 CCB+ARB II C+I 
524 0 10 1 CCB+ARB A I 
543 12 2 13 CCB+ARB U C+I+R 
501 30 19 -8 CCB+ARBHCT A I 
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    Continuation of  
Table 3.1 
  
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
526 13 9 4 CCB+ARBHCT A I 
531 12 9 3 CCB+ARBHCT A I 
559 6 1 -5 CCB+ARBHCT II C+I 
593 -10 -7 16 CCB+ARBHCT+(BB)* II I 
594 1 -6 -12 CCB+ARBHCT A I 
599 -1 11 0 CCB+ARBHCT U C+I+R 
625 





538 -18 -18 0 TD+BB+ARB U C+I+R 
565 5 1 5 TD+BB+ARB A I 
548 -5 -12 -14 TD+CCB+ACEinh A C+I 
532    LD+PSD+ARB   
554 13 2 3 LD+BB+ACEinh II C+I 
639 -2 -7 -3 LD+BB+ARB A AND II C+I 
576 7 12 7 TPSD+CCB+ARB U C+I+R 
508 
-6 -9 -2 BB+CCB+ACEinh 
A AND 
IR I 
517    BB+CCB+ACEinh   
560 12 1 3 BB+CCB+ACEinh A C+I 
566 -10 -1 -7 BB+CCB+ACEinh U C+I+R 
623 -9 -13 -9 BB+CCB+ACEinh U C+I+R 
635 6 4 -25 BB+CCB+ACEinh A AND II C+I 
651    BB+CCB+ACEinh   
515 -1 -5 4 BB+CCB+ACEinhHCT A I 
584 7 0 -5 BB+CCB+ACEinhHCT U C+I+R 
597 






    Continuation of  
Table 3.1 
  
PN ChSBP ChDBP ChPulse AHMG ADSG INT 
624 20 9 -5 BB+CCB+ARBHCT U C+I+R 
637 -7 -3 -1 TD+PSD+CCB+ARB A I 
509 2 -6 -8 LD+PSD+BB+ACEinh U C+I+R 
530 -11 -11 -11 LD+PSD+BB+ACEinh U C+I+R 
605 -14 0 0 LD+PSD+BB+ACEinh A C+I 
533 
-10 -4 9 
TPSD+CCB+ACEinh 
+ARB A I 
546 


















Abbreviations for Table 3.1: ACEinh=Angiotensin Converting Enzyme (ACE) inhibitor; ACEinhHCT= Angiotensin 
Converting Enzyme (ACE) inhibitor and hydrochlorothiazide; ADSG=Adherence subgroup; AHMG=Antihypertensive 
medication group; Alpha=Alpha blocker; ARB=Angiotensin-II receptor blocker; ARBHCT=Angiotensin-II receptor blocker 
and hydrochlorothiazide; BB=Beta-blocker; BBCCB=Beta-blocker and calcium channel blocker; CCB=Calcium-channel 
blocker; ChDBP=Change in diastolic blood pressure; ChPulse=Change in pulse; ChSBP=Change in systolic blood pressure; 
INT=Intervention; LD=Loop diuretic; PN=Participant number; PSD=Potassium-sparing diuretic; TD=Thiazide diuretic; 




3.3.2.1 Adherence subgroups 
 
These are the 8 adherence subgroups with the n values for each subgroup (Table 3.2). The 
largest adherence subgroups are the A (n=62) and U (n=59) subgroups being similar in patient 
numbers. These are followed by the II (n=13) subgroup. The (A and IR) (n=4) and (A and II) 
(n=5) subgroups are also similar with small patient numbers. The (IR and U) and (II and U) 
subgroups are very small each consisting of 2 patients. 
Table 3.2. Number (n) of patients in each adherence subgroup. The largest adherence subgroups are the A (n=62) and U 
(n=59) subgroups, followed by II (n=13). They are then followed by the smaller subgroups A and II (n=5), A and IR (n=4). 




A AND IR 4 
A AND II 5 
II 13 
IR AND U 2 
II AND U 2 
U 59 
A=adherent; IR=intentional non-adherent rational; II=intentional non-adherent irrational; U=unintentional non-adherent 
 
3.3.3 Deviations from study protocol 
 
For a few patients, there were a small number of deviations from the study protocol to 
accommodate the authentic community pharmacy practice situation. At the request of three 
patients: participants 501, 502 and 539, rather than measuring the BP at the community 
pharmacy, they were measured in the patients’ domiciliary environment. It was acknowledged 
that a patient may be more relaxed in their home compared to the community pharmacy.   
For participant 605 a larger cuff size was used since a smaller cuff size was not comfortable. 
Patient 535 had almost a 7-month study duration to facilitate the scheduling of the last study 
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visit. Participant 588 had to stop administering antihypertensive medication 14 days prior to 
visit 2 by request of the physician. Similarly, participant 625 stopped administering 
antihypertensive medication 4 weeks prior to visit 2, though this patient intended to contact 
the physician to restart the therapy. Despite this, on examination of the results there really no 
difference in their results and performance, so they were included in the cohort. 
3.3.4 Baseline (visit 0) analysis 
 
The multivariate analysis at visit 0 showed the between-group difference in blood pressure 
and pulse at visit 0 to be significant (p<0.05). The p-values of the four different test statistics 
in the multivariate analysis are shown in Table 3.3. Univariate analysis showed a significant 













Table 3.3. MANOVA at visit 0. Multivariate analysis showed a significant between-group difference (p<0.05) on 
BP and pulse at visit 0 as shown by four test statistics: Pillai’s Trace, Wilk’s λ, Hotelling’s Trace and Roy’s Largest 
Root. The univariate analysis displayed a significant difference (p<0.05) for pulse at visit 0. 
MANOVA visit 0 
Multivariate F statistic p value  
Pillai’s 
Trace=0.095 F(6, 270)=2.24 0.040  
Wilk’s λ=0.91 F(6, 268)=2.25 0.039  
Hotelling’s 
Trace=0.10 F(6, 266)=2.27 0.038  
Roy’s Largest 
Root=0.089 F(3, 135)=4.00 0.009  
Univariate F statistic p value  
Pulse visit 0 F(2, 136)=4.30 0.015  
 
3.3.5 Deviation from intervention protocol 
 
A deviation from the intervention protocol was necessary for 25 patients. Table 3.4 indicates 
to which patients these deviations occurred and on what basis the deviation was done. In 
general, deviations were more common for adherence subgroup A.
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Table 3.4. Patients to which deviations occurred from the intervention protocol. The evidence for the deviations is shown. 
Codes for the questions and statements in the actual adherence screening questionnaires are indicated in this table. 
  
A subgroup, 
Participant number Intervention 8-item MMAS* MARS BMQ 
523 C+I   Specific Necessity score 1.4 
548 C+I   Specific Necessity score 2.8 
550 C+I   Specific Necessity score 3.6 
552 C+I   
Agree BS5, General Overuse 
score 3, Agree BG1 
558 C+I   
Strongly Agree BS2, Uncertain 
BS5, BS9, Agree BG1, BG7, 
Uncertain BG8 
560 C+I   
Uncertain BS2, BS5, Agree 
BS11, General Overuse score 3.3, 
Agree BG8 
561 C+I   
Specific Necessity score 2.4, 
Agree BS2, BS11, Uncertain 
BS5, Agree BG8 
570 C+I   
Specific Necessity score 2.6, 
Agree BS2, BS5, BS9, Gen 
Overuse score 3, General Harm 
score 2.6 
572 C+I   
Specific Necessity score 3.4, 
Agree BS2, BS5, BS9, Uncertain 
BG7, BG8 
575 C+I   
Specific Necessity score 3, 
Uncertain BS9, General Overuse 
score 4.3, General Harm score 
3.2 
585 C+I   
Specific Necessity score 2.6, 
Uncertain BS6, BS9, General 
Overuse score 3, General Harm 
score 2.6 
587 C+I   
Specific Necessity score 2, 
Uncertain BG7, BG8 
590 C+I   
Specific Necessity score 3.4, 
Specific Concerns score 2.5, 
Agree BS2, BS9, Agree BG1, 
BG8. 
592 C+I   
Strongly Disagree BS3, 
Uncertain BS2, BS9, BS11, 
Agree BS5, Strongly Agree BG1, 






































Abbreviations for Table 3.4: C=counselling; I=medication explanation leaflet; R=reminder sheet. 
*Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available 
from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of 
Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772. 
 
3.3.6 Patients requesting blood pressure (BP) and pulse measurement at visit 1 
 
There were 30 patients who requested BP and pulse measurement during visit 1. However, the 
readings for these measurements are not reported in this thesis since they do not contribute to 




Table 3.4   
A subgroup, 
Participant 
number Intervention 8-item MMAS* MARS BMQ 
603 C+I   
Specific Necessity score 2.6, 
Specific Concerns score 2.7, 
General Overuse score 4 
605 C+I   Uncertain BS6, BS11, BG7 
606 C+I   
Specific Necessity score 3, 
Specific Concerns score 2.8, 
Agree BS5, General Overuse 
score 3.7 (Agree BG7, BG 8, 
participant note on BG7, 
BG8: not always/sometimes) 
609 C+I   
Uncertain BS2, Agree BS5, 
BS9, BS11. General Overuse 
score 2.7 
631 C+I   
Specific Necessity score 2.4, 
Specific Concerns score 2.5, 
Agree BS2, General Overuse 
score 3 
649 C+I   
Specific Concerns score 3, 
Agree BS5, BS8, BS9, 
General Overuse score 3 
A and IR 
subgroup, 
Participant 
number Intervention 8-item MMAS* MARS BMQ 
507 C+I   
Specific Necessity score 2.6, 
Strongly Agree BG5 
II subgroup, 
Participant 
number Intervention 8-item MMAS* MARS BMQ 
516 C+I+R 






3.3.7 Blood pressure (BP) and pulse results 
 
The BP and pulse results at visit 0 and visit 2 for the cohort and each adherence subgroup is 
shown in the following section. The results are based on repeat BP measurements or last 
repeat BP measurement as noted in each figure/table.  
3.3.7.1 Cohort (n=153) 
 
Table 3.5 shows two different ways of representing the BP and pulse results based on either a) 
repeat measurements or b) the last repeat measurement. 
In general, the BP and pulse results at visit 0 based on repeat measurements do not differ 
when compared to the last repeat measurement. The BP and pulse results at visit 0 and visit 2 
are displayed in Table 3.5. SBP at visit 0 is around 140 mmHg, DBP at around 80 mmHg and 
a pulse surrounding 70 beats/minute. When reaching visit 2 the SBP reaches 137 mmHg, a 
DBP still around 80 mmHg and pulse at about 70 beats/minute.  
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.6. 
A statistically significant result was obtained on the change in SBP between visit 0 and 2 for 
the overall study population based on repeat blood pressure measurements. There was no 






























































































































































































































































































































































































































































































































































































































































































3.3.7.2 Adherent (A) subgroup (n=62) 
 
Table 3.7. shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. In general, the BP and pulse results at 
visit 0 based on repeat measurements do not differ when compared to the last repeat 
measurement.  
Table 3.7 displays the BP and pulse results at visit 0 and visit 2. The SBP at visit 0 is around 
140 mmHg, DBP at around 80 mmHg and a pulse surrounding 70 beats/minute. When 
reaching visit 2 the SBP reaches a level of 136 mmHg, a DBP almost remaining at 80 mmHg 
and a pulse at about 70 beats/minute.  
Changes in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.8. The 
A subgroup generally showed small improvements in SBP and DBP and almost no change in 






























































































































































































































































































































































































































































































































































































































































3.3.7.2.1 Within-group blood pressure (BP) changes in Adherent (A) subgroup 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup A 
(n=62) are demonstrated in Figures 3.4 (repeat measurements) and 3.5 (last repeat 
measurement). It is shown that subgroup A generally has small improvements in SBP and 
DBP.  Patients in this subgroup exhibit a stable BP control. Apart from the clinically 
acceptable -10 to +10 mmHg band, there is seen a large variability in BP results between 
patients reaching up to about 70 mmHg in SBP and 20 mmHg in DBP. 
 
 
Figure 3.4. Change in SBP and DBP between visit 0 and visit 2 based on repeat BP measurements for each patient in 




Figure 3.5. Change in SBP and DBP between visit 0 and visit 2 based on last repeat BP measurement for each patient in 
adherence subgroup A (n=62). 
 
3.3.7.3 Adherent and Intentional non-adherent rational (A and IR) subgroup (n=4) 
 
Table 3.9 shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. In general, the BP and pulse results 
based on repeat measurements do not differ when compared to the last repeat measurement.  
Table 3.9 displays the BP and pulse results at visit 0 and visit 2. SBP at visit 0 is around 130 
mmHg, DBP at around 70 mmHg and a pulse at 61 beats/minute. When reaching visit 2 the 
SBP reaches a level of about 140 mmHg, a DBP almost at 75 mmHg and a pulse at 64 
beats/minute.  
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.10. 
The A and IR subgroup showed a worsening in BP and pulse between visit 0 and 2. Despite 
this, there is a stable BP control in this adherence subgroup in relation to the target SBP <140 
















































































































































































































































































































































































































































































































































































































































































3.3.7.3.1 Blood pressure (BP) levels at visit 0 and visit 2 in Adherent and Intentional non-
adherent rational (A and IR) subgroup 
 
The SBP and DBP at visit 0 and visit 2 for each patient in subgroup A and IR (n=4) are 
demonstrated in Figures 3.6 and 3.7.  The figures highlight the SBP at visit 0 is around 130 
mmHg, DBP at around 70 mmHg. When reaching visit 2 the SBP reaches a level of about 140 
mmHg, a DBP almost at 75 mmHg. In general, there is a stable BP control in the A and IR 
subgroup in relation to the target SBP <140 mmHg and DBP <90 mmHg, despite there being 
a worsening in BP between visit 0 and visit 2. 
 
 
Figure 3.6. SBP and DBP at visit 0 and visit 2 based on repeat BP measurements for each patient in adherence subgroup A 




Figure 3.7. SBP and DBP at visit 0 and visit 2 based on last repeat BP measurement for each patient in adherence subgroup 
A and IR (n=4). 
 
3.3.7.3.2 Within-group blood pressure (BP) changes between visit 0 and visit 2 in Adherent 
and Intentional non-adherent rational (A and IR) subgroup 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup A and 
IR (n=4) are demonstrated in Figures 3.8 and 3.9. There is a worsening in BP and pulse 
between visit 0 and visit 2. Despite this, there is generally a stable BP control in the A and IR 




Figure 3.8. Change in SBP and DBP between visit 0 and visit 2 based on repeat BP measurements for each patient in 




Figure 3.9. Change in SBP and DBP between visit 0 and visit 2 based on last repeat BP measurement for each patient in 




3.3.7.4 Adherent and Intentional non-adherent irrational (A and II) subgroup (n=5) 
 
Table 3.11 shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. In general, the BP and pulse results at 
visit 0 based on repeat measurements do not differ when compared to the last repeat 
measurement.  
The BP and pulse results at visit 0 and visit 2 are displayed in Table 3.11. SBP at visit 0 is 
around 140 mmHg, DBP at around 80 mmHg and a pulse around 70 beats/minute. There is a 
slight difference in BP results at visit 2 based on repeat measurements or the last repeat 
measurement. Considering the repeat measurements, when reaching visit 2 the SBP reaches 
140 mmHg, a DBP of 74 mmHg and a pulse of 70 beats/minute. At visit 2 the last repeat 
measurement displays an SBP of 136 mmHg, DBP at 70 mmHg and a pulse of 71 
beats/minute. 
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.12. 
The A and II subgroup had mixed outcome in SBP – some improvement and some worsening, 
an improvement in DBP and almost no change in pulse between visit 0 and visit 2. Despite 
this, there is a stable BP control in the A and II subgroup in relation to the target SBP <140 






























































































































































































































































































































































































































































































































































































































































3.3.7.4.1 Blood pressure (BP) levels at visit 0 and visit 2 in Adherent and Intentional non-
adherent irrational (A and II) subgroup 
 
The SBP and DBP at visit 0 and visit 2 for each patient in subgroup A and II (n=5) are 
demonstrated in Figures 3.10 and 3.11.  There is a mix of SBP levels between patients at both 
visit 0 and visit 2. It is also about the two different ways of representing the BP as either being 
based on repeat measurements or last repeat measurement.  However, the DBP is generally 
≤90 mmHg. Nonetheless, overall there is a stable BP control in the A and II subgroup in 
relation to the target SBP <140 mmHg and DBP <90 mmHg. 
 
 
Figure 3.10. SBP and DBP at visit 0 and visit 2 based on repeat BP measurements for each patient in adherence subgroup 




Figure 3.11. SBP and DBP at visit 0 and visit 2 based on last repeat BP measurement for each patient in adherence 
subgroup A and II (n=5). 
 
3.3.7.4.2 Within-group blood pressure (BP) changes between visit 0 and visit 2 in Adherent 
and Intentional non-adherent irrational (A and II) subgroup  
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup A and II 
(n=5) are demonstrated in Figures 3.12. and 3.13. In some patients, there is an improvement 
in SBP, whereas some patients have a worsening in SBP. This is also about the two different 
ways of representing the BP as either being based on repeat measurements or last repeat 
measurement. Overall, there is an improvement in DBP in this adherence subgroup. Despite 
this, generally, there is a stable BP control in the A and II subgroup in relation to the target 




Figure 3.12. Change in SBP and DBP between visit 0 and visit 2 based on repeat BP measurements for each patient in 




Figure 3.13. Change in SBP and DBP between visit 0 and visit 2 based on last repeat BP measurement for each patient in 




3.3.7.5 Intentional non-adherent irrational (II) subgroup (n=13) 
 
Table 3.13. shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement.  
In general, the BP and pulse results at visit 0 based on repeat measurements do not differ 
when compared to the last repeat measurement. 
BP and pulse results at visit 0 and visit 2 are displayed in Table 3.13. SBP at visit 0 is around 
150 mmHg, DBP at around 80 mmHg and a pulse around 70 beats/minute. At visit 2 the SBP 
remains around 150 mmHg, DBP has increased to about 85 mmHg and a pulse at 67 
beats/minute. As these results show, there is no BP control in subgroup II. 
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.14. 
The II subgroup showed almost no change in SBP, a small worsening in DBP and a small 










































































































































































































































































































































































































































































































































































































































































3.3.7.5.1 Blood pressure (BP) levels at visit 0 and visit 2 in Intentional non-adherent irrational 
(II) subgroup 
 
The SBP and DBP at visit 0 and visit 2 for each patient in subgroup II (n=13) are 
demonstrated in Figures 3.14 and 3.15.  The figures indicate an SBP at visit 0 around 150 
mmHg and DBP being around 80 mmHg. At visit 2 the SBP remains around 150 mmHg, 
whereas DBP has increased to about 85 mmHg. As seen in Figures 3.14 and 3.15, patients in 
the II subgroup had high SBP values at both visit 0 and visit 2, thereby having no BP control. 
 
 






Figure 3.15. SBP and DBP at visit 0 and visit 2 based on last repeat BP measurement for each patient in adherence 
subgroup II (n=13). 
 
3.3.7.5.2 Within-group blood pressure (BP) changes between visit 0 and visit 2 in Intentional 
non-adherent irrational (II) subgroup 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup II 
(n=13) are demonstrated in Figures 3.16 and 3.17. The II subgroup showed almost no change 




Figure 3.16. Change in SBP and DBP between visit 0 and 2 based on repeat BP measurements for each patient in 




Figure 3.17. Change in SBP and DBP between visit 0 and 2 based on last repeat BP measurement for each patient in 
adherence subgroup II (n=13). 
169 
 
3.3.7.6 Intentional non-adherent rational and Unintentional non-adherent (IR and U) 
subgroup (n=2) 
 
Table 3.15. shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. SBP at visit 0 and visit 2 based on 
repeat measurements differed when compared to the last repeat measurement results. This did 
not apply to DBP or pulse results. BP and pulse results at visit 0 and visit 2 are displayed in 
Table 3.15. Considering repeat measurements, the SBP at visit 0 is 140 mmHg, whereas at 
visit 2 SBP is 131 mmHg. Based on last repeat measurement SBP at visit 0 is 133 mmHg and 
drops to 128 mmHg at visit 2.  
Overall, DBP at visit 0 is around 70 mmHg and a pulse around 60-65 beats/minute. At visit 2 
the DBP drops to around 65 mmHg and a pulse at 63 beats/minute. The BP results indicate a 
BP control in subgroup IR and U. 
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.16. 
The IR and U subgroup showed an improvement in BP and almost no change in pulse 


































































































































































































































































































































































































































































































































































































































































3.3.7.6.1 Blood pressure (BP) levels at visit 0 and visit 2 in Intentional non-adherent rational 
and Unintentional non-adherent (IR and U) subgroup 
 
The SBP and DBP at visit 0 and visit 2 for each patient in subgroup IR and U (n=2) are 
demonstrated in Figures 3.18 and 3.19.  There is a difference when SBP at visit 0 and visit 2 
is displayed as either being based on repeat measurements or the last repeat measurement. 
However, this did not apply to the DBP and pulse results. The mean value of SBP at visit 0 is 
140 mmHg, whereas at visit 2 the SBP drops to 131 mmHg. Based on last repeat 
measurement, the mean value of SBP at visit 0 is 133 mmHg and drops to 128 mmHg at visit 
2. Overall, DBP at visit 0 is around 70 mmHg, whereas at visit 2 the DBP drops to around 65 
mmHg. The results indicate a BP control in this adherence subgroup. 
 
 
Figure 3.18. SBP and DBP at visit 0 and visit 2 based on repeat BP measurements for each patient in adherence subgroup 





Figure 3.19. SBP and DBP at visit 0 and visit 2 based on last repeat BP measurement for each patient in adherence 
subgroup IR and U (n=2). 
 
3.3.7.6.2 Within-group blood pressure (BP) changes between visit 0 and visit 2 in Intentional 
non-adherent rational and Unintentional non-adherent (IR and U) subgroup 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup IR and 
U (n=2) are demonstrated in Figures 3.20 and 3.21. The IR and U subgroup showed an 
improvement in BP control between visit 0 and visit 2. The results indicate a BP control in 




Figure 3.20. Change in SBP and DBP between visit 0 and 2 based on repeat BP measurements for each patient in 




Figure 3.21. Change in SBP and DBP between visit 0 and 2 based on last repeat BP measurement for each patient in 




3.3.7.7 Intentional non-adherent irrational and Unintentional non-adherent (II and U) 
subgroup (n=2) 
 
Table 3.17. shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. In general, there was a difference 
based on repeat measurements in comparison to the last repeat measurement results. BP and 
pulse results at visit 0 and visit 2 are displayed in Table 3.17. Considering repeat 
measurements, the SBP at visit 0 is 127 mmHg, DBP 75 mmHg and pulse at 73 beats/minute. 
At visit 2 the SBP is 129 mmHg, DBP 78 mmHg and a pulse at 75 beats/minute. Based on 
last repeat measurement, SBP at visit 0 is 117 mmHg, DBP at 75 mmHg and pulse at 72 
beats/minute. At visit 2 the SBP is 129 mmHg, DBP at 81 mmHg and pulse at 78 
beats/minute. The BP results indicate a BP control in subgroup II and U. 
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.18. 

















































































































































































































































































































































































































































































































































































































































































3.3.7.7.1 Blood pressure (BP) levels at visit 0 and visit 2 in Intentional non-adherent irrational 
and Unintentional non-adherent (II and U) subgroup 
 
The SBP and DBP at visit 0 and visit 2 for each patient in subgroup II and U (n=2) are 
demonstrated in Figures 3.22 and 3.21.  There is a general difference in BP results based on 
the way the results are being portrayed – either as repeat measurements or last repeat 
measurement. Considering repeat measurements, the mean value of SBP at visit 0 is 127 
mmHg and DBP 75 mmHg. At visit 2 the SBP is 129 mmHg and DBP 78 mmHg. Based on 
last repeat measurement, mean value of SBP at visit 0 is 117 mmHg and DBP 75 mmHg. At 




Figure 3.22. SBP and DBP at visit 0 and visit 2 based on repeat BP measurements for each patient in adherence subgroup 





Figure 3.23. SBP and DBP at visit 0 and visit 2 based on last repeat BP measurement for each patient in adherence 
subgroup II and U (n=2). 
 
3.3.7.7.2 Within-group blood pressure (BP) changes between visit 0 and visit 2 in Intentional 
non-adherent irrational and Unintentional non-adherent (II and U) subgroup 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup II and U 
(n=2) are demonstrated in Figures 3.24 and 3.25. The II and U subgroup showed a worsening 





Figure 3.24. Change in SBP and DBP (between visit 0 and 2) based on repeat BP measurements for each patient in 





Figure 3.25. Change in SBP and DBP (between visit 0 and 2) based on last repeat BP measurement for each patient in 




3.3.7.8 Unintentional non-adherent (U) subgroup (n=59) 
 
Table 3.19 shows two different ways of representing the BP and pulse results based on a) 
repeat measurements or b) the last repeat measurement. There was basically was no difference 
in BP and pulse based on repeat measurements in comparison to the last repeat measurement. 
BP and pulse results at visit 0 and visit 2 are displayed in Table 3.19. The table shows the 
SBP at visit 0 being around 140 mmHg, DBP at 80 mmHg and pulse at 69 beats/minute. At 
visit 2 the SBP is 135 mmHg, DBP 80 mmHg and a pulse around 70 beats/minute. The U 
subgroup had BP control. 
The change in blood pressure and pulse between visit 0 and visit 2 is displayed in Table 3.20. 
There was in the U subgroup a small improvement in SBP and almost no change in DBP or 






































































































































































































































































































































































































































































































































































































































































































3.3.7.8.1 Within-group blood pressure (BP) changes between visit 0 and visit 2 in 
Unintentional non-adherent subgroup (U) 
 
The changes in SBP and DBP between visit 0 and visit 2 for each patient in subgroup U 
(n=59) are demonstrated in Figures 3.26 and 3.27. There was in the U subgroup a small 




Figure 3.26. Change in SBP and DBP (between visit 0 and 2) based on repeat BP measurements for each patient in 




Figure 3.27. Change in SBP and DBP (between visit 0 and 2) based on last repeat BP measurement for each patient in 
adherence subgroup U. 
 
3.3.7.9 Comparison on between-group blood pressure (BP) results: subgroups Adherent (A) 
(n=62) and Unintentional non-adherent (U) (n=59) 
 
Subgroups A (n=62) and U (n=59) are pretty much matched groups with similar sizes. It is 
worthwhile to do a comparison on these subgroups to determine between-group differences in 
SBP and DBP at visit 0 and visit 2 respectively.  
The SBP and DBP at visit 0 for each patient in subgroups A or U are demonstrated in Figures 
3.28 and 3.30. Likewise, the SBP and DBP at visit 2 is demonstrated in Figures 3.29 and 3.31. 
For subgroup A, the mean value of SBP at visit 0 is around 140 mmHg and DBP around 80 
mmHg (Figures 3.28 and 3.30). When reaching visit 2 the mean value of SBP reaches a level 
of 136 mmHg and a DBP almost remaining at 80 mmHg (Figures 3.29 and 3.31).  Thus, this 
adherence subgroup has a stable BP control. 
186 
 
Subgroup U had at visit 0 an SBP at around 140 mmHg and a DBP at 80 mmHg (Figures 3.28 
and 3.30). At visit 2 the SBP is 135 mmHg and DBP at 80 mmHg (Figures 3.29 and 3.31). 
Thus, the U subgroup had BP control. 
Figures 3.28, 3.29, 3.30 and 3.31 confirm that there is a wider scatter in BP data in the A 
subgroup in comparison to the U subgroup. 
 
Figure 3.28. SBP and DBP at visit 0 based on repeat BP measurements for each patient in adherence subgroups A (n=62) 






Figure 3.29. SBP and DBP at visit 2 based on repeat BP measurements for each patient in adherence subgroups A (n=62) 




Figure 3.30. SBP and DBP at visit 0 based on last repeat BP measurement for each patient in adherence subgroups  






Figure 3.31. SBP and DBP at visit 2 based on last repeat BP measurement for each patient in adherence subgroups 
 A (n=62) and U (n=59). 
 
3.3.8 Scores from adherence screens 
 
Scores from questionnaires used in adherence screens at visit 0 and visit 2 are presented in 
Table 3.21 as mean values for the overall study population and each adherence subgroup. 
When everything was piled together to compare the results on adherence screens from visit 0 







Table 3.21. Mean values of scores from questionnaires used in adherence screens for the cohort and each adherence 
subgroup. There is really no difference when everything is piled together comparing the scores at visit 0 and visit 2. 
 







adj.3 BMQN4 BMQC5 BMQO6 BMQH7 
Cohort 
(n=153) 7.5 24.3 4.9 3.7 2.1 3.0 2.1 
A (n=62) 8.0 25.0 5.0 3.7 1.9 2.9 2.0 
A and IR 
(n=4) 8.0 25.0 5.0 3.8 2.1 2.4 2.2 
A and II 
(n=5) 8.0 25.0 5.0 3.8 2.6 3.2 2.8 
II (n=13) 6.9 22.9 4.6 3.8 2.7 3.4 2.5 
IR and U 
(n=2) 6.5 23.0 4.6 4.3 2.0 3.5 1.9 
II and U 
(n=2) 7.5 21.5 4.3 3.0 1.8 3.5 1.6 
U (n=59) 7.0 23.9 4.8 3.6 2.1 3.0 2.2 
        







adj.3 BMQN4 BMQC5 BMQO6 BMQH7 
Cohort 
(n=153) 7.6 24.4 5.0 3.6 2.0 3.1 2.1 
A (n=62) 7.9 24.7 4.9 3.6 1.9 3.0 1.9 
A and IR 
(n=4) 8.0 25.0 5.0 3.4 2.2 2.4 2.0 
A and II 
(n=5) 8.0 25.0 5.0 4.2 2.3 3.2 2.4 
II (n=13) 7.6 24.1 4.8 3.8 2.5 3.3 2.3 
IR and U 
(n=2) 8.0 25.0 5.0 3.9 2.3 3.3 2.4 
II and U 
(n=2) 6.5 23.5 4.7 3.3 1.9 3.4 1.7 
U (n=59) 7.4 23.9 5.2 3.5 2.0 3.1 2.1 
18-item Morisky Medication Adherence Scale score 2Medication Adherence Report Scale score 3Medication Adherence 
Report Scale adjusted mean score 4Beliefs about Medicines Questionnaire Specific Necessity score 5Beliefs about 
Medicines Questionnaire Specific Concerns score 6Beliefs about Medicines Questionnaire General Overuse score 7Beliefs 
about Medicines Questionnaire Harm score *Use of the ©MMAS is protected by US copyright laws. Permission for use is 
required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 




3.3.9 Spearman correlation 
 
Spearman correlation was performed to see if a correlation existed between the scores from 
the adherence screens (8-item MMAS, MARS, and BMQ) and the outcomes SBP, DBP, and 
pulse. Inspection of the results showed that BMQ scale scores were dominant with significant 
and very significant correlations to SBP, DBP and pulse outcomes. The significant and very 

















Table 3.22. Significant and very significant results from Spearman correlations for the cohort (n=153). A Spearman 
correlation was performed with the scores from the adherence screening questionnaires and the SBP, DBP and pulse 
outcomes (repeat measurements, last repeat measurements) at visit 0 and visit 2 respectively. 




 Visit 0 Spearman’s rho p value n 
8-item MMAS1 DBP -0.17** 0.033 153 
BMQ Necessity 
scale DBP -0.22* 0.006 153 
BMQ Necessity 
scale Pulse 0.19** 0.018 153 
BMQ Concerns 
scale DBP 0.22* 0.005 153 
BMQ Overuse 
scale SBP 0.26* 0.001 153 
BMQ Overuse 
scale DBP 0.23* 0.005 153 




Visit 2 Spearman’s rho p value n 
8-item MMAS1 SBP 0.17** 0.036 147 




Visit 0  Spearman’s rho p value n 
MARS score DBP -0.16** 0.048 153 
MARS adjusted 
mean score DBP -0.16** 0.048 153 
BMQ Necessity 
scale DBP -0.19** 0.016 153 
BMQ Necessity 
scale Pulse 0.19** 0.022 153 
BMQ Concerns 
scale DBP 0.23* 0.005 153 
BMQ Overuse 
scale SBP 0.28* <0.001 153 
BMQ Overuse 
scale DBP 0.24* 0.003 153 
BMQ Harm scale SBP 0.16** 0.043 153 




Visit 2 Spearman’s rho p value n 
8-item MMAS1 SBP 0.19** 0.022 147 
*=statistically significant at the 0.01 level (2-tailed) **=statistically significant at the 0.05 level (2-tailed) 
1Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available 
from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of 








Table 3.23. Statistically significant results from Spearman correlations for adherence subgroups A (n=62) and U (n=59). 
A Spearman correlation was performed with the scores from the adherence screening questionnaires and the SBP, DBP 
and pulse outcomes (repeat measurements, last repeat measurements) at visit 0 and visit 2 respectively. 




Visit 0 Spearman’s rho p value n 
BMQ Concerns 
scale DBP 0.29** 0.023 62 
BMQ Concerns 
scale Pulse -0.35* 0.005 62 
Adherence screen 
Last repeat 
measurement Visit 0  Spearman’s rho p value n 
BMQ Concerns 
scale DBP 0.26** 0.043 62 
BMQ Concerns 
scale Pulse -0.36* 0.004 62 
     
     




Visit 0 Spearman’s rho p value n 
BMQ Necessity 
scale SBP -0.34* 0.008 59 
BMQ Overuse 




Visit 0  Spearman’s rho p value n 
BMQ Necessity 
scale SBP -0.36* 0.005 59 
BMQ Concerns 
scale DBP 0.29** 0.028 59 
BMQ Overuse 
scale DBP 0.34* 0.008 59 











3.3.10 Multivariate analysis of variance (MANOVA) 
 
Post-hoc analysis with Tukey’s HSD and Bonferroni showed significantly higher SBP 
(p<0.05) in II subgroup compared to subgroups A or U. The post-hoc analysis also showed 
patients who received interventions C+I had significantly higher SBP (p<0.05) in comparison 
to patients receiving either of the interventions I or C+I+R (Table 3.24).  
 
Table 3.24. Post-hoc analysis for MANOVA at visit 2. The post-hoc analysis with Tukey’s HSD and Bonferroni showed 
a significantly higher SBP (p<0.05) in II subgroup compared to A and U subgroups. Patients who received interventions 
C+I had significantly higher SBP (p<0.05) compared to patients receiving interventions I or C+I+R. 
Post-hoc analysis 
(Tukey’s HSD) 
adherence subgroups  
Mean difference in visit 
2 SBP (mmHg) Standard error p value 
Subgroup II - Subgroup A 15 5 0.030 




Mean difference in visit 
2 SBP (mmHg)  Standard error p value 
Subgroup II - Subgroup A 15 5 0.040 




Mean difference in visit 
2 SBP (mmHg) Standard error p value 
Interventions C+I - 
Interventions I 8 3 0.047 
Interventions C+I - 




Mean difference in visit 
2 SBP (mmHg)  Standard error p value 
Interventions C+I - 








3.3.11 Multivariate analysis of covariance (MANCOVA) 
 
Post-hoc analysis with Bonferroni adjustment showed significantly higher DBP (p<0.05) in II 
subgroup compared to subgroup IR and U when having monotherapy/polypharmacy as a 
covariate (Table 3.25).  
Table 3.25. Post-hoc analysis with monotherapy/polypharmacy as a covariate. The post-hoc analysis with Bonferroni 




Mean difference in visit 
2 DBP (mmHg) Standard error p value 
Subgroup II - Subgroup IR 






3.4.1 Screening of antihypertensive medication adherence and blood pressure (BP) 
assessment of community pharmacy hypertensive patients 
 
The present pilot study sought to I) assess the feasibility of performing adherence screening in 
community pharmacy hypertensive patients, II) to deliver community pharmacist-led 
interventions targeting adherence status according to adherence subgroups to optimise blood 
pressure (BP) and III) establish (a) any issues with the adherence screen (b) any indications of 
outcomes from the allocated interventions (c) any indication if certain interventions were 
detrimental.  
This pilot study shows potential value in screening antihypertensive adherence in community 
pharmacy. Patients can be categorized into different adherence subgroups. In addition, the 
present study indicates that generic interventions might not suit all patients. Certain adherence 
subgroups appear to react negatively to the pharmaceutical interventions used, possibly with 
detrimental outcomes on adherence and their blood pressure control.  
The power calculation should be interpreted in the light of the present study is a feasibility 
study. Despite some subgroups not reaching the 25-patient target, the target number of 
patients was achieved for the A and U subgroups. Results from the present study show that 
there exist subgroups which are more definitive than others. This is reflected by the number of 
patients in each subgroup. The A (n=62), II (n=13), U (n=59) subgroups all appear to be 
discrete groupings. By contrast, the IR subgroup (n=0) appears not to be discrete. In addition, 
there is a cross-over between subgroups A and IR (n=4), A and II (n=5), IR and U (n=2), II 
and U (n=2). The subgroups with the smaller numbers of patients appear to be the more 
problematic groups. Intuitively, the smaller subgroups consist of patients with more issues, 
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e.g. patients who may worry about their medicines and those patients who change their views. 
The findings from this study indicate that patients who appear to conform to specific 
adherence sub-type groups are likely to require personalised interventions to facilitate the 
enhancement of their adherence. It is likely that these interventions will differ depending on 
the subgroup attribution. However, the exact nature of the optimal intervention requires 
further confirmation studies. 
Tracking results of the changes in SBP and DBP across adherence subgroups results often 
deviate from the clinically acceptable -10 to +10 mmHg band, exhibiting more extreme 
changes as indicators of patient adherence worsen. This confirms that poor medication 
adherence results in unsatisfactory blood pressure control in the present pilot study.  
3.4.2 Patients requesting for blood pressure (BP) and pulse measurement at visit 1 
 
BP and pulse measurement at visit 1 demonstrates the importance of the community 
pharmacist as a provider of information and extended clinical services in healthcare, i.e. a 
clinician with the competence of performing hands-on examinations and making clinical 
decisions. The present study also demonstrates examples of patients requesting a hands-on 
physical examination involving diagnostics from community pharmacists.  
3.4.3 Blood pressure (BP) outcome in the cohort 
 
The mean age of the patients in the study cohort was 66 years, an age group with high SBP 
probably resulting at least in part from arterial stiffness increasing with age. The obtained 
statistical significant SBP change between visit 0 and 2 is clinically meaningful as SBP is the 
most important BP marker regarding cardiovascular risk (Kaplan et al., 2015; Warrell, 2010). 
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Elevated SBP has a larger effect on angina, myocardial infarction, and peripheral arterial 
disease. However, compared to SBP, an elevated DBP has a stronger effect on abdominal 
aortic aneurysm (Rapsomaniki et al., 2014). 
3.4.4 Blood pressure (BP) outcome in adherence subgroups  
3.4.4.1 Adherent (A) subgroup (n=62) 
 
 
Patients in subgroup A generally exhibited blood pressure change between -10 to +10 mmHg 
over the study period and therefore appear to be adherent: their adequate blood pressure 
control reflecting the use of antihypertensive medication in an appropriate, stable manner. 
However, the present study results indicate that targeted pharmacist intervention may produce 
some additional benefits in blood pressure control even in this adherent group. A significant 
number of patients in the A subgroup exhibited optimal blood pressure control. However, 
there was a significant level of noise in the blood pressure data. The variance in BP readings 
in the A subgroup could possibly be explained if some patients have deliberately manipulated 
their responses in assessments of their attitudes towards adherence, which is a known 
limitation of self-reported adherence screening (Wiffen et al., 2012).  
3.4.4.2 Intentional non-adherent rational (IR) subgroup (n=0) 
 
The IR subgroup did not appear to be a discrete grouping making it appropriate to consider 
possible flaws in the adherence subgroup categorization. The adherence screening 
questionnaires may not accurately assess these patients. However, another explanation is that 
pharmacological management is generally adequate in the patient cohort.  
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It is postulated that in an efficient healthcare system, the extent of any IR subgroup would be 
low: findings otherwise might imply poor prescribing. Almost 50% of patients discontinue 
administering their antihypertensive medication during the first year of treatment (Kaplan et 
al., 2015; Mancia et al., 2013). Therefore, the likelihood of identifying patients who conform 
to an IR group type, from patients newly commenced on antihypertensive therapy would be 
higher compared to those who have already been stabilized on antihypertensive 
pharmacotherapy for a significant period. 
3.4.4.3 Intentional non-adherent irrational (II) subgroup (n=13) 
 
Patients in the intentional non-adherent irrational subgroup exhibited highly variable blood 
pressure control (some worse, some better). Post-hoc analysis from MANOVA at visit 2 
showed that in this subgroup there was a significantly higher SBP compared to A and U 
subgroups. It is likely that II patients have a higher blood pressure, which indicates they are 
probably not taking their therapy. The present pilot study may well indicate that community 
pharmacist intervention in those patients with irrational beliefs about antihypertensive 
medicines (the II subgroup) could reinforce such misbeliefs leading to further deterioration in 
their blood pressure control.  
As clinical practitioners, pharmacists need to be aware that practice interventions are not 
necessarily universally good in outcome in certain subsets of the patient population. Hence, 
the present pilot study indicates the proposition for targeted interventions on an individual 
basis. Working on the ethical principle “primum non nocere“ (first do no harm), this aspect of 
improving patient adherence requires further study in terms of identifying risks associated 
with pharmaceutical interventions.  
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3.4.4.4 Mixed subgroups: Adherent and Intentional non-adherent rational (A and IR) (n=4); 
Adherent and Intentional non-adherent irrational (A and II) (n=5); Intentional non-
adherent rational and Unintentional non-adherent (IR and U) (n=2); Intentional non-
adherent irrational and Unintentional non-adherent (II and U) (n=2) 
 
The inconsistency in adherence subgroup allocation resulting from the application of the 8-
item MMAS, MARS and BMQ necessitated some patients being simultaneously assigned into 
four different mixed adherence categories: A and IR; A and II; IR and U; II and U.  
Patients who were allocated to subgroups A and IR or A and II appeared to exhibit stable BP 
control; generally, these patients were close to being fully adherent.  
Subgroup IR and U showed an improvement in BP, whereas the II and U subgroup had a 
worsening in BP. A possible explanation is that the IR and U subgroup may have benefited 
from the intervention. Also, it could be that the scope of IR is diminished in comparison to U 
within this subgroup considering there being good therapeutics in the entire cohort. The 
explanation for a worsening in BP for the II and U subgroup could possibly be traced back to 
the reasoning for the BP outcome in the II subgroup.  In any case, the patient numbers were 
very low in the IR and U, II and U subgroups. Hence, the blood pressure results for these two 
mixed adherence subgroups should be interpreted with caution.  
3.4.4.5 Unintentional non-adherent (U) subgroup (n=59) 
 
The present study indicates the potential for improvements in blood pressure control through 
targeted pharmaceutical intervention in those patients appearing to be unintentionally non-
adherent. The intervention package provided to this adherence subgroup shows it may be 
effective in reaching blood pressure reduction. 
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3.4.5 Comparability with other studies and covariates influencing blood pressure (BP) 
outcome  
 
Comparability of study results has not been carried out since no other studies have been found 
reporting similar results. Therefore, it is difficult to pinpoint definite reasons for the obtained 
BP results in this pilot study. However, examining factors which determine blood pressure 
variability provide a possible guidance to reasons although not being definite. 
There are numerous factors that could affect blood pressure. Some patients would have 
controlled BP due to being adherent to the oral antihypertensive medication therapy and good 
antihypertensive therapeutics. In those patients where there is a reduction in BP, patients may, 
for example, commence an exercise regimen or implement a dietary measure to reduce 
sodium intake. By contrast, a BP elevation could be caused by a white-coat effect or stress 
prior to or during the study visit. Moreover, in Sweden, there is a long season with a cold 
climate. The fact that visit 0 and/or visit 2 could have occurred during the cold season may 
have contributed to increased peripheral resistance in some patients, thereby causing a BP 
elevation.  
As there is an indication of significance to a covariate such as monotherapy/polypharmacy, a 
larger study would probably show some significant issues with covariates which are of 
importance in future planning of adherence research and in the therapy and assessment of 
hypertension. Consequently, some of the variations in blood pressure might be explained by 
factors not controlled for in the study design. Nonetheless, the results are strongly suggestive 
that patients with hypertension can be routinely allocated to generic adherence subtypes in a 
community pharmacy, with the intent of targeting appropriate interventions to optimize 
antihypertensive medication adherence.  
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It has been shown that with some disease states, increasing polypharmacy results in lower 
adherence for various reasons (Anthierens et al., 2010; Lehane and McCarthy, 2007; WHO, 
2003; Volpe et al., 2010). By large, the interventions C+I+R or C+I was provided to patients 
on more than two antihypertensive drugs. These patients had a worsening in BP, showing 
these interventions were provided when non-adherence was present. This suggests that it may 
well be medication non-adherence that causes the negative values in blood pressure. Despite 
non-adherence, it should be investigated if there are pathophysiological factors contributing to 
the resistant hypertensive state. This would best be done by the pharmacist referring the 
patient to a specialist hypertension clinic. 
3.4.6 Interventions and blood pressure (BP) outcome 
 
The questionnaire scores from adherence screens at visit 0 and 2 strictly underpin the 
hypothesis that any adherence intervention probably will not work for everybody. Besides, the 
post-hoc analysis in MANOVA at visit 2 showed that to patients which interventions C+I was 
delivered exhibited a worsening in blood pressure outcome. This being intuitively correct 
since C+I was to a great extent delivered to the II subgroup, whereas intervention I was 
targeted to the A subgroup and C+I+R to the U subgroup, suggesting there is a possibility that 
reinforcement of multiple interventions in those patients who are accepting of these methods 
may be the best way forward. Consequently, there are indications in the present study that in 
patients who are adherent, informatics and basic reminder interventions may be suitable and 





3.4.7 Variability in blood pressure (BP) and pulse results 
 
The reflection of a significant statistical between-group difference at visit 0 and a non-
significant between-group difference at visit 2 in a pragmatic approach portrays the variability 
in the BP and pulse results that are leading to flaws in the statistics which need to be 
interpreted with caution.  
Inspection of the numerical values of BP and pulse results at visit 0 and visit 2 display a 











Figure 3.32. Box-and-whisker plot with systolic blood pressure (mmHg) based on repeat measurements at visit 0 and 





Figure 3.33. Box-and-whisker plot with systolic blood pressure (mmHg) based on repeat measurements at visit 0 and 
visit 2 for adherence subgroup A and IR. 
  
1. Subgroup A having a 
higher SBP level at visit 0 
and visit 2 relative to 
subgroup A and IR. 
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Figures 3.32 and 3.33 show the SBP levels for A and A and IR subgroups at visit 0 and visit 2 
respectively. Arrows initiating from box number 1 point at the SBP levels at visit 0 and visit 2 
for each of these two adherence subgroups. It is seen a higher SBP level for A subgroup both 





Figure 3.34. Box-and-whisker plot with diastolic blood pressure (mmHg) based on repeat measurements at visit 0 and 






Figure 3.35. Box-and-whisker plot with diastolic blood pressure (mmHg) based on repeat measurements at visit 0 and 
visit 2 for adherence subgroup A and II. 
 
2. Subgroup II having a higher 
DBP level at visit 0 and visit 2 
relative to subgroup A and II. 
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Figures 3.34 and 3.35 show the DBP levels for II and A and II subgroups at visit 0 and visit 2 
respectively. Arrows initiating from box number 1 point at the DBP levels at visit 0 and visit 
2 for each of these two adherence subgroups. It is seen a higher DBP level for II subgroup 





Figure 3.36. Box-and-whisker plot with a pulse (beats/minute) based on repeat measurements at visit 0 and visit 2 for 






Figure 3.37. Box-and-whisker plot with a pulse (beats/minute) based on repeat measurements at visit 0 and visit 2 for 
adherence subgroup A and II. 
  
3. Subgroup II having a higher 
pulse level at visit 0 and visit 




Figures 3.36 and 3.37 show the pulse levels for A and A and II subgroups at visit 0 and visit 2 
respectively. Arrows initiating from box number 1 point at the pulse levels at visit 0 and visit 
2 for each of these two adherence subgroups. It is seen a higher pulse level for A subgroup at 
both visit 0 and visit 2 compared to pulse levels for subgroup A and II.  
Although a pragmatic statistic approach has been employed, this does not match up to a 
situation when some subgroups relative to other subgroups at visit 0 would have higher levels 
of BP and pulse resulting in a larger magnitude of BP and pulse change relative to other 
subgroups once reaching visit 2 due to all adherence subgroups ending up at the same BP and 
pulse level at visit 2.  
3.4.8 Limitations 
 
First, this pilot study was a relatively modest size study in a single community pharmacy. It 
was too small to accommodate the constraints of the statistical methods employed. However, 
evidence from this small study shows that within the constraints of the statistical tests there 
are some significant findings. In a larger study, this would maybe show some larger issues 
with adherence and the major cardiovascular parameters. Thus, it is possible that a larger 
study allowing discrimination of larger numbers of patients in each adherence subgroup 
would show significant differences in important cardiovascular parameters relevant to 
hypertension.  
Secondly, the questionnaires used for the adherence screens were used outside of their 
validation, i.e. how they are supposed to be used. Since there was no proper correlation 
between the questionnaires scores from the adherence screens and the blood pressure 
outcomes, it is not the fault of the questionnaires. Rather, it must do with the way the 
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questionnaires were employed in the study. The questionnaires were merely used as tools to 
categorize patients in adherence subgroups and not used in their strictest sense as adherence 
screens. There was no validation of the thresholds of questionnaire scores in this study. Each 
of the questionnaires used in adherence screens in this study has been validated previously, 
but only for evaluation of adherence to a single agent.  
Thirdly, there is a potential limitation in that a patient may respond differently to a general 
adherence scale when applied to a specific pathological condition. However, it has been 
assumed that scales developed to be non-specific for disease could be applied to hypertension. 
Furthermore, the current study design did not restrict to patients receiving antihypertensive 
monotherapy, rather patients were asked to consider their therapy for hypertension in general. 
Besides, there was no confirmation of the patient’s diagnosis of hypertension with the 
patient’s physician. It was mainly considered that the patient was on oral antihypertensive 
pharmacotherapy. It is possible that patients’ attitudes to adherence might vary between 
different antihypertensive drugs even though they are prescribed for the same condition. 
Finally, the study pharmacist not making a full objective judgement during adherence 
subgroup categorization could create a potential bias. It is also recognized that the study 
pharmacist and/or patients were not blinded in the present study creating a possibility for 
selection bias and a Hawthorne effect. There is a potential flaw that patients may sit between 
adherence groups, which is a limitation when doing this in practice.  Despite this, it informs 
about the future requirement for a refinement of the allocation process to simplify this process 




3.4.9 Restrictions on the use of pharmacy refill data 
 
The intention was to calculate pharmacy refill data from pill count and an electronic 
dispensing database. It was soon clear that the pill count method did not work due to reasons 
such as the patient forgetting to bring the medicine/s bottle/s to the study pharmacy during 
medicine refills etc.  
In the Swedish community pharmacy system, the study pharmacist could have collected 
pharmacy refill data from the Swedish electronic dispensing database 
Läkemedelsförteckningen. If it was done, MPR would have shown or not shown an interesting 
result. However, the attempt to use MPR was halted due to structural methodological reasons. 
The electronic dispensing database was not feasible because the study pharmacist’s 
understanding of Swedish law is that it does not permit using the data in the dispensing 
database for research purposes, despite prior ethical approval and patient consent. 
Nonetheless, in another healthcare system, MPR might show an interesting result. 
3.4.10 Future work 
 
To refine the methods, it would be of importance to confirm with the medical practitioner the 
number of patients with a hypertension diagnosis and identify the number of patients who 
visit the physician and then do not even present their prescription. In a future study, when 
screening medication adherence, the effect of the total drug load of the patient should be 
considered including therapies for conditions other than hypertension. 
To build on this pilot study the first step is to conduct a larger comparative trial to evaluate if 
targeted community pharmacist-led interventions really work. It would be necessary to test 
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various combinations of interventions in different sub-types e.g. would IR subgroup benefit 
from counselling to establish the nature of their rational problem and implement any 
solutions. This would be done by performing a four-armed parallel randomized trial with 
subdivision into study groups. There would be measures of adherence in all four study groups. 
To see if the study groups behave differently the intentional non-adherent patients would be in 
group A and B. Group A would receive an intervention with reminders, whereas group B 
would receive an informatics type of intervention. Unintentional non-adherent patients would 
belong to either group C or D. Group C would receive reminders targeting forgetfulness, 
whereas group D would receive informatics. 
The second step would involve a larger study to confirm the prevalence of the smaller 
adherence subgroups and identify the measures to which the patients in these subgroups 
would respond to. In these smaller subgroups, the patients might be really showing 
significance in pathology and negative outcomes. There is at least one small, but important 
group of individuals who are resistant to being adherent.  However, due to the relatively small 
patient cohort in the present study, the results should be treated with caution and a larger 
study should be conducted.  
 Conclusions  3.5
 
The pilot study has shown that it is likely to be useful to categorize community pharmacy 
hypertensive patients into adherence subgroups based on their responses to questionnaire 
format adherence screens.  It is feasible to deliver different intuitively designed community 
pharmacist-led interventions to each adherence subgroup to optimize antihypertensive 
medication adherence whilst assessing blood pressure control and changes in attitudes to 
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adherence. The results from the smaller subgroups form a small, but still an important group 
of patients who are problematic from an adherence perspective. The present study is 



















4 General discussion 
This chapter will provide a general discussion based on the studies described in chapters 2 and 
3. 
 The research domain community pharmacy practice, hypertension, 4.1
and adherence  
 
The current research programme was focused on community pharmacy practice in relation to 
cardiovascular disease, specifically examining patients with hypertension in a community 
pharmacy setting. It might be argued the systematic review presented in Chapter 2 solely 
focused on studies with an outcome to optimize blood pressure, whereas the community 
pharmacy-based in vivo adherence project in Chapter 3 examined the optimisation of patients’ 
antihypertensive adherence with the intent to optimize BP control. Indeed, the overarching 
theme of the present research was not the specifics of patients’ adherence to antihypertensive 
medication. Rather, the focus was aimed at ensuring that BP was improved in patients, albeit 
that the participants’ primary therapy comprised antihypertensive pharmacotherapy.  
Developments in pharmacy practice have promoted disease state management, i.e. not 
explicitly concentrating on medicines management, as a clear focus for pharmacy 
practitioners, with the patient and the illness at the centre of care. Patient adherence to 
medication is often used as an outcome measure for research (Armour et al., 2008). Hence, in 
the present community pharmacy studies a convenient model to use to optimize BP was 





 Research findings 4.2
4.2.1 A systematic review of pharmacist-led interventions within a community 
pharmacy setting aimed at optimising blood pressure (BP) in patients undergoing 
oral antihypertensive medication therapy  
 
A systematic review was conducted (see Chapter 2) to explore the scope of the evidence-base 
within the research domain of mixed-method studies. The focus was community pharmacist-
led interventions within a community pharmacy setting aimed at blood pressure optimisation 
in patients undergoing oral antihypertensive medication therapy. The overall aim of the 
systematic review was to explore the research area as a scoping exercise.  
4.2.1.1 Findings from the systematic review 
 
Outputs in varying quantity were derived from five selected electronic biomedical databases. 
Visual interpretation of funnel plots with grey literature revealed publication bias. However, 
the statistical test for funnel plot asymmetry showed the opposite. These opposing findings 
highlight the subjective role of visual inspection of funnel plots. In addition, these 
observations point to the possibility of reasons other than publication bias to explain funnel 
plot asymmetry such as poor methodological quality, heterogeneity between studies and 
chance (Higgins and Green, 2011). 
4.2.1.1.1 Patients 
 
It is highlighted in the present systematic review that patient screening should be 
standardized. A standardization process could involve the creation of an algorithm in relation 
to patient characteristics, screening, and recruitment. Moreover, community pharmacy 
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working together with GPs has an important function in the framework to optimize adherence 
(Herborg et al., 2008). Collaboration with physicians and other healthcare staff would provide 
points of referral of patients to the community pharmacy. This would facilitate the foundation 
on to which to build the community pharmacist’s provision of pharmaceutical care to patients. 
However, it should be noted that this would be a complementary methodological approach to 
self-referred patients. In addition, in those healthcare systems where clinical data sharing is 
allowed, such an inter-professional collaboration would enable clinical data sharing. 
4.2.1.1.2 Interventions 
 
There is a wide spectrum of pharmaceutical interventions targeted at improving patient 
adherence: this raises the problem of which interventions are effective (and in which 
situations). Established interventions are often complex and appear to be delivered to patients 
without consideration of individual attitudes to pharmacotherapy (Horne et al., 2001; 
Hugtenburg et al., 2013; Nieuwlaat et al., 2014; Stewart et al., 2014; Stewart et al., 2015). 
Currently, the evidence from the present systematic review points to community pharmacy-
based, pharmacist-led interventions lead to a positive effect, no effect or a negative effect. 
Hence, it may even be detrimental to intervene in some patients.  
Since the present feasibility study in Chapter 3 appears to indicate that patients could be 
subgrouped according to their attitudes to adherence, there is a need for well-designed studies 
which could establish the patient subgroups likely to benefit from particular intervention. In 







In the present systematic review, there is a wide representation of the randomised controlled 
trial study design with intervention and control groups. From the perspective of the risk of 
bias, the RCT design provides the lowest risk. However, there are studies in the present 
systematic review with a before-and-after comparison resulting in increased risk of bias 
(Khan et al., 2011; Wiffen et al., 2012). Indeed, there also exist evaluations of outcomes in 




Blood pressure outcome among the studies in the present systematic review is highly variable 
mirroring the variation in study design among the included studies. The present meta-analysis 
shows interventions either leading to no effect or a minor positive effect on BP. 
Consequently, the outcome of the meta-analysis is possible since pharmaceutical interventions 
with regards to medicines usage are simplistic. As such, these interventions do not work. In 
the light of this, it should be recognized that manoeuvres which community pharmacists take 
with a good intention could even be detrimental to patients. In fact, the outcome from the 
present meta-analysis stands in contrast to the premise of earlier research where it appears that 
intervention/s produce a positive effect. Another possible explanation relating to the meta-
analytic outcome is the low quality of some studies in the present systematic review leading 
to unsatisfactory results. Among the studies in the present systematic review, there is an array 
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of outcomes to which researchers investigate, making it difficult to know which outcomes are 
of relevance for assessing the pharmacy service.  
4.2.1.1.5 Study design 
 
Measures of consistency show heterogeneity existing between the included studies in the 
present systematic review. Different study designs among the studies in the present systematic 
review make the research unnecessarily complex. Moreover, the barriers on current study 
designs are not represented in the evidence-base. Thus, all this calls for a requirement of 
standardization of study design. Standardising the study design would mean to apply a study 
design which lowers the risk of bias. This would include the study population rigorously 
being defined. Moreover, it should be considered if the patient is on monotherapy or 
polytherapy since the total drug load would have an impact on adherence. In addition, the 
patient’s attitudes to different antihypertensive medications may vary. Study duration should 
set to last at least 6 months, allowing for an optimal data collection period. Adherence 
assessment would include a triangulative approach of different adherence screening tools 
considering different adherence models have their own strengths and limitations. 
4.2.2 A pilot study evaluating the impact of community pharmacist-led interventions to 
optimize antihypertensive medicines adherence  
 
The community pharmacy-based in vivo adherence study (see Chapter 3) sought to assess the 
feasibility of screening antihypertensive medicine adherence in community pharmacy 
hypertensive patients and delivering pharmacist-led interventions targeting adherence status 
according to adherence subgroups to optimise blood pressure (BP). The pilot study was 
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performed in a 153-ambulatory hypertensive patient population at a community pharmacy in 
Uppsala, Sweden with 147 patients completing all study visits.  
The study findings indicate that it is possible and beneficial to categorize patients into 
different adherence subgroups, which supports the concept that generalised adherence 
interventions might not suit all patients. Furthermore, the pilot study highlights the potential 
value in screening antihypertensive adherence in community pharmacy. It is feasible to 
perform this service in a community pharmacy.  
In some adherence subgroups identified in the present study, certain targeted interventions 
appear to optimize BP when compared to other interventions. For example, pharmaceutical 
interventions involving memory aids or reminders appear to be particularly effective in those 
patients exhibiting an unintentional attitude towards their non-adherence. By contrast, there 
was some indication that patients in certain adherence subgroups react negatively to 
pharmaceutical interventions possibly with detrimental outcomes on adherence and their 
blood pressure control. Using reminder interventions in those exhibiting intentional, irrational 
attitudes to non-adherence could well reinforce negative perceptions of medicines usage 
exacerbating the avoidance of prescribed medication use. 
4.2.2.1 Blood pressure (BP) outcomes 
4.2.2.1.1 Cohort (n=153) 
 
There was a statistically significant SBP reduction between visit 0 and visit 2 in the cohort. 
This outcome is of clinical importance since it is highlighted SBP is a marker connected to 
cardiovascular risk, but it is also shown that an elevated SBP has a larger effect on angina, 
myocardial infarction, and peripheral arterial disease. By contrast, an elevated DBP has a 
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stronger connection to abdominal aortic aneurysm (Kaplan et al., 2015; Rapsomaniki et al., 
2014; Warrell, 2010). 
4.2.2.1.2 Adherent subgroup (A) (n=62) 
 
Patients in subgroup A had a stable blood pressure control although showing administration 
of antihypertensive medicines in a stable manner. The results indicate the intervention 
resulted in additional benefit for this subgroup. There is noise in the BP data, possibly 
indicating that some patients may not have given accurate indications of their attitudes to 
adherence, which is a known limitation of self-reported adherence (Wiffen et al., 2012). 
Patients in this subgroup are unlikely to be at risk unless contrary clinical evidence is 
obtained. 
4.2.2.1.3 Intentional non-adherent rational (IR) subgroup (n=0) 
 
There was no IR subgroup existing alone which raises two possible explanations: I) there 
either may be a flaw in the adherence subgroup categorization and/or II) there is good 
therapeutics in the entire cohort. 
4.2.2.1.4 Intentional non-adherent irrational (II) subgroup (n=13) 
 
The II subgroup had highly variable BP control. In addition, post-hoc analysis from 
MANOVA at visit 2 showed a significantly higher SBP compared to A and U subgroups. 
Therefore, it is intuitive that those patients having higher BP are not using their 
antihypertensive medication optimally. Hence, pharmacists should be aware that delivering 
interventions to patients with irrational beliefs may strengthen the position of their beliefs, 
resulting in worsened BP control. 
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4.2.2.1.5 Mixed subgroups: Adherent and Intentional non-adherent rational (A and IR) (n=4); 
Adherent and Intentional non-adherent irrational (A and II) (n=5); Intentional non-
adherent rational and Unintentional non-adherent (IR and U) (n=2); Intentional non-
adherent irrational and Unintentional non-adherent (II and U) (n=2) 
 
There was inconsistency in the allocation process resulting from the application of 8-item 
MMAS, MARS and BMQ. Thus, patients were categorized in mixed adherence subgroups A 
and IR; A and II; IR and U; II and U. Patients in the A and IR; A and II subgroups had stable 
BP control considering these patients were almost fully adherent. Subgroup IR and U showed 
an improvement in BP possibly showing a beneficial effect of the intervention. Another 
possible explanation is the scope of IR being low compared to U since there may be good 
therapeutic control in the cohort. The II and U subgroup showed a worsening in BP control, 
possibly owing to the II portion of this mixed subgroup. The patient numbers in the IR and U; 
II and U subgroups were very low. Consequently, the results for these two subgroups should 
be treated with caution. 
4.2.2.1.6 Unintentional non-adherent (U) subgroup (n=59) 
 
BP improvements for the U subgroup was achieved showing the intervention package may be 
effective in reaching BP reductions for this subgroup. 
 Implications for the profession, practice, and policy 4.3
 
Accessibility of the community pharmacy and pharmacist to the public potentially constitutes 
a positive environment for disease management programmes. Being a complementary 
function to the general practitioner, the pharmacist can assist in the management of 
hypertension (WHO, 2005).  
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The community pharmacy-based in vivo project in Chapter 3 has highlighted the feasibility of 
conducting a pharmacist-led, community pharmacy-based hypertension service. 
The findings from the present feasibility study suggest that patients should not receive generic 
interventions irrespective of their adherence status. Hence, the findings stand in direct contrast 
to the interventional approach included in the RCT investigating the effectiveness of the New 
Medicines Service (NMS) in England. The NMS is a community pharmacy service in 
England provided to patients prescribed a new medication for a chronic condition. To 
participate in the service, patients can be self-referred, referred by their prescriber or 
identified by the community pharmacist. The intervention being face-to-face or telephone 
consultation with the patient one to two weeks after including the patient into the service. A 
follow-up consultation is held two to three weeks after the initial consultation. During the 
consultation, drug-related problems the patient is experiencing will be resolved. Referral to 
the prescriber may done if required (Elliott et al., 2014; Elliott et al., 2016). However, the 
intervention in the NMS is generic in nature and does not consider that patients have 
individual attitudes to adherence. 
The systematic review in Chapter 2 has examined the patient screening process, to establish 
which patients are likely to benefit from the community pharmacy service. The present study 
has investigated the contribution of the community pharmacist in hypertension management 
being suggestive of pharmacist-led interventions leading to highly variable outcomes being 
positive, negative or no effect. Again, this indicates that generic pharmacist-led interventions 
cannot be delivered to ambulatory hypertensive patients in a community pharmacy. Thus, 
beginning to look at groups of patients for individual interactions with interventions is the 
proper way to go forward. 
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Indeed, the community pharmacy-based in vivo adherence project suggests a way forward to 
categorize patients into adherence subgroups based on their adherence status assessed through 
a set of adherence screening questionnaires whilst assessing BP and pulse. Consequently, it 
appears that the community pharmacist could direct the pharmacy service to those patients 
who are in greatest need of interventions. In addition, there is an indication that some 
pharmaceutical interventions could be avoided where they might be detrimental to certain 
patients.  
Notwithstanding the above, the research base needs to be expanded to obtain definitive results 
on which to base practice and policy. This would enhance the possibility of extending the role 
of the community pharmacist to patient-centred hypertension care and make the community 
pharmacy a hub for hypertension management being a complementary approach to the 
physician.  A standardization of processes relating to the delivery of community pharmacy 
services in patients with hypertension is required.  
As suggested by Mancia and co-workers, a team-based approach may be the best way forward 
for hypertension management (Mancia et al., 2013). A different perspective has been taken in 
the present studies. In fact, the system for hypertension management suggested here could be 
a point were ”at risk” hypertensive patients are referred to by physicians and other healthcare 
staff. Collaboration with the physician would enable the confirmation of the hypertension 
diagnosis and other clinical data. However, at present, when a pharmacist needs to obtain 
clinical data, this is often hampered owing to legal aspects, links between professions and 
healthcare system factors (Farris et al., 2005; Mansoor et al., 2015). Efforts should be put into 
investigating solutions to overcoming these challenges. Information for the pharmacist to 
223 
 
obtain during assessment consist of patient data, disease data and drug data (Cipolle et al., 
2012).  
For the delivery of pharmaceutical care in pharmacy practice, it requires a management 
system which embraces logistics, evaluation and financial aspects, e.g. adequate number of 
competent pharmacists and pharmacy staff, private or semi-private space, availability of 
literature, a management system to schedule appointments and documenting the 
pharmaceutical care (Cipolle et al., 2012; Puspitasari et al., 2015). Moreover, the location of 
the pharmacy, as well as a neighbouring GP practice, increases the likelihood of 
implementation of the service (Puspitasari et al., 2015).  
Hence, accommodating special pharmacists on appointment to fully take on the role of 
patient-centred pharmaceutical care is mandatory. The level of community pharmacist 
competency is a relevant parameter to ensure delivery of quality pharmaceutical care. In 
addition, it is of importance to establish the working role of the community pharmacist in 
order not to cross the professional boundaries of other health care staff. 
 Limitations 4.4
4.4.1 Systematic review 
 
During the screening process, the databases retrieved some interesting studies (Amariles et 
al., 2012; Blenkinsopp et al., 2000). However, these studies did not meet the systematic 
review inclusion criteria.  
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A draw-back in some studies is that they did not report data for inclusion in the meta-analysis 
or assessing publication bias. It was not always successful to reach study authors to obtain 
data even though the contact information was available.  
The application of the EPOC study design criteria was affected by the mixed-methods 
approach. However, the studies which did not conform to the EPOC study design criteria 
were marked in the results section in Chapter 2. Even though the systematic review employed 
a mixed-methods approach, it is considered not to have any impact on the quantitative and 
qualitative outputs.  
4.4.2 Community pharmacy-based in vivo adherence project 
 
This was a small-scale study, though a large-scale from the perspective of this pilot study 
being conducted by an independent single researcher in a single community pharmacy. Thus, 
there was no expectation to obtain fully definitive results. However, the results are highly 
suggestive of there being groups of patients who are resistant to therapy/intervention and there 
being variability within a specific adherence subgroup. Therefore, this pilot study provides an 
intimation of points were the likely success will be. 
For the community pharmacy-based in vivo adherence project, a pragmatic approach to the 
statistical analysis was sought. However, this was not always feasible and the results were 
interpreted in the light of those constraints.  
4.4.2.1 Non-pharmacological interventions 
 
It is recognized that non-pharmacological interventions such as recommending physical 
activity and restricting sodium in the diet can be valuable and have a pronounced effect on BP 
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(Mancia et al., 2013; Nadar and Lip, 2009; Warrell et al., 2010). In the community pharmacy-
based in vivo adherence project, non-pharmacological interventions were not measured 
relating to performing or following any of those kinds of interventions. It was not considered 
if the patient initiated or halted any non-pharmacologic intervention and any potential impact 
it could have on BP. In addition, there was no measurement included on any change in 
following non-pharmacologic interventions.  
There is no strong evidence in the pilot study to suggest that patients were changing their 
behaviour relating to non-pharmacologic interventions during the study. Consequently, there 
is not much reason to believe changes in non-pharmacological behaviour had any impact on 
BP readings. 
4.4.2.2 Challenges encountered during the research endeavor 
 
There was no real issue in recruiting patients for the pilot study. Besides, there was a low 
amount of patient drop-outs. This shows there is a public interest for community pharmacy-
based, pharmacist-led services. Working collaboratively between the UK and Sweden 
unmasked some unexpected challenges, as community pharmacy regulations and operating 
systems somewhat differ between these countries. This led to some redesign of the planned 
research methods and data collection: differences between ethical permissions and patient 
data management systems were of most significance in necessitating these modifications. 
Nonetheless, pharmaceutical research such as the community pharmacy-based in vivo 
adherence project has been able to utilize a shared experience and knowledge to promote the 
advancement of pharmaceutical care to improve BP in patients with hypertension.  
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As the endorsed definition of pharmaceutical care includes improved quality of life, neither an 
assessment of the quality of life aspect or a pharmacoeconomic evaluation was conducted in 
the community pharmacy-based in vivo project (Hepler and Strand, 1990). Also, the project 
did not follow the research proposal on a setup with monotherapy or polypharmacy groups. 
The reason for this was not being able to frame these outcome measures within the authentic 
practice situation, considering that all research was carried out by a single researcher in a 
single community pharmacy. In addition, MPR was not used due to the understanding of the 
Swedish law that does not permit collection of MPR data in pharmacy practice. Moreover, the 
adherence screening questionnaires were not used as adherence measurement tools to measure 
adherence, rather to allocate patients into adherence subgroups. Despite this, the project went 
along meeting all the other stated aims and objectives. 
4.4.2.3 Study design 
 
The gold standard in clinical research is to conduct a blinded randomized controlled trial. 
However, as the community pharmacy-based in vivo adherence project employed a before-
and after study design with a single researcher in a single community pharmacy, it is difficult 
to know how to conduct a blinded trial as there are different elements to different patients by 
default. In addition, in a community population, there is always the risk of contamination in 
the study by a patient receiving one type of intervention talking to another patient receiving 
another type of intervention.  
It is acknowledged, in terms of bias, that there are potentially more reliable, less risk 
methodological approaches. However, since this was a pilot study being conducted by a 
single researcher in a single community pharmacy with a defined patient population, the 
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before-and-after design was deemed to be the most robust as each patient was their own 
control. There is a possibility of risk of bias from the perspective of the single 
investigator/assessor. However, the psychosocial way to influence the risk on BP readings and 
questionnaire responses is judged not to have any larger impact on the results. 
4.4.2.4 Interventions and persistence in blood pressure (BP) control 
 
The present pilot study did not incorporate a study design which enabled to explore the 
persistence of effect caused by the interventions. This requires a different study over a longer 
period to investigate such an effect. It was not feasible to carry out such a long study within 
the specified time frame. Consequently, it is not known if these types of interventions lead to 
persistence in effect. 
A pharmacist is likely to see a hypertensive patient more often than a general practitioner as 
they collect refills of their medication. Intuitively, any kind of intervention involving regular 
reminders and interaction with the community pharmacy is likely to give persistent and 
beneficial effects. However, providing the patient with education does not cause a persistent 
effect on behaviours surrounding medicines administration (Lee et al., 2006). A systematic 
review by Conn and co-workers, 2016 provided an assessment of studies with adherence 
interventions in adult patients with adherence issues. The authors conclude face-to-face 
interventions being important as well as connecting medication-taking with routines and 
reminders. The latter is more likely to produce a persistent effect since it is a continuous 
intervention in comparison to when a patient receives education, which is provided at a single 
time point or within a set time frame (Conn et al., 2016). In contrast, there is an intimation in 
the present pilot study there being a certain subgroup where it might be detrimental to be 
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persistent in reminders and such an approach may reinforce the incorrect views in those 
patients who do not respond well to traditional medications and interventions. 
 Future directions 4.5
4.5.1 General considerations 
  
As suggested in Chapter 3, a first step is to conduct a larger comparative trial to evaluate if 
targeted community pharmacist-led interventions really work. It would be necessary to test 
various combinations of interventions in different adherence subgroups. The systematic 
review and community pharmacy-based in vivo adherence project indicate the possibility of 
negative outcome arising from pharmacist-led interventions. There is an indication of at least 
one resistant patient subgroup to pharmacist-led interventions. Thus, caution with pharmacist-
led interventions to a certain subset of patients. A future study should establish the prevalence 
of these patient subgroups and a decision pathway on how to proceed with treating these 
patients. Some patients may require referral to specialist hypertension care. There is a definite 
possibility to gear up towards a longer study duration with improved study design such as the 
application of RCT trials and conducting larger multi-centre studies to provide definite 
evidence for the community pharmacy-based service. This would possibly throw light on the 
methodological deviations occurring in the community pharmacy-based in vivo adherence 
project and pave the way for refinement of the methods. 
In addition, further future work would include: 
 Going forward to evaluate the interventions in each adherence subgroup 
relating to effect and persistence in effect bearing in mind any subgroup being 
resistant to pharmaceutical interventions which could reinforce the incorrect 




 Antihypertensive medicines adherence would be interesting to investigate as an 
outcome measure. In those healthcare systems where it is allowed to go 
forward with MPR, it would be of interest to explore this outcome looking at 
MPR at different time points. 
 
 Consider a study design with data collection through a triangulated 
methodological approach which manifests the data collection from different 
perspectives possibly creating more robust data.  
 
 A collaborative approach with GPs and other healthcare staff should be sought. 
Not all same health-systems have the same attitudes on physician and 
community pharmacy interactions. However, there is a huge opportunity for 
community pharmacists to take on these clinical pharmacy roles in situations 
where the setting is such not being feasible to provide sufficient physicians or 
where physicians claim to be underfunded and overworked. Therefore, this 
study has shown that it is physically and technically possible that patients can 
be monitored in the community pharmacy. In a future study, it would be 
interesting to investigate if the methods used in this pilot study could equally 
be applied to the management of other disease states. 
 
 The working role of the community pharmacist in the light of a changing 
professional role should be defined, not crossing the borders of the other 
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healthcare professions which could lead to an acceptance of the extended 
pharmacist role by other healthcare staff.  
 
 To embrace the concept of pharmaceutical care, quality of life as an outcome 
measure should be included and assessed. 
 
 Further investigation into the aspect of pharmacist prescribing as an 
interventional element. In a randomized controlled trial conducted by Tsuyuki 
and co-workers, 2015, in community pharmacies, hospitals and primary care 
teams in Alberta, Canada, the impact of pharmacist prescribing on BP control 
was investigated in patients 18 years and above. The results were a clinically 
and statistically significant effect of pharmacist prescribing on BP control 
(Tsuyuki et al., 2015). 
 
 Pharmacists, professional pharmacist organizations, other healthcare staff and 
governments should through communication make the community pharmacy 
services known to the public. 
4.5.2 Financing pharmaceutical care service in community pharmacy 
 
Pharmacy services are moving into being a part of both the professional practice as well as the 
business model (Moullin et al., 2013). Payers of the service will tend to look at the benefit of 
a safe and rational use of medicines (Cipolle et al., 2012). However, payment for service in 
the community pharmacy has not been taken forward to the larger arena. For example, in 
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Australia, an agreement between the professional organization for community pharmacists 
and the government has resulted in remuneration for pharmaceutical services in community 
pharmacy. However, the community pharmacy is required to meet certain criteria to receive 
this payment (Puspitasari et al., 2015).  
In community pharmacy, the cost of dispensing prescription medicines is declining (Cipolle et 
al., 2012; Puspitasari et al., 2015). This results in a larger amount of prescriptions required to 
be filled to gain profit in the pharmacy business. As such, interventions aimed at the time of 
refill may not produce the best results and distort the prescription-handling process (Cipolle et 
al., 2012).  
There is a call for pharmacoeconomic evaluations to provide evidence on the cost-
effectiveness of interventions relating to hypertension (Santschi et al., 2015). Evaluations 
such as these would possibly increase the likelihood of securing funding for future studies and 
reimbursement for community pharmacy implementation of the service. Reimbursement and 
cost for the service are the responsibilities of the governments, health insurance companies, 
pharmacists, researchers, pharmacy companies and patients (Hourihan et al., 2003; Maher et 
al., 2014). For the pharmacy service to be successful, there should be a minimum requirement 
of delivering pharmaceutical care to 10-15 patients a day (Cipolle et al., 2012). 
 Conclusion 4.6
 
Tying together the systematic review and the community pharmacy-based in vivo project 
results in a joint effort for an opportunistic role for the community pharmacist to bring 
together a service intended to optimize patients’ BP. There are challenges along the way, 
though future studies have the possibility to influence the evidence-base which will form the 
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basis to include the fully developed pharmaceutical care service into practice and policy. 
Regarding this, this thesis has established: 
 It is feasible for ambulatory hypertension patients to attend a community 
pharmacy-based hypertension management program with pharmacist-led 
interventions aimed at optimizing BP. 
 
 There is a possibility in a community pharmacy to deliver targeted pharmacist-
led interventions tailored to the patient’s adherence status, although bearing in 
mind for certain patients, pharmaceutical interventions may have a detrimental 
effect. As such, there is a need to establish the subgroups which need or do not 
need the pharmaceutical intervention package. 
 
 
 A collaborative approach with GP’s and other healthcare staff should be 
sought as a point of referral of ”at risk” patients to benefit from the pharmacy 
service as well as for clinical data sharing for the benefit of optimizing the 
hypertension therapy of the patient. 
 
 A multi-centre randomized controlled trial with the utilization of adherence 
screening tools through a triangulated approach to categorizing patients into 
adherence subgroups together with an interventional approach individually 
tailored to the patient’s adherence status would be the next step to build upon 





 Systematic review protocol 5.1
 
Research question: What is the scope of pharmacist-led interventions within a community 
pharmacy setting aimed at optimising blood pressure? 
 
Aim: To perform a systematic literature review to identify and evaluate studies aimed at 
blood pressure optimisation in patients undergoing oral antihypertensive medication therapy. 
 
Process 
 Study population:  
Patients 18 years and above, undergoing treatment with at least one oral antihypertensive 
medicine, community pharmacy setting, no language restrictions on obtained papers 
 Study design: Mixed-methods design 
 Interventions: Interventions in a community pharmacy aimed at blood pressure 
optimisation 
 Search terms and key words (MESH): 
1. pharmacists hypertension antihypertensive agents medication adherence pharmacies 
intervention studies pharmaceutical care  




3.   pharmacies hypertension intervention studies medication adherence pharmaceutical 
care 
4. pharmacies antihypertensive agents intervention studies medication adherence 
pharmaceutical care 
5. pharmacists hypertension medication adherence pharmaceutical care 
6.   pharmacists antihypertensive agents medication adherence pharmaceutical care 
7.    pharmacies hypertension medication adherence pharmaceutical care 
8. pharmacies antihypertensive agents medication adherence pharmaceutical care 
 
 Appropriate databases 
PubMed, Embase, Medline, Cinahl, Cochrane Database  
Grey literature was searched using LexisNexis, Web of Science and Google. 
 
 Study outcome measures 







 R Code for testing of funnel plot asymmetry based on odds ratio as an 5.2
effect estimate of systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) as a combined outcome 
 
#loading the meta package 
> library(meta) 
Loading 'meta' package (version 4.4-1). 
 
#importing data from RevMan 5 
> hypertension<-read.rm5("hypertension.csv", numbers.in.labels=FALSE) 
 
#calculating arscine test  
> hyper <- metabin(event.e, n.e, event.c, n.c, data=hypertension, sm="ASD") 
 
#testing for funnel plot asymmetry 
> metabias(hyper, method.bias="mm") 
 
        Linear regression test of funnel plot asymmetry (methods of moment) 
 
data:  hyper 
t = 2.8174, df = 9, p-value = 0.02013 
alternative hypothesis: asymmetry in funnel plot 
sample estimates: 
      bias    se.bias      slope  









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Abbreviations for Table 5.1: 
AC=Allocation concealment (selection bias); BI= Baseline imbalance; BOA=Blinding of outcome assessment (detection 
bias); BPP=Blinding of participants and personnel (performance bias); CWIRT=Comparability with individually randomized 
trials; HR=High risk; IA=Incorrect analysis; IODA=Incomplete outcome data addressed (attrition bias); LOC=Loss of 
clusters; LR=Low risk; OB=Other bias; RB=Recruitment bias; RSG=Random sequence generation (selection bias); 


























  Research Proposal 5.4
Abstract  
 
The aim of this research is to evaluate pharmacist-led intervention among patients in a single-
community pharmacy to improve antihypertensive medicines adherence. This investigation 
will consist of a longitudinal before-and-after study, undertaken at a single-community 
pharmacy in Uppsala, Sweden. Ethics approval will be sought for at ethics board in Sweden. 
Patients recruited should be at least 18 years old or above, having minimum one prescription 
on an antihypertensive medicine, been using the medicine/s for the past 3 months and should 
get the medicine refill done at the study pharmacy while the study is ongoing. The 
participants will be serving as their own controls. The study duration is set to 6 months. Data 
will be collected at baseline and after a 6-month follow-up: adherence (8-item Morisky 
Medication Adherence Scale, Medication Adherence Report Scale, Medication Possession 
Ratio), a questionnaire on patient perception on medicines (Belief about Medicines 
Questionnaire) and a pharmacoeconomic evaluation of the pharmacist-led intervention. The 
intervention will be implemented after 3 months from baseline.   
Research question 
 
Can pharmacist-led adherence intervention/s in a single-community pharmacy contribute to 
improved antihypertensive medication adherence? 
Aims and Objectives 
Aim: to evaluate pharmacist-led intervention/s among patients in a single-community 





 measure the change in blood pressure, pulse and antihypertensive medicine adherence  
 establish the cost-effectiveness of a pharmacist intervention in improving 
antihypertensive medicines adherence 
Research design 
  
 Longitudinal before-and-after study 
 Single community pharmacy in Uppsala, Sweden 
 Six-month study duration 
 Two study groups run in parallel: monotherapy and polypharmacy 
 Patients serve as their own control 
 Quantitative measurement at baseline (first visit) and after 6 months (last visit): blood 
pressure and pulse, 8-item Morisky scale (8-item MMAS), Medication Adherence 
Report Scale (MARS) Medication Possession Ratio (MPR), Belief about Medicines 
Questionnaire (BMQ) 
 Intervention implemented after 3 months from baseline 
 Pharmacoeconomic evaluation of the implemented pharmacist-led intervention 
 
This study uses a triangulated research approach which revolves around: 
1. Personal contact and review of elements 
2. Self-reported scale devices: 8-item MMAS, MARS, and BMQ 
3. The long-term chronic historical record of the usage of medication 
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The project will be undertaken as a longitudinal before-and-after study in a single-community 
pharmacy in Uppsala, Sweden. There will be two study groups run in parallel: one group with 
patients having one antihypertensive agent (monotherapy) and the other group in which each 
participant has two or more antihypertensive medicines (polypharmacy). Patients will serve as 
their own control. A significant reduction in blood pressure is in this project set out to be 10 
mmHg systolic pressure and 5 mmHg in diastolic pressure. 
 
The research procedure is as follows: 
1. Participant recruitment 
Participants being dispensed antihypertensive medicines at the dispensing counter at the 
pharmacy will be approached by the dispensing pharmacist (researcher) and will be 
informed about the study with the following information: “There will be an ongoing study 
here at this pharmacy for patients undergoing treatment with blood pressure lowering 
medicines. This study is aimed at evaluating if a pharmacist can contribute to improving 
patient blood lowering medicines taking. Does this sound interesting to you?”. The 
participant will also be asked by the researcher for how long they have been taking 
antihypertensive medicine/medicines.  If they inform that they are interested to participate, 
they will be handed the participant information leaflet which they should carefully read 
through. They will then be given at least 24 hours to decide whether they would like to 
participate. If they decide to participate, they should contact the researcher either by 
phone/e-mail and a date is mutually agreed upon when the patient can return to the 
pharmacy to meet the researcher and opportunity will be given to ask questions and discuss 
the study. If the eligible participant then after this decides that he/she wants to participate, 
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an informed consent will be handed the eligible participant and this consent sheet should 
be carefully read through and then signed by both the participant and the researcher. 
Informed consents will be stored in a locked safe at the pharmacy, accessible only to the 
researcher, two pharmacy managers, and pharmacy managers’ assistant.  
 
1.1. After signing the informed consent, the participant will be assigned a participant code 
(number). They will be asked by the researcher for how long they have been taking 
antihypertensive medicine/medicines and which antihypertensive medicine/s they are 
currently taking. The researcher will ask the participants permission to approach their 
GP/prescriber. The researcher will then go and approach the prescriber with the full 
details of this project. It will be explained to the them that under Swedish law the 
researcher is not allowed to download prescription data from the pharmacy dispensing 
computer system in front of the researcher, so, therefore, the researcher is requesting 
their assistance which is legal on how many prescriptions they wrote and what for and 
if the researcher can have permission to ask your practice manager to give the 
researcher that data when a patient has given the researcher ethical consent to do so. 
The GP/prescriber/practice manager can be provided with copies of the ethical consent 
and the researcher will not trouble the GP/prescriber each time if the practice manager 
could provide the researcher this data off the prescribing system. This information will 
be registered electronically linking it with the participant code. The participant will be 
assigned to a monotherapy or poly pharmacy study arm depending if they are taking 




1.2. The participant will be handed a protocol sheet where the participant must record 
when they begin to take the first pill in the medicine/s bottle/s. Participant names will 
not appear on any of these data collection papers, only the assigned participant code. 
Patient name, demographic details, assigned participant codes and which medicines 
they are taking will be stored in a master computer file in two USB memory sticks 
(one backup) which both will be protected by encryption using the encryption software 
TrueCrypt. These two USB memory sticks will be stored in a locked safe in the 
pharmacy only accessible to the researcher, 2 pharmacy managers, and one pharmacy 
managers’ assistant.  
 
2. Data collection questionnaires 
The participant will be handed the questionnaires containing the 8-item MMAS, MARS, 
and BMQ which the participant will be partially facilitated by the pharmacist to answer in 
a quiet room in the pharmacy building. After the participant has filled out the 
questionnaires these will be handed back to the researcher. 
 
3. Blood pressure and pulse measurement 
The participant will then be asked to be seated on a chair in a quiet room in the pharmacy 
and rest for 5 minutes (Mancia et al., 2007; O’Brien et al., 2005; The British Hypertension 
Society, 2012). Blood pressure and pulse of the participant will then be measured using the 
clinically validated electronic blood pressure monitor Omron 705-IT and take up to 3 
readings to check for continuity (The British Hypertension Society, 2012). Step 1.1, 1.2, 2 
and 3 is set to take maximum 1 hour. Blood pressure data will be recorded on a separate 
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paper sheet for each participant containing only the participant code. The participant will 
also be informed about the result of the blood pressure and pulse measurement. 
 
4. Pill count  
The participant will be asked to bring their medication bottles to the pharmacy to enable the 
researcher to perform pill counts. This will be done each time the participant comes to the 
pharmacy for medicines refill (usually after 3 months or depending on the prescribed 
amount). Now the participant would have to bring in the pill count protocol to show it to the 
researcher. 
 
5. Intervention  
After 3 months from baseline, the intervention will be implemented for each participant 
based on their individual results received on the 8-item MMAS and MARS. Participants 
will be contacted preferably by telephone and informed about the intervention and should 
visit the pharmacy. Depending on the individual 8-item MMAS and MARS results 
participants receive the following intervention separately or in combination/s will be 
implemented: 
(a) Targeted counselling from the pharmacist – explaining the disease state, medication 
mechanism and importance, outcomes and importance of adherence (this targeted 
counselling will take place in a separate, calm and quiet room in the pharmacy 




(b) A patient medication explanation leaflet (titrated to the individual patient’s drugs 
regime/condition 
(c) A reminder sheet (to be put up at home in a convenient, prominent position) that is 
titrated to the individual patient and has tick boxes to show when and if a dose was 
taken. 
 
6. After 6 months from the first blood pressure measurement visit, the participant should 
make their last study visit to the pharmacy. The participant will be handed the 
questionnaires containing the 8-item MMAS, MARS, and BMQ which the participant 
will be partially facilitated by the pharmacist to answer in a quiet room in the pharmacy 
building. After the participant has filled out the questionnaires these will be handed back 
to the researcher in the pharmacy. 
 
7. For blood pressure measurement, the participant will be asked to be seated on a chair in a 
separate, quiet room in the pharmacy and rest for 5 minutes (Mancia et al., 2007; O’Brien 
et al., 2005; The British Hypertension Society, 2012). Blood pressure and pulse of the 
participant will then be measured using the clinically validated electronic blood pressure 
monitor Omron 705-IT and take up to 3 readings to check for continuity (The British 
Hypertension Society, 2012). Step 1.1 and 1.2 is set to take around 1 hour. Blood pressure 
data will be recorded on a separate paper sheet for each participant containing only the 
participant code. The participant will after this also be informed about the result of the 




A pharmacoeconomic evaluation of delivering a pharmacist-led intervention will be done 
throughout the duration of the study:  
 Cost per increment: How much it costs to deliver 1 mmHg in blood pressure reduction 
(cost per unit change in clinical outcome) – Following data will be considered: The 
measured change in systolic, diastolic and mean arterial pressure. 
Capital cost will be calculated during the study duration addressing questions such as: 
 How much time does it take to administer various counselling as a pharmacist? 
 How much does the pharmacist cost per minute and per hour? 
 If a special counselling area does not exist – how much will this cost? 
 Cost of paper? 
  Waste cost of the medication is calculated: Physical pill count provides information how 
much is wasted or not. Level of adherence data obtained from 8-item MMAS and MARS 
will also provide data on waste cost. Drug cost is available through The Dental and 
Pharmaceutical Benefits Agency, TLV website (Tandvård- och Läkemedelsförmånsverket, 
2012). 
Population and sample 
 
Inclusion criteria: age at least 18 and above, must be having at least one active prescription on 
an antihypertensive medicine or fixed combinations of antihypertensive medicine, been using 
the medicine within the past 3 months, medicine refill done only at the study pharmacy 
throughout the duration of the study, can understand, write and speak Swedish.  





Blood pressure and pulse measurement using a clinically validated blood pressure monitor 
accordingly to The British Hypertension Society (The British Hypertension Society, 2012). 
Adherence: (8-item Morisky Medication Adherence Scale, Medication Adherence Report 
Scale, Medication Possession Ratio), a questionnaire on patient perception on medicines 




The researcher will apply for ethics approval through the Central Ethical Review Board, 
Sweden. Ethical issues will involve dealing with human subjects and dealing/gathering 
personal/confidential data. No identity of any participant will be disclosed in the 
dissemination of the results. The participant is free to withdraw from the study at any time 
without giving a reason and no penalty is involved at any stage. 
Impact  
 
The impact of this research is to show the significance of antihypertensive medicines 
adherence check in a pharmacy by a pharmacist is beneficial to contribute to the best 
pharmacist-led intervention which not only shows to increase antihypertensive medicines 
adherence, but also results in a decrease in blood pressure and pulse, an increase of quality in 













 Information for research participants 5.6
 
Evaluation of pharmacist-led intervention for improving adherence to treatment with 
antihypertensive medicines 
 
Background and Purpose   The purpose of this research project is to evaluate the efforts 
made by a pharmacist at a community pharmacy to improve adherence to antihypertensive 
medication therapy. 
  
Inquiry concerning participation   You are asked to participate in this project because you 
have in the last three months undergone treatment with antihypertensive medicines. We have 
gained access to this information because you have collected your medications at 
Apoteksamariten AB. To participate, you are at least 18 years of age, have at least one active 
prescription on antihypertensive medicine, you are not participating in another clinical trial, 
you can self-administer the medicine, and that you can understand, speak and write Swedish 
unhindered. 
  
How will the study be conducted?   The study will be conducted at Apoteksamariten AB in 
Uppsala for 6 months and you are asked to visit Apoteksamariten AB at regular intervals. 
  
 Your blood pressure and your pulse will be measured by the researcher (the 
pharmacist) during your visit to Apoteksamariten AB at the beginning and end of the 
study. You will also at each of these two occasions get to answer three different 
questionnaires which show your adherence to your antihypertensive medication 
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therapy as well as your beliefs about medications. Every visit were blood pressure and 
pulse measurement is carried out as well as answering the three questionnaires is 
expected to take up to 40 minutes. 
 You will get a paper protocol and if you been dispensed a refill of your 
antihypertensive medications from the pharmacy, you should make a note of the date 
on which you started taking your medications. During the 6-month study period, you 
should always pick up your medication at Apoteksamariten AB. 
 Every time you pick up a refill of your antihypertensive medication you should bring 
your recently used medicine’s package. The researcher will count the remaining pills in 
the medicine’s package. If for any reason you would pick up your medicine at another 
pharmacy, you should inform the researcher of this to take account of this in the 
research results/analysis.  
 The researcher will with your permission contact the doctor who has prescribed your 
anti-hypertensive medicine. The researcher will also explain what this project is about. 
The researcher will then ask for your doctor’s help to provide the researcher with 
information on the number of prescriptions written for you, and for what purpose and 
date the prescription/s were written. 
 Three months after the beginning of the study it will be conducted an intervention 
aimed at increasing your adherence to your antihypertensive medicines treatment. The 




(a) Targeted counselling from the pharmacist – explaining the disease state, medication 
mechanism, outcomes and importance of adherence. Counselling will take place in 
the pharmacy. This counselling will take a maximum of 30 minutes. 
(b) An information leaflet about antihypertensive medication/s which is titrated to your 
medication therapy. 
(c) A reminder sheet (to be put up at home in a prominent position) that is titrated to 
you with tick boxes to show when and if a dose was taken. 
 
What are the risks? The possible risks in this project are that you can feel anxious over your 
antihypertensive medication therapy, any issues about privacy (to talk about your medications 
in an open pharmacy environment) and feel embarrassed/singled out to participate in a study. 
Another potential risk is if the automatic blood pressure monitor used provides incorrect 
results during blood pressure and pulse measurement. If any problem occurs during the study 
which puts the safety of the participant and/or the researcher at risk, the project will 
immediately be stopped until the problem has been investigated and resolved.  
 
Are there any advantages? The project’s effects are unknown.  
 
Dealing with data and confidentiality 
 All personal data collected in this project are stored and handled in accordance with the 
Swedish Personal Data Act (1998:204). Responsible for the personal data is 
Apoteksamariten AB. According to the Personal Data Act, you have the right to once a 
year at no cost receive all the details about you which are handled and, where 
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necessary, to have any errors corrected. Contact person is researcher Amirthan 
Amirthalingam (see contact information under the heading Responsibility).  
 Your answers and results will be dealt with to avoid unauthorized access to them. The 
researcher is a licensed pharmacist and covered by the obligation of professional 
secrecy applying within health care. You will be assigned an individual participant 
code. Data will be handled both in paper and electronic form. All material in paper 
form will only contain your participant code except the consent form which will 
include your name and personal identity number. The consent form is securely stored at 
Apoteksamariten AB. Participant code along with your name and your contact 
information is stored electronically protected by encryption technology.  
 Anonymous data will be shared with the University of Birmingham in the United 
Kingdom which is the academic institution that supervises the study. Personal 
information is retained until the researcher’s doctoral thesis is approved. If the study is 
being published and presented to the public your identity will not be revealed. If you 
want to take part of your results in the study or the full study results, we will make sure 
you do so. 
  
Insurance, compensation Insurance for participation in this study is provided through 
Länsförsäkringar which is the insurance company Apoteksamariten AB is connected to. No 





Voluntariness   Participation in the project is voluntary. You may, at any time and without 
specific explanation withdraw your study participation without any impact on your usual care.  
 
What happens if something goes wrong or if you have complaints? You should then 














































Principal Researcher: (communicates in English) 
John Marriott, Professor of Clinical Pharmacy 
  
Pharmacy, Pharmacology and Therapeutics Section,  
School of Clinical and Experimental Medicine,  
College of Medical and Dental Sciences (CMDS),  
Medical School Building, University of Birmingham,  







 Consent form 5.7
 
Project title: Evaluation of pharmacist-led intervention for improving adherence to treatment 
with antihypertensive medicines 
I have read the information sheet (information for research participants) and I have also been 
given an oral explanation of the research project by the researcher. I have had the opportunity 
to ask questions and discuss participation in the study and the study in general, and received 
at least 24 hours for me to decide whether I want to participate in the study or not. I give my 
consent to the treatment of my personal data as described in the information for research 
participants. I give the researcher permission to contact my doctor who prescribed my 
antihypertensive medicines to get information on how many prescriptions on antihypertensive 
medications has been written to me and for what purpose and what date the prescription/s are 
written. I also give permission for the researcher to give my doctor a copy of this consent 
form, if my doctor requires this. I am aware that my participation in the study is voluntary and 
that I may at any time cancel my participation without providing an explanation, and that this 













Study participant's signature:    Study participant's personal identity number:  
 
_________________________     ______________________________________ 
 






Place and date:  The researcher’s signature: 
 
________________________________       ______________________________  






 Information leaflet for improving your blood pressure medicine’s 5.8
adherence 
________________________________________ 
In the year 2000, hypertension existed in 26% of the adult population. It is estimated to be 
responsible for 4% of the global disease burden. It is a world-wide public health problem. 
Lowered blood pressure can lead to a reduction in the incidence of stroke and cardiovascular 
heart disease. According to WHO, treatment of hypertension has shown to prevent 
cardiovascular diseases, extend and enhance life. Despite this, hypertension is everywhere 
still inadequately managed. The lack of adherence to blood pressure lowering medicines plays 
a major role. The concept adherence can be defined as to which extent the patient follows 
instructions to the treatment which has been prescribed. It is a concept which is non-
judgmental and is not thought to be used to blame the treatment, patient or prescriber. 
 
Non-adherence can exist due to many reasons, for example, due to adverse effects, poor 
instructions, and poor memory. Low adherence is very common: adherence rates to prescribed 
medicines are about 50% (on a 0-100% scale). This is particularly critical when the treatment 
response relates to the dose and therapy schedule. In turn, this leads to reduced treatment 
benefits. The adherence rate to blood pressure lowering medicines depends on the population 
being studied but is in the range between 50-70 percent. The purpose of this information sheet 






 Consult your doctor to make sure that you have understood the disease state.  
 Consult your doctor and/or pharmacist to make sure that you have understood the 
benefit of your treatment. 
 Take your medicine only as instructed on your medication label and instructed by your 
doctor. Ask your doctor or pharmacist if you do not know and/or understand how to 
take your medicine. 
 Never by yourself decide to alter the dose or stop taking the medicine before 
consulting with your doctor. 
 Consult your doctor or pharmacist if you are concerned about possible side-effects or 
the risks of the treatment.  
 Consult your doctor or pharmacist if you experience unpleasant side effects from your 
treatment. 
 Consult your doctor and/or pharmacist if you encounter issues with tablet form, 
medicines combination, the timing of the dose/s, the cost of the treatment and 
insurance coverage of the medicine. 
 Store your medicine bottle in an environment accordingly to the instructions on your 
medicine bottle. Make this storage environment will be easily accessible for you. 
 Visit your local pharmacy and ask the pharmacy staff to help you with dose aids that 
will help you remember to take your medicine as prescribed by your doctor. 
 When travelling remember to bring your medicine with you and take it as instructed 
on the label and instructed by your doctor.  
283 
 
 Find a pharmacy which is easily accessible to you. Ask somebody you trust for help 
when you are not able to visit the pharmacy and make your medicine refill by 
yourself. 
 Make sure to have your blood pressure checked at regular intervals and that there will 
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